Peter Rossing
Consultant
Steno Diabetes Center Copenhagen
Type of address: Visiting address.
Borgmester Ib Juuls Vej 83
2730
Herlev
Denmark
Email: peter.rossing@regionh.dk
Phone: 30913383

Main research areas

Diabetic nephropathy, cardiovascular disease, neuropathy, metabolomics

Employment

Consultant
Steno Diabetes Center Copenhagen
The Capital Region of Denmark
Herlev, Denmark
1 Jan 2017 → present

board member
Bagger Sørensen Fonden
Vejle, Denmark
1 Jan 2024 → present

member(chair (2024+2025))
Sundhed og Sygdom, Det Frie Forskningsråd
1 Jan 2021 → present

Steno Diabetes Center A/S
Gentofte, Denmark
past → 1 Jan 2016

Professor in endocrinology with focus on vascular complications
University of Copenhagen
Copenhagen, Denmark

Activities

Speaker
Rossing, P. (Consultant)
Aug 2024

Board member
Rossing, P. (Consultant)
1 Jan 2024 → …

SGLT2 inhibition and Finerenone in Diabetic Kidney Disease
medicine, D. (Lecturer)
4 Dec 2023

Precision Medicine in Diabetes Complications
Rossing, P. (Lecturer)

30 Nov 2023

teaching
Rossing, P. (Consultant)
Sept 2023

adivisory board member
Rossing, P. (Consultant)
2022

teaching
Rossing, P. (Consultant)
2022 → 2023

Atrial Fibriallation and Diabetes
Rossing, P. (Lecturer)
14 Apr 2021

New treatments for Diabetic Kidney Disease
copenhagen, U. (Lecturer)
14 Jan 2021

member and chair (2024-)
Rossing, P. (Consultant)
2021 → …

steering Group member Mosaic
Rossing, P. (Consultant)
2021 → …

DIABETESBEHANDLING AF DEN NYRESYGE PATIENT
Rossing, P. (Lecturer)
20 Jan 2020

56th EASD Annual Meeting of the European Association for the Study of Diabetes
Rossing, P. (Organizer)
2020

CKD in Patients With T2D
Rossing, P. (Lecturer)
2020

DAPA CKD background
Rossing, P. (Lecturer)
2020

Diabetes and atrial fibrillation
Rossing, P. (Lecturer)
2020

DIABETESBEHANDLING AF DEN NYRESYGE PATIENT
Rossing, P. (Lecturer)
2020

Empagliflozin: cardiorenal benefits in patients with type 2 diabetes, beyond glycemic control
Rossing, P. (Lecturer)
2020

Intervention and monitoring of diabetic nephropathy in 2020
Rossing, P. (Lecturer)
2020

ISN-ISE Webinar: Current management of diabetes in patients with kidney diseases
Rossing, P. (Lecturer)
2020

KDIGO diabetes management guideline
Rossing, P. (Lecturer)
2020

KDIGO DKD Guideline
Rossing, P. (Lecturer) & Rossing, P. (Lecturer)
2020

KDIGO guideline for Diabetes
Rossing, P. (Lecturer)
2020

KDIGO guideline for management of diabetes in CKD
Rossing, P. (Lecturer)
2020

leadership
Rossing, P. (Other)
2020 → …

Management of Diabetes in CKD
Rossing, P. (Lecturer)
2020

Mechanisms That Matter: CKD and T2D."
Rossing, P. (Lecturer)
2020

Metabolic Determinants of Cardiac and Renal Complications in Type 1 Diabetes
Rossing, P. (Lecturer)
2020

Navigating through the treatment options after metformin
Rossing, P. (Lecturer)
2020

New Treatment Options for Kidney Disease in Diabetes
Rossing, P. (Lecturer)
2020

Novel Mineralocorticoid Receptor Antagonists and cardio-renal protection in diabetes--- Beyond SGLT2 Inhibitors and GLP-1 Receptor Agonists
Rossing, P. (Lecturer)
2020

Patient eligible for finerenone
Rossing, P. (Lecturer)
2020

Patient for SGLT2i
Rossing, P. (Lecturer)
2020

Patients with AF and Diabetes: Is it Possible to Avoid Irreversible Complications?
Rossing, P. (Lecturer)
2020

Recommendations for Glycemia Monitoring and Targets in CKD
Rossing, P. (Lecturer)
2020

Results and Sub-Analysis of DAPA-CKD Trial
Rossing, P. (Lecturer)
2020

Results and Sub-Analysis of DAPA-CKD Trial
Rossing, P. (Lecturer)
2020

Role of SGLT2 Inhibitors for Management of Cardiorenal Syndrome in Diabetes: From Prevent to Treatment
Rossing, P. (Lecturer)
2020

Seeing the forest for the trees
Rossing, P. (Lecturer)
2020

study collaboration
Rossing, P. (Advisor)
2020 → …

suPAR and Complications of Diabetes Mellitus
Rossing, P. (Lecturer)
2020

Targeting the mineralocorticoid receptor to reduce CKD in T2D: is it time for a new treatment paradigm?
Rossing, P. (Lecturer)
2020

Targeting the Mineralocorticoid Receptor to Reduce the Risk of Chronic Kidney Disease Progression in Type 2 Diabetes/
Rossing, P. (Lecturer)
2020

What is next after Metformin? Understanding the guidelines
Rossing, P. (Lecturer)

2020

Where are we now, and how should we move forward Update guideline from KDIGO 2020 DM in CKD
Rossing, P. (Lecturer)
2020

Linking kidney and cardiovascular complications - impact on prognosis and treatment
Rossing, P. (Lecturer)
14 Dec 2019

Ecchocardiography in Diabetes and Heart Failure
Rossing, P. (Lecturer)
5 Dec 2019

Management of hyperglycemia in type 2 diabetes
Rossing, P. (Consultant)
5 Dec 2019

GLP 1 in diabetic kidney disease
Rossing, P. (Lecturer)
4 Dec 2019

Pathophysiology of diabetic kidney disease
Rossing, P. (Lecturer)
27 Nov 2019

EASD Scientist training course 2019
Rossing, P. (Organizer)
18 Nov 2019

KDIGO guideline on Diabetic Nephropathy
Rossing, P. (Lecturer)
17 Oct 2019

Diabetic Kidney Disease
Rossing, P. (Lecturer)
11 Oct 2019

Diabetic Nephropathy
Rossing, P. (Lecturer)
7 Oct 2019

Diabetic Nephropathy update
Rossing, P. (Lecturer)
21 Sept 2019

Metformin safety and efficacy in CKD
Rossing, P. (Lecturer)
19 Sept 2019

Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetes with normoalbuminuria (PRIORITY) study
Rossing, P. (Lecturer)
19 Sept 2019

Mechanisms of Kidney Disease Progression: Understanding the role of inflammation and fibrosis
Rossing, P. (Lecturer)
16 Sept 2019

Steering group member
Rossing, P. (Consultant)
1 Aug 2019 → 31 Jan 2021

Diabetic kidney disease: Learnings so far
Rossing, P. (Lecturer)
14 Jun 2019

Edwin Bierman award: The link between the kidney and heart
Rossing, P. (Lecturer)
8 Jun 2019

Diabetic Kidney Disease
Rossing, P. (Lecturer)
26 Mar 2019

Sonar Study of Atrasentan in diabetic kidney disease
Rossing, P. (Lecturer)
13 Mar 2019

Guidelines for diabetes
Rossing, P. (Lecturer)
10 Mar 2019

New EASD ADA guidelines, and Nephroprotection with Type 2 DMtreatment
Rossing, P. (Lecturer)
27 Jan 2019

International Diabetes Federation 2019
Rossing, P. (Organizer)
1 Jan 2019 → 6 Dec 2019

steering group member
Rossing, P. (Consultant)
1 Jan 2019 → 31 Dec 2019

Myocardial Flow Reserve Assessed by Cardiac 82Rb PET/CT Is Associated with Albumin Excretion in Patients with Type 1 Diabetes
Zobel, E. H. (Lecturer), Winther, S. A. (Other), von Scholten, B. J. (Other), Holmvang, L. (Other), Kjær, A. (Other), Rossing, P. (Other) & Hansen, T. W. (Other)
26 Oct 2018

EASD ADA guidline on treatment of hyperglycaemia in Type 2 Diabetes
Rossing, P. (Lecturer)
5 Oct 2018

Diabetes and Hypertension
Rossing, P. (Lecturer)
10 Aug 2018

Steering group member
Rossing, P. (Consultant)
1 Aug 2018 → 31 Jan 2021

ADA EASD position paper on treatment of hyperglycaemia in Type 2 Diabetes
Rossing, P. (Lecturer)
25 Jun 2018

Diabetes and Hypertension
Rossing, P. (Lecturer)
27 May 2018

Urine proteome - is there a role in predicting and monitoring diabetic nephropathy
Rossing, P. (Lecturer)
26 May 2018

New Treatments in Diabetic Kidney Disease
Rossing, P. (Lecturer)
24 May 2018

Prognosis and treatment of diabetic nephropathy :recent advances and perspectives
Rossing, P. (Lecturer)
22 Apr 2018

KDIGO guideline on Diabetic Kidney Disease
Rossing, P. (Consultant)
20 Jan 2018 → 1 May 2020

Steering group member
Rossing, P. (Consultant)
1 Jan 2018 → 31 Jan 2021

advisor
Rossing, P. (Consultant)
2018 → …

IDF Congress 2017
Flyvbjerg, A. (Participant), Rossing, P. (Participant), Willaing, I. (Participant), Vilsbøll, T. (Participant), Hempler, N. F. (Participant), Nexø, M. A. (Participant) & Cleal, B. (Participant)
4 Dec 2017 → 8 Dec 2017

ASN Kidney Week 2017
Rossing, P. (Participant), Frimodt-Møller, M. (Participant), Hansen, T. W. (Participant), Eickhoff, M. K. (Participant), Tofte, N. (Participant) & Viktor Rotbain , C. (Participant)
31 Oct 2017 → 5 Nov 2017

53rd Annual Meeting of the European Association for the study of Diabetes EASD
Flyvbjerg, A. (Participant), Brock, B. (Participant), Rossing, P. (Participant), Jørgensen, M. E. (Participant), Engberg, S. (Participant), Frimodt-Møller, M. (Participant), Safai, N. (Participant), Tofte, N. (Participant), Vilsbøll, T. (Participant), Curovic, V. R. (Participant), Cleal, B. (Participant) & Olesen, K. (Participant)
11 Sept 2017 → 15 Sept 2017

American Diabetes Association's 77th Scientific Sessions, ADA 2017
Flyvbjerg, A. (Participant), Rossing, P. (Participant), Brock, B. (Participant) & Suvitaival, T. (Participant)

9 Jun 2017 → 13 Jun 2017

30th Annual General Meeting of the European Diabetic Nephropathy Study Group, EDNSG
Rossing, P. (Participant)
19 May 2017 → 20 May 2017

Diabetic Nephropathy
Rossing, P. (Lecturer)
2017 → …

Treatment of Diabetes in CKD
Rossing, P. (Lecturer)
2017 → …

steering group member, advisor
Rossing, P. (Consultant)
2014 → …

consultancy
Rossing, P. (Consultant)
2012 → …

steering group member, advisor, collaboration on study
Rossing, P. (Consultant)
2012 → …

Prizes

16th Ricardo E. Fernando Endowed Lecturer
Rossing, P. (Recipient), 2022

Claus Bruun Honorary Lecture
Rossing, P. (Recipient), 2010

Dandy foundation honorary award
Rossing, P. (Recipient), 2000

Edward Bierman Award
Rossing, P. (Recipient), 9 Jun 2019

Erhoff Prisen
Rossing, P. (Recipient), 29 Nov 2021

European Hormone Medal
Rossing, P. (Recipient), 2022

GOLGI prize
Rossing, P. (Recipient), 2016

Knud Lundbæk award
Rossing, P. (Recipient), 2017

Minkowski Prize
Rossing, P. (Recipient), 2005

Niels A Lassen prize
Rossing, P. (Recipient), 2015

Niels Schwartz-Sørensen Prize
Rossing, P. (Recipient), 2008

Novartis Young Investigator Award
Rossing, P. (Recipient), 2008

Nyreprisen
Rossing, P. (Recipient), 2023

Professor Vishvanathans Honorary Award
Rossing, P. (Recipient), 2012

Ruth Østerby Honorary Award
Rossing, P. (Recipient), 2013

Publications

1. **Red cell Na+/Li+ countertransport in non-insulin-dependent diabetics with diabetic nephropathy.** / Gall, M A; Rossing, P; Jensen, J S et al.
   In: Kidney International, Vol. 39, No. 1, 01.1991, p. 135-40.
2. **Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients.** / Gall, M A; Rossing, P; Skøtt, P et al.
   In: Diabetologia, Vol. 34, No. 9, 09.1991, p. 655-61.
3. **3. Comparison of captopril, metoprolol and hydrochlorothiazide in hypertensive type-2 (non-insulin-dependent) diabetic patients.** / Rossing, P.; Gall, M.; Skott, P. et al.
   In: Journal of Hypertension, Vol. 10, No. 8, 01.01.1992.
4. **Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension.** / Gall, M A; Rossing, P; Skøtt, P et al.
   In: American Journal of Hypertension, Vol. 5, No. 5 Pt 1, 05.1992, p. 257-65.
5. **Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.** / Hommel, E; Andersen, P; Gall, M A et al.
   In: Diabetologia, Vol. 35, No. 5, 05.1992, p. 447-51.
6. **Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy.** / Gall, M A; Rossing, P; Hommel, E et al.
   In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 52, No. 6, 10.1992, p. 513-21.
7. **Effekten af captopril-, metoprolol- og hydroklortiazidbehandling hos ikke-insulinkraevende diabetikere (NIDDM) med primaer hypertension. En dobbeltblind, randomiseret overkrydsningsundersøgelse.** / Gall, M A; Rossing, P; Skøtt, P et al.
   In: Ugeskrift for Laeger, Vol. 155, No. 9, 01.03.1993, p. 636-41.
8. **Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.** / Nielsen, F S; Voldsgaard, A I; Gall, M A et al.
   In: Diabetologia, Vol. 36, No. 5, 05.1993, p. 438-44.
9. **Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients.** / Rossing, P; Hommel, E; Smidt, U M et al.
   In: Diabetes, Vol. 42, No. 5, 05.1993, p. 715-9.
10. **Calcium antagonists and the diabetic hypertensive patient.** / Parving, H H; Rossing, P.
    In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 21, No. 6 Suppl 3, 06.1993, p. 47-52.

11. **Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy.** / Parving, H H; Smidt, U M; Hommel, E et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 22, No. 1, 07.1993, p. 188-95.

12. **The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus.** / Myrup, B.; Rossing, P.; Jensen, T. et al.
In: Fibrinolysis and Proteolysis, Vol. 8, No. SUPPL. 2, 01.01.1994, p. 22-24.

13. **Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.** / Gall, M A; Rossing, P; Kofoed-Enevoldsen, A et al.
In: Diabetologia, Vol. 37, No. 2, 02.1994, p. 195-201.

14. **Reduction in albuminuria predicts diminished progression in diabetic nephropathy.** / Rossing, P; Hommel, E; Smidt, U M et al.
In: Kidney International, Supplement, Vol. 45, 02.1994, p. S145-9.

15. **Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.** / Rossing, P; Hommel, E; Smidt, U M et al.
In: Diabetologia, Vol. 37, No. 5, 05.1994, p. 511-6.

16. **The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.** / Parving, H H; Rossing, P.
In: Current opinion in nephrology and hypertension, Vol. 3, No. 3, 05.1994, p. 292-300.

17. **Monitoring kidney function in diabetic nephropathy.** / Rossing, P; Astrup, A S; Smidt, U M et al.
In: Diabetologia, Vol. 37, No. 7, 07.1994, p. 708-12.

18. **Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.** / Nielsen, F S; Rossing, P; Gall, M A et al.
In: Diabetes, Vol. 43, No. 9, 09.1994, p. 1108-13.

19. **Prevalence of arterial hypertension in diabetic patients before and after the JNC-V.** / Tarnow, L; Rossing, P; Gall, Mari-Anne et al.
In: Diabetes Care, Vol. 17, No. 11, 11.1994, p. 1247-51.

20. **Procoagulant activity and intimal dysfunction in IDDM.** / Myrup, B; Rossing, P; Jensen, T et al.
In: Diabetologia, Vol. 38, No. 1, 01.1995, p. 73-8.

21. **Short stature and diabetic nephropathy.** / Rossing, P; Tarnow, L; Nielsen, F S et al.
In: British Medical Journal, Vol. 310, No. 6975, 04.02.1995, p. 296-7.

22. **Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients.** / Tarnow, L; Cambien, Francois; Rossing, P et al.
In: Diabetes, Vol. 44, No. 5, 05.1995, p. 489-94.

23. **Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.** / Hansen, H P; Rossing, P; Tarnow, L et al.
In: Kidney International, Vol. 47, No. 6, 06.1995, p. 1726-31.

24. **Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.** / Parving, H H; Rossing, P; Hommel, E et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 26, No. 1, 07.1995, p. 99-107.

25. **Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.** / Tarnow, L; Cambien, Francois; Rossing, P et al.
In: Diabetologia, Vol. 38, No. 7, 07.1995, p. 798-803.

26. **On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy.** / Nielsen, Flemming Steen; Rossing, P; Bang, L E et al.
In: Diabetes, Vol. 44, No. 7, 07.1995, p. 783-9.

27. **Unchanged incidence of diabetic nephropathy in IDDM patients.** / Rossing, P; Rossing, K; Jacobsen, P et al.
In: Diabetes, Vol. 44, No. 7, 07.1995, p. 739-43.

28. **Low birth weight. A risk factor for development of diabetic nephropathy?** / Rossing, P; Tarnow, L; Nielsen, F S et al.
In: Diabetes, Vol. 44, No. 12, 12.1995, p. 1405-7.

29. **Correlation between microalbuminia and height.** / Rossing, P.
In: Biomedicine and Pharmacotherapy, Vol. 49, No. 9, 01.12.1995.

30. **Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs.** / Parving, H.H.; Rossing, Peter; Tarnow, Lise et al.
In: Nephrology, Vol. 2, 1996, p. 45-48.

31. **The angiotensin converting enzyme- its gene and inhibition.** / Parving, H.H.; Tarnow, Lise; Rossing, Peter.
In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 3, 1996, p. 315-321.

32. **Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy.** / Myrup, B.; Rossing, P.; Jensen, T. et al.
In: Fibrinolysis, Vol. 10, No. 5-6, 01.01.1996, p. 331-335.

33. **Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy.** / Myrup, B; de Maat, M; Rossing, P et al.
In: Thrombosis Research, Vol. 81, No. 4, 15.02.1996, p. 485-90.

34. **Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy.** / Tarnow, L; Cambien, Francois; Rossing, P et al.
In: Diabetes, Vol. 45, No. 3, 03.1996, p. 367-369.

35. **Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.** / Yokoyama, H; Myrup, B; Rossing, P et al.
In: Diabetes Care, Vol. 19, No. 5, 05.1996, p. 441-5.

36. **Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy.** / Tarnow, L; Cambien, Francois; Rossing, P et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 11, No. 6, 06.1996, p. 1019-23.

37. **Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy.** / Parving, H H; Jacobsen, P; Rossing, K et al.
In: Kidney International, Vol. 49, No. 6, 06.1996, p. 1778-82.

38. **Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy.** / Hansen, H P; Rossing, P; Tarnow, L et al.
In: Kidney International, Vol. 50, No. 2, 08.1996, p. 579-85.

39. **Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.** / Parving, H H; Jacobsen, P; Tarnow, L et al.
In: British Medical Journal, Vol. 313, No. 7057, 07.09.1996, p. 591-4.

40. **Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.** / Rossing, P; Hougaard, P; Borch-Johnsen, K et al.
In: British Medical Journal, Vol. 313, No. 7060, 28.09.1996, p. 779-84.

41. **Diabetisk nefropati. Uaendret forekomst hos patienter med insulinkraevende diabetes mellitus.** / Rossing, P; Rossing, K; Jacobsen, P et al.
In: Ugeskrift for Laeger, Vol. 158, No. 42, 14.10.1996, p. 5940-3.

42. **Fish oil in diabetic nephropathy.** / Rossing, P; Hansen, B V; Nielsen, F S et al.
In: Diabetes Care, Vol. 19, No. 11, 11.1996, p. 1214-9.

43. **Renal protection in diabetes: an emerging role for calcium antagonists.** / Parving, H H; Tarnow, L; Rossing, P.
In: Journal of Hypertension, Supplement, Vol. 14, No. 4, 11.1996, p. S21-5.

44. **Genetics of diabetic nephropathy.** / Parving, H H; Tarnow, L; Rossing, P.
In: Journal of the American Society of Nephrology : JASN, Vol. 7, No. 12, 12.1996, p. 2509-17.

45. **Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy.** / Tarnow, L; Rossing, P; Nielsen, F S et al.
In: Diabetes Care, Vol. 19, No. 12, 12.1996, p. 1382-7.

46. **Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy.** / Parving, H H; Nielsen, F S; Bang, L E et al.
In: Diabetologia, Vol. 39, No. 12, 12.1996, p. 1590-7.

47. **Lav fødselsvaegt--øget risiko for diabetisk nefropati?** / Rossing, P; Tarnow, L; Nielsen, F S et al.
In: Ugeskrift for Laeger, Vol. 159, No. 1, 30.12.1996, p. 41-4.

48. **Renal protection in diabetes--an emerging role for calcium antagonists.** / Parving, H H; Tarnow, L; Rossing, P.
In: Cardiology, Vol. 88 Suppl 3, 1997, p. 56-62.

49. **Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.** / Rossing, P; Tarnow, L; Boelskifte, S et al.
In: Diabetes, Vol. 46, No. 3, 03.1997, p. 481-7.

50. **Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM.** / Tarnow, L; Pociot, F; Hansen, P M et al.
In: Diabetes, Vol. 46, No. 6, 06.1997, p. 1075-6.

51. **Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy.** / Nielsen, F S; Ali, S; Rossing, P et al.
In: Diabetic Medicine, Vol. 14, No. 7, 07.1997, p. 538-46.

52. **Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.** / Nielsen, F S; Rossing, P; Gall, M A et al.
In: Diabetes, Vol. 46, No. 7, 07.1997, p. 1182-8.

53. **Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.** / Nielsen, F S; Rossing, P; Gall, M A et al.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 57, No. 5, 08.1997, p. 427-34.

54. **Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.** / Hansen, H P; Nielsen, F S; Rossing, P et al.
In: Kidney International, Supplement, Vol. 63, 12.1997, p. S49-53.

55. **Differences between the effect of nisoldipine and lisinopril on microvascular dysfunction in hypertensive IDDM patients with nephropathy.** / Sørensen, V. B.; Rossing, P.; Tarnow, L. et al.
In: Scandinavian Cardiovascular Journal, Supplement, Vol. 31, No. 45, 01.12.1997.

56. **Doubling of serum creatinine: is it sensitive and relevant?** / Rossing, P.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 13, No. 2, 02.1998, p. 244-6.

57. **Risikofaktorer for død hos insulinkraevende diabetikere.** / Rossing, P; Hougaard, P; Borch-Johnsen, K et al.
In: Ugeskrift for Laeger, Vol. 160, No. 9, 23.02.1998, p. 1315-9.

58. **Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.** / Jacobsen, P; Rossing, K; Rossing, P et al.
In: Kidney International, Vol. 53, No. 4, 04.1998, p. 1002-6.

59. **Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA.** / Hansen, H P; Rossing, P; Mathiesen, E R et al.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 58, No. 5, 08.1998, p. 405-13.

60. **Betydningen af deletionspolymorfi i ACE-genet for progression af ACE-haemmerbehandlet diabetisk nyresygdom.** / Tarnow, L; Parving, H H; Jacobsen, P et al.
In: Ugeskrift for Laeger, Vol. 160, No. 34, 17.08.1998, p. 4886-9.

61. **Promotion, prediction, and prevention of progression in diabetic nephropathy.** / Rossing, P.
In: Danish Medical Bulletin, Vol. 45, No. 4, 09.1998, p. 354-69.

62. **Diabetes and risk of adverse events with calcium antagonists.** / Parving, H H; Rossing, P.
In: Diabetes Care, Vol. 21, No. 10, 10.1998, p. 1779-80.

63. **Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy.** / Rossing, K; Jacobsen, P; Rossing, P et al.
In: Diabetes Care, Vol. 21, No. 11, 11.1998, p. 2007-15.

64. **Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus.** / Rossing, P.
In: Diabetic Medicine, Vol. 15, No. 11, 11.1998, p. 900-19.

65. **Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.** / Sørensen, V B; Rossing, P; Tarnow, L et al.
In: Clinical science (London, England : 1979), Vol. 95, No. 6, 12.1998, p. 709-17.

66. **Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus A sign of vascular damage in patients with diabetic nephropathy?** / Myrup, B.; Rossing, P.; Jensen, T. et al.
In: Fibrinolysis, Vol. 13, No. 3, 01.01.1999, p. 142-147.

67. **Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.** / Parving, H H; Tarnow, L; Nielsen, F S et al.
In: Diabetes Care, Vol. 22, No. 3, 03.1999, p. 478-83.

68. **Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.** / Tarnow, L; Sato, A; Ali, S et al.
In: Diabetes Care, Vol. 22, No. 3, 03.1999, p. 491-4.

69. **Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy.** / Christensen, P K; Rossing, P; Nielsen, F S et al.
In: Diabetic Medicine, Vol. 16, No. 5, 05.1999, p. 388-94.

70. **Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy.** / Nielsen, F S; Hansen, H P; Jacobsen, P et al.
In: Diabetic Medicine, Vol. 16, No. 7, 07.1999, p. 555-62.

71. **Progression of diabetic nephropathy in normotensive type 1 diabetic patients.** / Jacobsen, P; Rossing, K; Tarnow, L et al.
In: Kidney International, Supplement, Vol. 71, 07.1999, p. S101-5.

72. **Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy.** / Tarnow, L; Rossing, P; Nielsen, F S et al.
In: Diabetes Care, Vol. 23, No. 1, 01.2000, p. 30-3.

73. **Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.** / Andersen, S; Tarnow, L; Rossing, P et al.
In: Kidney International, Vol. 57, No. 2, 02.2000, p. 601-6.

74. **Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.** / Bos, H; Andersen, S; Rossing, P et al.
In: Kidney International, Supplement, Vol. 75, 04.2000, p. S32-7.

75. **QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes.** / Christensen, P K; Gall, M A; Major-Pedersen, A et al.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 60, No. 4, 07.2000, p. 323-32.

76. **Risikofaktorer for progression af diabetisk nefropati.** / Rossing, P.
In: Ugeskrift for Laeger, Vol. 162, No. 38, 18.09.2000, p. 5057-61.

77. **Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.** / Tarnow, L; Rossing, P; Jensen, C et al.
In: Diabetes Care, Vol. 23, No. 12, 12.2000, p. 1725-30.

78. **Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy.** / Myrup, B; Rossing, P; Jensen, T et al.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 61, No. 5, 2001, p. 349-56.

79. **Preventing diabetic nephropathy: an audit.** / Hansen, H P; Lund, S S; Rossing, P et al.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 61, No. 6, 2001, p. 471-7.

80. **Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.** / Parving, H H; Rossing, P.
In: Diabetes Care, Vol. 24, No. 1, 01.2001, p. 177-80.

81. **Progression of diabetic nephropathy.** / Hovind, P; Rossing, P; Tarnow, L et al.
In: Kidney International, Vol. 59, No. 2, 02.2001, p. 702-9.

82. **Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus.** / Rossing, P; Breum, L; Major-Pedersen, A et al.
In: Diabetic Medicine, Vol. 18, No. 3, 03.2001, p. 199-205.

83. **Attitudes towards diabetes and its care: Evaluation before, immediately post-course and ≥ 1 year after a practical, international inter-disciplinary course for diabetes teams.** / Rossing, Peter; Andersen, Henning; Hesselholdt, Lone et al.
In: Practical Diabetes International, Vol. 18, No. 2, 24.04.2001, p. 39-44.

84. **Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively.** / Hovind, P; Rossing, P; Tarnow, L et al.
In: Kidney International, Vol. 60, No. 1, 07.2001, p. 277-83.

85. **Remission of nephrotic-range albuminuria in type 1 diabetic patients.** / Hovind, P; Rossing, P; Tarnow, L et al.
In: Diabetes Care, Vol. 24, No. 11, 11.2001, p. 1972-7.

86. **Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1.** / Hovind, P; Tarnow, L; Rossing, P et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 38, No. 6, 12.2001, p. 1376-80.

87. **Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?** / Andersen, Steen; Tarnow, Lise; Cambien, Francois et al.
In: Kidney International, Vol. 62, No. 1, 2002, p. 192-8.

88. **Pregnancy and progression of diabetic nephropathy.** / Rossing, K; Jacobsen, P; Hommel, E et al.
In: Diabetologia, Vol. 45, No. 1, 01.2002, p. 36-41.

89. **Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study.** / Rossing, Peter; Hougaard, Philip; Parving, Hans-Henrik.
In: Diabetes Care, Vol. 25, No. 5, 05.2002, p. 859-64.

90. **Optimal dose of losartan for renoprotection in diabetic nephropathy.** / Andersen, Steen; Rossing, Peter; Juhl, Tina R et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 17, No. 8, 08.2002, p. 1413-8.

91. **Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.** / Hovind, Peter; Tarnow, Lise; Rossing, Kasper et al.
In: Diabetes Care, Vol. 26, No. 4, 2003, p. 1258-64.

92. **Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?** / Andersen, Steen; Tarnow, Lise; Cambien, Francois et al.
In: Diabetes Care, Vol. 26, No. 5, 2003, p. 1501-6.

93. **Smoking and progression of diabetic nephropathy in type 1 diabetes.** / Hovind, Peter; Rossing, Peter; Tarnow, Lise et al.
In: Diabetes Care, Vol. 26, No. 3, 2003, p. 911-6.

94. **Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.** / Andersen, Steen; Jacobsen, Peter; Tarnow, Lise et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 18, No. 2, 02.2003, p. 293-7.

95. **Birth weight--a risk factor for progression in diabetic nephropathy?** / Jacobsen, P; Rossing, P; Tarnow, L et al.
In: Journal of Internal Medicine, Vol. 253, No. 3, 03.2003, p. 343-50.

96. **Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.** / Parving, Hans-Henrik; Andersen, Steen; Jacobsen, Peter et al.
In: Seminars in Nephrology, Vol. 24, No. 2, 2004, p. 147-57.

97. **Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.** / Hovind, Peter; Tarnow, Lise; Rossing, Peter et al.
In: Kidney International, Vol. 66, No. 3, 2004, p. 1180-6.

98. **Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study.** / Hovind, Peter; Tarnow, Lise; Rossing, Peter et al.
In: BMJ, Vol. 328, No. 7448, 2004, p. 1105.

99. **Progression of nephropathy in type 2 diabetic patients.** / Rossing, Kasper; Christensen, Per Klitgaard; Hovind, Peter et al.
In: Kidney International, Vol. 66, No. 4, 2004, p. 1596-605.

100. **Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.** / Schjoedt, K J; Andersen, S; Rossing, Peter et al.
In: Diabetologia, Vol. 47, No. 11, 11.2004, p. 1936-9.

101. **Risikofaktorer for udvikling af mikro- og makroalbuminuri ved type 1-diabetes: et incidenskohortestudie--en sekundaerpublikation.** / Hovind, Peter; Tarnow, Lise; Rossing, Peter et al.
In: Ugeskrift for Laeger, Vol. 167, No. 1, 2005, p. 57-60.

102. **Telmisartan vs. enalapril in type 2 diabetes.** / Parving, Hans-Henrik; Hovind, Peter; Rossing, Peter.
In: The New England journal of medicine, Vol. 352, No. 8, 24.02.2005, p. 835-6; author reply 835-6.

103. **Renoprotection with and without blood pressure reduction.** / Laverman, Gozewijn Dirk; Andersen, Steen; Rossing, Peter et al.
In: Kidney International, Supplement, Vol. 67, No. 94, 04.2005, p. S54-9.

104. **Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.** / Andersen, Steen; van Nieuwenhoven, Frans A; Tarnow, Lise et al.
In: Kidney International, Vol. 67, No. 6, 06.2005, p. 2325-9.

105. **Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.** / Ahmed, Sofia B; Hovind, Peter; Parving, Hans-Henrik et al.
In: Diabetes Care, Vol. 28, No. 8, 08.2005, p. 1988-94.

106. **The changing epidemiology of diabetic microangiopathy in type 1 diabetes.** / Rossing, P.
In: Diabetologia, Vol. 48, No. 8, 08.2005, p. 1439-44.

107. **Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study.** / Astrup, Anne Sofie; Tarnow, Lise; Rossing, Peter et al.
In: Kidney International, Vol. 68, No. 3, 09.2005, p. 1250-7.

108. **Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study.** / Rossing, Peter; Hougaard, Philip; Parving, Hans-Henrik.
In: Kidney International, Vol. 68, No. 4, 10.2005, p. 1446-50.

109. **Beneficial impact of spironolactone in diabetic nephropathy.** / Schjoedt, Katrine Jordan; Rossing, Kasper; Juhl, Tina Ragnholm et al.
In: Kidney International, Vol. 68, No. 6, 12.2005, p. 2829-36.

110. **Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.** / Schjoedt, K J; Lajer, Mathilde; Andersen, S et al.
In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 66, No. 3, 2006, p. 173-80.

111. **Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.** / Rossing, P.
In: Diabetologia, Vol. 49, No. 1, 01.2006, p. 11-9.

112. **Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.** / Astrup, Anne Sofie; Tarnow, Lise; Rossing, Peter et al.
In: Diabetes Care, Vol. 29, No. 2, 02.2006, p. 334-9.

113. **Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes.** / Rossing, Peter; Cooper, Mark E; Parving, Hans-Henrik.
In: Diabetes Care, Vol. 29, No. 3, 03.2006, p. 747-8; author reply 748-9.

114. **Renoprotective effects of renin-angiotensin-system inhibitors.** / Parving, Hans-Henrik; Rossing, Peter.
In: Lancet, Vol. 367, No. 9514, 18.03.2006, p. 898-9; author reply 900-2.

115. **ACE-haemmere og AT-II-antagonister--beskytter de mod nyresygdom?** / Rossing, Peter; Parving, Hans-Henrik.
In: Ugeskrift for Laeger, Vol. 168, No. 15, 10.04.2006, p. 1564; author reply1564-5.

116. **Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy.** / Rossing, Peter; Rossing, Kasper; Gaede, Peter et al.
In: Diabetes Care, Vol. 29, No. 5, 05.2006, p. 1024-30.

117. **Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.** / Jacobsen, Peter Karl; Rossing, Peter; Parving, Hans-Henrik.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 21, No. 7, 07.2006, p. 2030-1.

118. **Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.** / Schjoedt, K J; Rossing, K; Juhl, Tina R et al.
In: Kidney International, Vol. 70, No. 3, 08.2006, p. 536-42.

119. **Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?** / Rossing, Peter; Parving, Hans-Henrik; de Zeeuw, Dick.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 21, No. 9, 09.2006, p. 2354-7; discussion 2357-8.

120. **Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history.** / Rossing, Peter.
In: Current Diabetes Reports, Vol. 6, No. 6, 12.2006, p. 479-83.

121. **Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.** / Persson, Frederik; Rossing, Peter; Hovind, Peter et al.
In: Diabetes, Vol. 55, No. 12, 12.2006, p. 3550-5.

122. **Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study.** / Astrup, Anne Sofie; Nielsen, Flemming S; Rossing, Peter et al.
In: Journal of Hypertension, Vol. 25, No. 12, 12.2007, p. 2479-85.

123. **Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.** / Astrup, A S; Tarnow, L; Christiansen, M et al.
In: Diabetic Medicine, Vol. 24, No. 12, 12.2007, p. 1381-5.

124. **Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.** / Persson, Frederik; Rossing, Peter; Hovind, Peter et al.
In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 68, No. 8, 2008, p. 731-8.

125. **ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.** / Parving, Hans-Henrik; de Zeeuw, Dick; Cooper, Mark E et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 19, No. 4, 04.2008, p. 771-9.

126. **Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.** / Lajer, Maria Stenkil; Tarnow, Lise; Jorsal, Anders et al.
In: Diabetes Care, Vol. 31, No. 4, 04.2008, p. 747-52.

127. **Long-term prevention of diabetic nephropathy: an audit.** / Schjoedt, K J; Hansen, H P; Tarnow, L et al.
In: Diabetologia, Vol. 51, No. 6, 06.2008, p. 956-61.

128. **Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.** / Astrup, Anne Sofie; Tarnow, Lise; Pietraszek, Lotte et al.
In: Diabetes Care, Vol. 31, No. 6, 06.2008, p. 1170-6.

129. **Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.** / Nguyen, Tri Q; Tarnow, Lise; Jorsal, Anders et al.
In: Diabetes Care, Vol. 31, No. 6, 06.2008, p. 1177-82.

130. **Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.** / Persson, F; Rossing, P; Schjoedt, K J et al.
In: Kidney International, Vol. 73, No. 12, 06.2008, p. 1419-25.

131. **The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy.** / Rossing, Kasper; Mischak, Harald; Rossing, Peter et al.
In: Proteomics - Clinical Applications, Vol. 2, No. 7-8, 07.2008, p. 997-1007.

132. **Urinary proteomics in diabetes and CKD.** / Rossing, Kasper; Mischak, Harald; Dakna, Mohammed et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 19, No. 7, 07.2008, p. 1283-90.

133. **Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.** / Leth, Henrik; Andersen, Kristian Kjær; Frystyk, Jan et al.
In: The Journal of clinical endocrinology and metabolism, Vol. 93, No. 8, 08.2008, p. 3186-91.

134. **Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.** / Jorsal, Anders; Tarnow, Lise; Frystyk, Jan et al.
In: Kidney International, Vol. 74, No. 5, 09.2008, p. 649-54.

135. **Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.** / Lund, Søren Søgaard; Tarnow, Lise; Astrup, Anne Sofie et al.
In: P L o S One, Vol. 3, No. 10, 09.10.2008, p. e3363.

136. **Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.** / Jorsal, A; Tarnow, L; Flyvbjerg, A et al.
In: Diabetologia, Vol. 51, No. 11, 11.2008, p. 2100-7.

137. **Is renal Na+,K+-ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?** / Rossing, Peter.
In: The Journal of physiology, Vol. 586, No. 22, 15.11.2008, p. 5283.

138. **Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.** / Schjoedt, K J; Astrup, A S; Persson, Frederik Ivar et al.
In: Diabetologia, Vol. 52, No. 1, 2009, p. 46-9.

139. **Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.** / Persson, Frederik; Rossing, Peter; Reinhard, Henrik et al.
In: Diabetes Care, Vol. 32, No. 10, 2009, p. 1873-9.

140. **Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.** / Hovind, Peter; Rossing, Peter; Tarnow, Lise et al.
In: Diabetes, Vol. 58, No. 7, 2009, p. 1668-71.

141. **Follow-up of intensive glucose control in type 2 diabetes.** / Lund, Søren S; Rossing, Peter; Vaag, Allan A.
In: The New England journal of medicine, Vol. 360, No. 4, 22.01.2009, p. 416; author reply 418.

142. **YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.** / Rathcke, Camilla Noelle; Persson, Frederik; Tarnow, Lise et al.
In: Diabetes Care, Vol. 32, No. 2, 02.2009, p. 323-8.

143. **Klinisk vurdering af ekskretorisk nyrefunktion dansk nefrologisk selskab.** / Petersen, Lars Juhl; Birn, Henrik; Ladefoged, Søren A. et al.
In: Ugeskrift for Laeger, Vol. 171, No. 13, 01.03.2009.

144. **Klinisk vurdering af ekskretorisk nyrefunktion.** / Petersen, Lars Juhl; Birn, Henrik; Ladefoged, Søren A et al.
In: Ugeskrift for Laeger, Vol. 171, No. 13, 23.03.2009, p. 1090.

145. **Hypertension og diabetes mellitus.** / Poulsen, Per Løgstrup; Hansen, Klavs Würgler; Gaede, Peter Haulund et al.
In: Ugeskrift for Laeger, Vol. 171, No. 24, 08.06.2009, p. 2031-4.

146. **Tubular and glomerular injury in diabetes and the impact of ACE inhibition.** / Nielsen, Stine E; Sugaya, Takeshi; Tarnow, Lise et al.
In: Diabetes Care, Vol. 32, No. 9, 09.2009, p. 1684-8.

147. **Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.** / Lund, S S; Tarnow, Lise; Bording Astrup, Anne Sofie et al.
In: Diabetes, Obesity and Metabolism, Vol. 11, No. 10, 01.10.2009, p. 966-77.

148. **Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.** / Schjoedt, Katrine J; Christensen, Per K; Jorsal, Anders et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 24, No. 11, 11.2009, p. 3343-9.

149. **Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.** / Tarnow, Inge; Michelson, Alan D; Barnard, Marc R et al.
In: Platelets, Vol. 20, No. 7, 11.2009, p. 513-9.

150. **Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy.** / Overgaard, Anne Julie; Hansen, Henning Gram; Lajer, Maria et al.
In: Proteome Science, Vol. 8, 2010, p. 4.

151. **Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.** / Lajer, Maria Stenkil; Tarnow, Inge; Michelson, Alan D et al.
In: Platelets, Vol. 21, No. 7, 2010, p. 525-32.

152. **Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.** / Andersen, Sten Peder; Mischak, Harald; Zürbig, Petra et al.
In: B M C Nephrology, Vol. 11, 01.01.2010, p. 29.

153. **Development and validation of GFR-estimating equations using diabetes, transplant and weight.** / Stevens, Lesley A; Schmid, Christopher H; Zhang, Yaping L et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 25, No. 2, 02.2010, p. 449-57.

154. **Systems biology to battle vascular disease.** / Dominiczak, Anna F; Herget-Rosenthal, Stefan; Delles, Christian et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 25, No. 4, 04.2010, p. 1019-22.

155. **Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.** / Nielsen, Stine Elkjaer; Sugaya, Takeshi; Hovind, Peter et al.
In: Diabetes Care, Vol. 33, No. 6, 01.06.2010, p. 1320-4.

156. **Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.** / Lajer, Maria Stenkil; Jorsal, Anders; Tarnow, Lise et al.
In: Diabetes Care, Vol. 33, No. 7, 01.07.2010, p. 1567-72.

157. **Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.** / Nin, Johanna W M; Jorsal, Anders; Merces Ferreira, Isabel Maria et al.
In: Diabetes, Vol. 59, No. 8, 01.08.2010, p. 2027-32.

158. **Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.** / Persson, Frederik Ivar; Rossing, P; Reinhard, H et al.
In: Diabetologia, Vol. 53, No. 8, 01.08.2010, p. 1576-80.

159. **Recommendations for biomarker identification and qualification in clinical proteomics.** / Mischak, Harald; Allmaier, Günter; Apweiler, Rolf et al.
In: Science translational medicine, Vol. 2, No. 46, 25.08.2010, p. 46ps42.

160. **Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis.** / Hansen, Henning G; Overgaard, Julie; Lajer, Maria et al.
In: Proteomics - Clinical Applications, Vol. 4, No. 8-9, 09.2010, p. 697-705.

161. **Proteomic biomarkers in diabetic nephropathy--reality or future promise?** / Mischak, Harald; Rossing, Peter.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 25, No. 9, 09.2010, p. 2843-5.

162. **Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.** / Maahs, David M; Siwy, Justyna; Argilés, Angel et al.
In: P L o S One, Vol. 5, No. 9, 28.09.2010.

163. **Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study (Diabetes (2009) 58 (1668-1671)).** / Hovind, P.; Rossing, P.; Tarnow, L. et al.
In: Diabetes, Vol. 59, No. 10, 01.10.2010.

164. **Vitamin D levels and mortality in type 2 diabetes.** / Joergensen, Christel; Gall, Mari-Anne; Schmedes, Anne et al.
In: Diabetes Care, Vol. 33, No. 10, 01.10.2010, p. 2238-43.

165. **Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy.** / Alkhalaf, Alaa; Zürbig, Petra; Bakker, Stephan J L et al.
In: P L o S One, Vol. 5, No. 10, 20.10.2010, p. e13421.

166. **Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.** / Persson, Frederik; Lewis, Julia B; Lewis, Edmund J et al.
In: Diabetes Care, Vol. 33, No. 11, 01.11.2010, p. 2304-9.

167. **Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals.** / Delles, Christian; Schiffer, Eric; von Zur Muhlen, Constantin et al.
In: Journal of Hypertension, Vol. 28, No. 11, 01.11.2010, p. 2316-22.

168. **Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients.** / Overgaard, Anne Julie; Thingholm, Tine E; Larsen, Martin R et al.
In: Clinical Proteomics, Vol. 6, No. 4, 12.2010, p. 105-114.

169. **Osteoprotegerin and mortality in type 2 diabetic patients.** / Reinhard, Henrik; Lajer, Maria Stenkil; Gall, Mari-Anne et al.
In: Diabetes Care, Vol. 33, No. 12, 01.12.2010, p. 2561-6.

170. **Urinary Neutrophil Gelatinase-Associated Lipocalin and Progression of Diabetic Nephropathy in Type 1 Diabetic Patients in a Four-Year Follow-Up Study.** / Nielsen, Stine Elkjaer; Hansen, Henrik Post; Jensen, Berit Ruud et al.
In: Nephron Clinical Practice, Vol. 118, No. 2, 15.12.2010, p. c130-c135.

171. **Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.** / Persson, Frederik; Lewis, Julia B; Lewis, Edmund J et al.
In: American Society of Nephrology. Clinical Journal, Vol. 6, No. 5, 2011, p. 1025-31.

172. **Diabetic Nephropathy.** / Parving, Hans-Henrik Dyring; Mauer, Michael; Fioretto, Paola et al.
Brenner and Rector's The Kidney. ed. / Maarten W. Taal et al. 9. ed. W. B. Saunders Company, 2011. p. 1411.

173. **Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.** / Reinhard, Henrik; Hansen, Peter R; Persson, Frederik et al.
In: Nephrology, Dialysis, Transplantation, Vol. 26, No. 10, 2011, p. 3242-9.

174. **Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy.** / Reinhard, Henrik; Jacobsen, Peter Karl; Lajer, Maria Stenkil et al.
In: Nephron Clinical Practice, Vol. 118, No. 3, 2011, p. c309-14.

175. **Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes.** / Cangemi, Claudia; Skov, Vibe; Poulsen, Michael Kjaer et al.
In: Clinical Chemistry (Washington, DC), Vol. 57, No. 11, 2011, p. 1556-65.

176. **initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.** / Hellemons, Merel E; Persson, Frederik; Bakker, Stephan J L et al.
In: Diabetes Care, Vol. 34, No. 9, 2011, p. 2078-83.

177. **NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis.** / Reinhard, Henrik; Wiinberg, Niels; Hansen, Peter R et al.
In: Cardiovascular Diabetology, Vol. 10, 2011, p. 71.

178. **Omics-bioinformatics in the context of clinical data.** / Mayer, Gert; Heinze, Georg; Mischak, Harald et al.
In: Methods in molecular biology, Vol. 719, 2011, p. 479-97.

179. **Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.** / Reinhard, Henrik; Nybo, Mads; Hansen, Peter R et al.
In: Cardiovascular Diabetology, Vol. 10, 2011, p. 70.

180. **The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes.** / Dendooven, Amélie; Nguyen, Tri Q; Brosens, Lodewijk et al.
In: Journal of Negative Results in BioMedicine, Vol. 10, 2011, p. 4.

181. **Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.** / Nielsen, Stine E; Andersen, Steen; Zdunek, Dietmar et al.
In: Kidney International, Vol. 79, No. 10, 2011, p. 1113-8.

182. **Serum uric acid as a new player in the development of diabetic nephropathy.** / Hovind, Peter; Rossing, Peter; Johnson, Richard J et al.
In: Journal of Renal Nutrition, Vol. 21, No. 1, 01.01.2011, p. 124-7.

183. **Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.** / Nin, Johanna W; Jorsal, Anders; Ferreira, Isabel et al.
In: Diabetes Care, Vol. 34, No. 2, 02.2011, p. 442-7.

184. **Need for better diabetes treatment for improved renal outcome.** / Rossing, Peter; de Zeeuw, Dick.
In: Kidney International, Supplement, No. 120, 03.2011, p. S28-32.

185. **Irbesartan treatment does not influence plasma levels of the advanced glycation end products N{varepsilon}(1-carboxymethyl)lysine and N{varepsilon}(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.** / Engelen, Lian; Persson, Frederik; Ferreira, Isabel et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 26, No. 11, 08.03.2011, p. 3573-3577.

186. **Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy.** / Broedbaek, Kasper; Henriksen, Trine; Weimann, Allan et al.
In: Diabetes Care, Vol. 34, No. 5, 01.05.2011, p. 1192-8.

187. **Vitamin D levels, microvascular complications, and mortality in type 1 diabetes.** / Joergensen, Christel; Hovind, Peter; Schmedes, Anne et al.
In: Diabetes Care, Vol. 34, No. 5, 01.05.2011, p. 1081-5.

188. **Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.** / Astor, Brad C; Matsushita, Kunihiro; Gansevoort, Ron T et al.
In: Kidney International, Vol. 79, No. 12, 06.2011, p. 1331-40.

189. **Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.** / O'goshi, Kenichiro; Serup, Jørgen; Blaaholm, Bente et al.
In: Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), Vol. 17, No. 4, 11.2011, p. 411-9.

190. **Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients.** / Mogensen, Ulrik Madvig; Jensen, Tonny; Køber, Lars et al.
In: Diabetes, Vol. 61, No. 7, 2012, p. 1822-30.

191. **Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.** / Rabbani, Naila; Adaikalakoteswari, Antonysunil; Rossing, Kasper et al.
In: Amino Acids, Vol. 42, No. 5, 2012, p. 1627-39.

192. **High YKL-40 levels predict mortality in patients with type 2 diabetes.** / Persson, Frederik; Rathcke, Camilla Noelle; Gall, Mari-Anne et al.
In: Diabetes Research and Clinical Practice, Vol. 96, No. 1, 2012, p. 84-9.

193. **Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.** / Persson, Frederik; Lewis, Julia B; Lewis, Edmund J et al.
In: Journal of the Renin-Angiotensin-Aldosterone System, Vol. 13, No. 2, 2012, p. 250-3.

194. **Kvalitetssikring i forbindelse med en folkesygdom: diabetes.** / Rossing, P; Adolphsen, H; Ravnkilde, SS et al.
In: Ugeskrift for Laeger, Vol. 174, No. 42, 2012, p. 2551.

195. **New susceptibility loci associated with kidney disease in type 1 diabetes.** / Sandholm, Niina; Salem, Rany M; McKnight, Amy Jayne et al.
In: P L o S Genetics, Vol. 8, No. 9, 2012, p. e1002921.

196. **NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients.** / Reinhard, Henrik; Hansen, Peter R; Wiinberg, Niels et al.
In: Cardiovascular Diabetology, Vol. 11, 2012, p. 19.

197. **Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients.** / Overgaard, Anne Julie; McGuire, James N; Hovind, Peter et al.
In: Journal of Diabetes and its Complications, Vol. 27, No. 1, 2012, p. 59-63.

198. **Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.** / Nielsen, S E; Persson, F; Frandsen, E et al.
In: Diabetic Medicine, Vol. 29, No. 8, 2012, p. e184-90.

199. **The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.** / Nielsen, Stine; Rossing, Kasper; Hess, Georg et al.
In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 72, No. 2, 2012, p. 137-42.

200. **Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.** / Nielsen, Stine; Reinhard, Henrik; Zdunek, Dietmar et al.
In: Diabetes Research and Clinical Practice, Vol. 97, No. 1, 2012, p. 71-6.

201. **Urinary proteomics for early diagnosis in diabetic nephropathy.** / Zürbig, Petra; Jerums, George; Hovind, Peter et al.
In: Diabetes, Vol. 61, No. 12, 2012, p. 3304-13.

202. **Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate.** / Joergensen, Christel; Reinhard, Henrik; Schmedes, Anne et al.
In: Diabetes Care, Vol. 35, No. 1, 2012, p. 168-72.

203. **Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.** / Persson, Frederik; Lewis, Julia B; Lewis, Edmund J et al.
In: Journal of the renin-angiotensin-aldosterone system : JRAAS, Vol. 13, No. 1, 03.2012, p. 118-21.

204. **The authors reply.** / Nielsen, Stine E.; Rossing, Peter.
In: Kidney International, Vol. 81, No. 7, 01.04.2012.

205. **Assessment of kidney function: UACR--two risk markers or a 24 h collection in a minute?** / Rossing, Peter.
In: Nature Reviews Nephrology, Vol. 8, No. 6, 08.05.2012, p. 320-1.

206. **Ambulatory tonometric blood pressure measurements in patients with diabetes.** / Theilade, Simone; Joergensen, Christel; Persson, Frederik et al.
In: Diabetes Technology and Therapeutics, Vol. 14, No. 6, 06.2012, p. 453-6.

207. **Implementation of proteomic biomarkers: making it work.** / Mischak, Harald; Ioannidis, John P A; Argilés, Angel et al.
In: European Journal of Clinical Investigation, Vol. 42, No. 9, 09.2012, p. 1027-36.

208. **Nyresygdom ved type 2-diabetes.** / Persson, Frederik; Rossing, Peter.
In: Ugeskrift for Laeger, Vol. 174, No. 37, 10.09.2012, p. 2150-4.

209. **Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes.** / Theilade, Simone; Lajer, Maria Stenkil; Joergensen, Christel et al.
In: Journal of Clinical Hypertension, Vol. 14, No. 10, 10.2012, p. 686-93.

210. **Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients.** / Reinhard, Henrik; Garde, Ellen; Skimminge, Arnold et al.
In: Cardiovascular Diabetology, Vol. 11, No. 1, 03.10.2012.

211. **Kvalitetssikring i behandling af en folkesygdom: diabetes.** / Rossing, Peter; Adolphsen, Helle; Stenkær Ravnkilde, Susanne et al.
In: Ugeskrift for Laeger, Vol. 174, No. 42, 15.10.2012, p. 2551.

212. **Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.** / Fox, Caroline S; Matsushita, Kunihiro; Woodward, Mark et al.
In: Lancet, Vol. 380, No. 9854, 10.11.2012, p. 1662-73.

213. **Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.** / Mahmoodi, Bakhtawar K; Matsushita, Kunihiro; Woodward, Mark et al.
In: Lancet, Vol. 380, No. 9854, 10.11.2012, p. 1649-61.

214. **Direct renin inhibition in chronic kidney disease.** / Persson, Frederik; Rossing, Peter; Parving, Hans-Henrik.
In: British Journal of Clinical Pharmacology, Vol. 76, No. 4, 2013, p. 580-86.

215. **Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.** / Nielsen, Stine; Schjoedt, Katrine J; Rossing, Kasper et al.
In: Journal of the Renin-Angiotensin-Aldosterone System, Vol. 14, No. 2, 2013, p. 161-6.

216. **Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population.** / Skaaby, Tea; Husemoen, Lise Lotte Nystrup; Pisinger, Charlotta et al.
In: Endocrine, Vol. 44, No. 2, 2013, p. 473-80.

217. **Diabetes: Effect of vitamin D on diabetic kidney disease in T1DM.** / Rossing, Peter; Joergensen, Christel.
In: Nature reviews. Endocrinology, Vol. 9, No. 1, 01.2013, p. 6-7.

218. **RNA oxidation and albuminuria in type 1 diabetes patients.** / Broedbaek, Kasper; Andersen, Jon T.; Jimenez-Solem, Espen et al.
In: Cardiovascular Endocrinology, Vol. 2, No. 4, 01.01.2013, p. 103-105.

219. **A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.** / Roscioni, S S; de Zeeuw, D; Hellemons, Merel E et al.
In: Diabetologia, Vol. 56, No. 2, 02.2013, p. 259-67.

220. **Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes.** / Alkayyali, S; Lajer, M; Deshmukh, H et al.
In: Diabetologia, Vol. 56, No. 2, 02.2013, p. 323-9.

221. **Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes.** / Theilade, Simone; Lajer, Maria Stenkil; Persson, Frederik et al.
In: Diabetes Care, Vol. 36, No. 3, 03.2013, p. 715-21.

222. **Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?** / Rossing, Peter.
In: Nature Reviews Nephrology, Vol. 9, No. 3, 03.2013, p. 128-30.

223. **Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes.** / Andrésdóttir, Gudbjörg ; Bakker, S J L; Hansen, H P et al.
In: Diabetic Medicine Online, Vol. 30, No. 5, 05.2013, p. 563-6.

224. **Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices.** / Theilade, Simone; Hansen, Tine W; Joergensen, Christel et al.
In: Blood Pressure Monitoring, Vol. 18, No. 3, 06.2013, p. 156-60.

225. **Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.** / Maahs, David M; Caramori, Luiza; Cherney, David Z I et al.
In: Current Diabetes Reports, Vol. 13, No. 4, 08.2013, p. 550-9.

226. **Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?** / Persson, Frederik; Lu, Xifeng; Rossing, Peter et al.
In: Journal of Hypertension, Vol. 31, No. 8, 08.2013, p. 1646-52.

227. **24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study.** / Theilade, Simone; Lajer, Maria Stenkil; Hansen, Tine Willum et al.
In: Cardiovascular Diabetology, Vol. 12, 27.08.2013, p. 122.

228. **Diabetes mellitus, hypertension and albuminuria in rural Zambia: a hospital-based survey.** / Rasmussen, Jon B; Thomsen, Jakúp A; Rossing, Peter et al.
In: Tropical medicine & international health : TM & IH, Vol. 18, No. 9, 09.2013, p. 1080-1084.

229. **Clinical use of estimated glomerular filtration rate for evaluation of kidney function.** / Broberg, Bo; Lindhardt, Morten; Rossing, Peter et al.
In: Ugeskrift for Laeger, Vol. 175, No. 40, 30.09.2013, p. 2333-2336.

230. **Can ADAMTS13 lead us to the paradise of personalized medicine?** / Rossing, Peter; Lajer, Maria.
In: Diabetes, Vol. 62, No. 10, 10.2013, p. 3331-2.

231. **Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment.** / Albalat, Amaya; Stalmach, Angelique; Bitsika, Vasiliki et al.
In: Proteomics, Vol. 13, No. 20, 10.2013, p. 2967-75.

232. **Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes.** / Jorsal, Anders; Petersen, Emilie Hein; Tarnow, Lise et al.
In: Journal of Diabetes and its Complications, Vol. 27, No. 6, 12.2013, p. 604-8.

233. **Cause-specific mortality according to urine albumin creatinine ratio in the general population.** / Skaaby, Tea; Husemoen, Lise Lotte Nystrup; Ahluwalia, Tarunveer Singh et al.
In: P L o S One, Vol. 9, No. 3, 2014, p. e93212.

234. **Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.** / Ruilope, Luis M; Agarwal, Rajiv; Chan, Juliana C et al.
In: American Journal of Nephrology, Vol. 40, No. 6, 2014, p. 572-81.

235. **Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia.** / Bello, Natalie A; Pfeffer, Marc A; Skali, Hicham et al.
In: BMJ open diabetes research & care, Vol. 2, No. 1, 2014, p. e000011.

236. **SVAR: Det nytter at diagnosticere diabetes tidligt.** / Rossing, Peter.
In: Ugeskrift for Laeger, Vol. 176, No. 21, 01.01.2014.

237. **Sequential RAAS blockade: is it worth the risk?** / Persson, Frederik; Rossing, Peter.
In: Advances in Chronic Kidney Disease, Vol. 21, No. 2, 03.2014, p. 159-65.

238. **Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study.** / Jensen, Magnus T; Sogaard, Peter; Andersen, Henrik U et al.
In: Diabetologia, Vol. 57, No. 4, 04.2014, p. 672-80.

239. **Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetes.** / von Scholten, Bernt Johan; Theilade, Simone; Lajer, Maria et al.
In: Nephron, Vol. 4, No. 2, 05.2014, p. 127-33.

240. **Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test.** / Fan, Li; Inker, Lesley A; Rossert, Jerome et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 29, No. 6, 06.2014, p. 1195-203.

241. **Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors.** / Andrésdóttir, Gudbjörg; Jensen, Majken; Carstensen, Bendix et al.
In: Diabetes Care, Vol. 37, No. 6, 06.2014, p. 1660-7.

242. **Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.** / Siwy, Justyna; Schanstra, Joost P; Argilés, Angel et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 29, No. 8, 08.2014, p. 1563-70.

243. **Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes.** / Theilade, Simone; Hansen, Tine W; Rossing, Peter.
In: American Journal of Hypertension, Vol. 27, No. 9, 09.2014, p. 1152-9.

244. **Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus.** / Pena, M J; Lambers Heerspink, H J; Hellemons, M E et al.
In: Diabetic Medicine Online, Vol. 31, No. 9, 09.2014, p. 1138-47.

245. **Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study.** / Østergaard, Jakob Appel; Thiel, Steffen; Hovind, Peter et al.
In: Diabetologia, Vol. 57, No. 10, 10.2014, p. 2201-7.

246. **Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes.** / Theilade, Simone; Lajer, Maria; Hansen, Tine Willum et al.
In: Acta Diabetologica, Vol. 51, No. 6, 12.2014, p. 973-80.

247. **Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness.** / Vestergaard Rosenlund, Signe; Theilade, Simone; Hansen, Tine Willum et al.
In: Acta Diabetologica, Vol. 51, No. 6, 12.2014, p. 955-62.

248. **Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes.** / von Scholten, Bernt Johan; Reinhard, Henrik; Hansen, Tine Willum et al.
In: Cardiovascular Diabetology, Vol. 14, 2015, p. 59.

249. **Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction.** / Gerritsen, Karin G F; Leeuwis, Jan Willem; Koeners, Maarten P et al.
In: Journal of Diabetes Research, Vol. 2015, 2015, p. 539787.

250. **Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study.** / Hove, K D; Brøns, C; Færch, K et al.
In: European journal of endocrinology / European Federation of Endocrine Societies, Vol. 172, No. 1, 01.2015, p. 11-20.

251. **Microalbuminuria: A parameter that has changed diabetes care.** / Parving, Hans-Henrik; Persson, Frederik; Rossing, Peter.
In: Diabetes Research and Clinical Practice, Vol. 107, No. 1, 01.2015, p. 1-8.

252. **Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy.** / Parving, Hans-Henrik; Rossing, Peter.
In: Nature Reviews Nephrology, Vol. 11, No. 2, 02.2015, p. 68-70.

253. **Improved prognosis of diabetic nephropathy in type 1 diabetes.** / Andrésdóttir, Gudbjörg; Jensen, Majken L; Carstensen, Bendix et al.
In: Kidney International, Vol. 87, No. 2, 02.2015, p. 417-26.

254. **Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.** / Theilade, S; Lyngbaek, S; Hansen, T W et al.
In: Journal of Internal Medicine, Vol. 277, No. 3, 03.2015, p. 362-71.

255. **SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes.** / Germain, Marine; Pezzolesi, Marcus G; Sandholm, Niina et al.
In: Diabetologia, Vol. 58, No. 3, 03.2015, p. 543-8.

256. **Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.** / von Scholten, B J; Lajer, M; Goetze, J P et al.
In: Diabetic Medicine, Vol. 32, No. 3, 03.2015, p. 343-52.

257. **Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.** / Joergensen, C; Tarnow, L; Goetze, J P et al.
In: Diabetic Medicine Online, Vol. 32, No. 3, 03.2015, p. 374-81.

258. **Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia-the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).** / Theilade, S; Claggett, B; Hansen, T W et al.
In: Journal of Hypertension, Vol. 30, 26.03.2015, p. 46-52.

259. **Global Longitudinal Strain Is Not Impaired in Type 1 Diabetes Patients Without Albuminuria: The Thousand & 1 Study.** / Jensen, Magnus Thorsten; Sogaard, Peter; Andersen, Henrik Ullits et al.
In: JACC. Cardiovascular imaging, Vol. 8, No. 4, 04.2015, p. 400-10.

260. **The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.** / Schievink, Bauke; de Zeeuw, Dick; Parving, Hans-Henrik et al.
In: British Journal of Clinical Pharmacology, Vol. 80, No. 4, 14.04.2015, p. 678-86.

261. **Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines.** / Warrer, Pernille; Jensen, Peter Bjødstrup; Aagaard, Lise et al.
In: Journal of Research in Pharmacy Practice, Vol. 4, No. 2, 20.05.2015, p. 64-72.

262. **Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.** / Theilade, Simone; Hansen, Tine Willum; Goetze, Jens Peter et al.
In: American Journal of Hypertension, Vol. 28, No. 6, 06.2015, p. 772-9.

263. **IGFBP-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients with and without nephropathy.** / Hjortebjerg, Rikke; Tarnow, Lise; Jorsal, Anders et al.
In: The Journal of clinical endocrinology and metabolism, Vol. 100, No. 8, 05.06.2015, p. 3032-40.

264. **Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes.** / Brott, David A; Furlong, Stephen T; Adler, Scott H et al.
In: Drug Design, Development and Therapy, Vol. 9, 22.06.2015, p. 3191-8.

265. **Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.** / von Scholten, Bernt Johan; Hansen, Tine Willum; Goetze, Jens Peter et al.
In: Journal of Diabetes and its Complications, Vol. 29, No. 5, 07.2015, p. 670-4.

266. **Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?** / Mann, Johannes F E; Rossing, Peter; Wicek, Andrzej et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 30 Suppl 4, 24.07.2015, p. iv1-5.

267. **Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.** / Pena, Michelle J; de Zeeuw, Dick; Mischak, Harald et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 30 Suppl 4, 24.07.2015, p. iv86-95.

268. **Diabetic kidney disease.** / Thomas, Merlin C; Brownlee, Michael; Susztak, Katalin et al.
In: Nature reviews. Disease primers, Vol. 1, 30.07.2015, p. 15018.

269. **Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.** / Schanstra, Joost P; Zürbig, Petra; Alkhalaf, Alaa et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 26, No. 8, 08.2015, p. 1999-2010.

270. **Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes.** / Swan, E J; Salem, R M; Sandholm, N et al.
In: Diabetic Medicine Online, Vol. 32, No. 8, 08.2015, p. 1104-9.

271. **Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.** / Bakris, George L; Agarwal, Rajiv; Chan, Juliana C et al.
In: JAMA - Journal of the American Medical Association, Vol. 314, No. 9, 01.09.2015, p. 884-94.

272. **Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study.** / Vestergaard Rosenlund, Signe; Hansen, Tine Willum; Andersen, Steen et al.
In: Diabetic Medicine Online, Vol. 32, No. 11, 02.09.2015, p. 1445-52.

273. **The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.** / von Scholten, Bernt Johan; Ørsted, David Dynnes; Svendsen, Anne Louise et al.
In: Journal of Diabetes and its Complications, Vol. 29, No. 8, 09.09.2015, p. 1146-51.

274. **Effect of sensor-augmented pump treatment vs. multiple daily injections on albuminuria: a 1 year randomized study.** / Vestergaard Rosenlund, Signe; Willum Hansen, Tine; Rossing, Peter et al.
In: The Journal of clinical endocrinology and metabolism, Vol. 100, No. 11, jc20152839, 21.09.2015, p. 4181-88.

275. **Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study.** / Østergaard, Jakob A; Thiel, Steffen; Lajer, Maria et al.
In: Diabetes Care, Vol. 38, No. 10, 10.2015, p. 1898-903.

276. **Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes.** / Pena, Michelle J; Jankowski, Joachim; Heinze, Georg et al.
In: Journal of Hypertension, Vol. 33, No. 10, 10.2015, p. 2123-32.

277. **Cuff inflations do not affect night-time blood pressure: comparison of 24 h ambulatory blood pressure measured by a cuff and a tonometric device in type 2 diabetes.** / Zobel, Emilie Hein; Theilade, Simone; Hansen, Tine W et al.
In: Blood Pressure Monitoring, Vol. 20, No. 6, 12.2015, p. 369-72.

278. **Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci.** / Nexø, Bjørn A; Villesen, Palle; Nissen, Kari K et al.
In: Immunologic Research, Vol. 64, No. 1, 2016, p. 55-63.

279. **Diabetic Nephropathy.** / Rossing, Peter; Fioretto, P; Feldt-Rasmussen, Bo Friis et al.
Brenner and Rector`s The Kidney. 10. ed. Elsevier, 2016. p. 1283-1321.

280. **Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.** / Currie, Gemma; Taylor, Alison H M; Fujita, Toshiro et al.
In: BMC Nephrology, Vol. 17, No. 1, 2016, p. 127.

281. **Glucose-Dependent Insulinotropic Polypeptide (GIP) Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB.** / Berglund, Lisa M; Lyssenko, Valeriya; Ladenvall, Claes et al.
In: Diabetes, Vol. 65, No. 1, 2016, p. 239-254.

282. **High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes.** / Zobel, Emilie Hein; von Scholten, Bernt J; Lajer, Maria et al.
In: Journal of Diabetes and its Complications, Vol. 30, No. 8, 2016, p. 1603-08.

283. **Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.** / von Scholten, Bernt Johan; Reinhard, Henrik; Hansen, Tine Willum et al.
In: Journal of Diabetes and its Complications, Vol. 30, No. 2, 2016, p. 248-55.

284. **Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.** / Persson, Frederik; Theilade, Simone; Eugen-Olsen, Jesper et al.
In: Journal of Diabetes and its Complications, Vol. 30, No. 8, 2016, p. 1440-42.

285. **The Danish Adult Diabetes Registry.** / Jørgensen, Marit Eika; Kristensen, Jette K; Reventlov Husted, Gitte et al.
In: Clinical Epidemiology, Vol. 8, 2016, p. 429-434.

286. **Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension.** / Rasmussen, Jon B; Nordin, Lovisa S; Thomsen, Jakúp A et al.
In: Journal of Clinical Hypertension, Vol. 18, No. 1, 01.2016, p. 27-30.

287. **Statins are independently associated with increased HbA1c in type 1 diabetes - The Thousand & 1 Study.** / Jensen, Magnus Thorsten; Andersen, Henrik Ullits; Rossing, Peter et al.
In: Diabetes Research and Clinical Practice, Vol. 111, 01.2016, p. 51-7.

288. **Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes.** / Zampetaki, Anna; Willeit, Peter; Burr, Simon et al.
In: Diabetes, Vol. 65, No. 1, 01.01.2016, p. 216-27.

289. **Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes.** / von Scholten, Bernt J; Hasbak, Philip; Christensen, Thomas E et al.
In: Diabetologia, Vol. 59, No. 2, 02.2016, p. 371-8.

290. **Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.** / Davies, Melanie J; Bain, Stephen C; Atkin, Stephen L et al.
In: Diabetes Care, Vol. 39, No. 2, 02.2016, p. 222-30.

291. **Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.** / Lindhardt, Morten; Persson, Frederik; Currie, Gemma et al.
In: B M J Open, Vol. 6, No. 3, 02.03.2016, p. e010310.

292. **Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R$^+$ T cells.** / von Scholten, Bernt Johan; Rosendahl, Alexander; Hasbak, Philip et al.
In: Cardiovascular Diabetology, Vol. 15, 19.04.2016, p. 67.

293. **Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study.** / Biering-Sørensen, Tor; Jensen, Jan Skov; Andersen, Henrik Ullits et al.
In: The international journal of cardiovascular imaging, Vol. 32, No. 5, 05.2016, p. 789-98.

294. **Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study.** / Jensen, Magnus Thorsten; Sogaard, Peter; Andersen, Henrik Ullits et al.
In: Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, Vol. 13, No. 4, 06.2016, p. 260-267.

295. **Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease.** / Theilade, Simone; Rossing, Peter; Eugen-Olsen, Jesper et al.
In: European journal of endocrinology / European Federation of Endocrine Societies, Vol. 174, No. 6, 06.2016, p. 745-753.

296. **Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients - The Thousand & 1 Study.** / Nouhravesh, Nina; Andersen, Henrik U; Jensen, Jan S et al.
In: Diabetes Research and Clinical Practice, Vol. 116, 06.2016, p. 263-9.

297. **Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.** / Persson, Frederik Ivar; Lindhardt, Morten; Rossing, Peter et al.
In: Journal of the renin-angiotensin-aldosterone system : JRAAS, Vol. 17, No. 3, 07.2016, p. pii: 1470320316652047.

298. **Self-reported dyspnea is associated with impaired global longitudinal strain in ambulatory type 1 diabetes patients with normal ejection fraction and without known heart disease - The Thousand & 1 Study.** / Jensen, Magnus Thorsten; Risum, Niels; Rossing, Peter et al.
In: Journal of Diabetes and its Complications, Vol. 30, No. 5, 07.2016, p. 928-34.

299. **Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.** / von Scholten, Bernt Johan; Reinhard, Henrik; Hansen, Tine Willum et al.
In: Diabetologia, Vol. 59, No. 7, 07.2016, p. 1549-57.

300. **Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function.** / Jørgensen, Peter G; Jensen, Magnus T; Mogelvang, Rasmus et al.
In: International Journal of Cardiology, Vol. 221, 05.07.2016, p. 114-121.

301. **Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.** / Pena, Michelle J; Heinzel, Andreas; Rossing, Peter et al.
In: Journal of Translational Medicine, Vol. 14, No. 1, 05.07.2016, p. 203.

302. **Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics.** / Jørgensen, Peter Godsk; Jensen, Magnus T; Mogelvang, Rasmus et al.
In: Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, Vol. 13, No. 5, 09.2016, p. 321-30.

303. **Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes.** / Jørgensen, Peter Godsk; Jensen, Magnus Thorsten; Biering-Sørensen, Tor et al.
In: Cardiovascular Diabetology, Vol. 15, No. 1, 22.09.2016, p. 137.

304. **Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes.** / von Scholten, Bernt Johan; Hansen, Christian Stevns; Hasbak, Philip et al.
In: Diabetes, Vol. 65, No. 10, 10.2016, p. 3129-38.

305. **Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.** / Gæde, Peter; Øllgaard, Jens Christian; Carstensen, Bendix et al.
In: Diabetologia, Vol. 59, No. 11, 11.2016, p. 2298-307.

306. **Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus.** / Jensen, T M; Vistisen, D; Fleming, T et al.
In: Diabetic Medicine Online, Vol. 33, No. 12, 15.11.2016, p. 1625-1631.

307. **Global Changes in Food Supply and the Obesity Epidemic.** / Zobel, Emilie H; Hansen, Tine W; Rossing, Peter et al.
In: Current Obesity Reports, Vol. 5, No. 4, 12.2016, p. 449-455.

308. **Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.** / Peeters, Stijn A; Engelen, Lian; Buijs, Jacqueline et al.
In: Cardiovascular Diabetology, Vol. 16, No. 1, 2017, p. e139.

309. **Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate.** / Christensen, Regitse Hoejgaard; von Scholten, Bernt Johan; Hansen, Christian S et al.
In: European journal of preventive cardiology, Vol. 24, No. 14, 2017, p. 1517-1524.

310. **Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes.** / Zobel, Emilie Hein; Theilade, Simone; Johan von Scholten, Bernt et al.
In: Diabetes Care, Vol. 40, No. 3, 2017, p. e32-e33.

311. **Higher Plasma Methylglyoxal Levels are Associated with Incident Cardiovascular Disease in Individuals with Type 1 Diabetes: a 12-Year Follow-Up Study.** / Hanssen, Nordin M J; Scheijen, Jean L J M; Jorsal, Anders et al.
In: Diabetes, Vol. 66, No. 8, 2017, p. 2278-83.

312. **Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.** / Peeters, S A; Engelen, Lian; Buijs, J et al.
In: Cardiovascular Diabetology, Vol. 16, No. 1, 2017, p. e55.

313. **Reduced sublingual endothelial glycocalyx in type 1 diabetic patients with diabetic nephropathy.** / Winther, Signe Abitz; Frimodt-Møller, Marie; Zobel, Emilie Hein et al.
2017. Abstract from 30th Annual General Meeting of the European Diabetic Nephropathy Study Group, EDNSG, Helsinki, Finland.

314. **Reduced sublingual endothelial glycocalyx in type 1 diabetics with diabetic nephropathy.** / Winther, Signe Abitz; Frimodt-Møller, Marie; Zobel, Emilie Hein et al.
2017. Abstract from Association for Research into Arterial Structure and Physiology (ARTERY) 17th Conference , Pisa, Toscana, Italy.

315. **Three-phase bone scintigraphy for diagnosis of Charcot neuropathic osteoarthropathy in the diabetic foot - does quantitative data improve diagnostic value?** / Fosbøl, M; Reving, S; Petersen, E H et al.
In: Clinical Physiology and Functional Imaging, Vol. 37, No. 1, 2017, p. 30-36.

316. **Trimethylamine N-oxide (TMAO) as a new potential therapeutic target for insulin resistance and cancer.** / Oellgaard, Jens; Winther, Signe Abitz; Hansen, Tobias Schmidt et al.
In: Current Pharmaceutical Design, Vol. 23, No. 25, 2017, p. 3699-3712.

317. **Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.** / Zobel, Emilie Hein; von Scholten, Bernt Johan; Lindhardt, Morten et al.
In: Journal of Diabetes and its Complications, Vol. 31, No. 1, 01.2017, p. 162-168.

318. **The effect of liraglutide on renal function: A randomized clinical trial.** / von Scholten, Bernt J; Persson, Frederik; Rosenlund, Signe et al.
In: Diabetes, Obesity and Metabolism, Vol. 19, No. 2, 02.2017, p. 239-247.

319. **The Genetic Landscape of Renal Complications in Type 1 Diabetes.** / Sandholm, Niina; van Zuydam, Natalie R; Ahlqvist, Emma et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 28, No. 2, 02.2017, p. 557-574.

320. **Effect of large weight reductions on measured and estimated kidney function.** / von Scholten, Bernt Johan; Persson, Frederik; Svane, Maria S et al.
In: BMC Nephrology, Vol. 18, No. 1, 01.02.2017, p. 52.

321. **Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans.** / Zois, Nora E; Terzic, Dijana; Færch, Kristine et al.
In: EBioMedicine, Vol. 17, 03.2017, p. 88-94.

322. **Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.** / Mayer, Gert; Heerspink, Hiddo J Lambers; Aschauer, Constantin et al.
In: Diabetes Care, Vol. 40, No. 3, 03.2017, p. 391-397.

323. **Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes.** / Ostergaard, J A; Thiel, S; Hoffmann-Petersen, I T et al.
In: Diabetes - Metabolism: Research and Reviews (Online), Vol. 33, No. 5, 04.2017, p. e2895.

324. **Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.** / Oellgaard, Jens; Gaede, Peter; Rossing, Peter et al.
In: Kidney International, Vol. 91, No. 4, 04.2017, p. 982-988.

325. **Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.** / Petrie, John R; Chaturvedi, Nish; Ford, Ian et al.
In: Diabetes, Obesity and Metabolism, Vol. 19, No. 4, 04.2017, p. 509-516.

326. **Comparison of manual and automated sample preparation techniques for lipidomics.** / Ahonen, Linda; Rossing, Peter.
2017. Abstract from 65th ASMS Conference on Mass Spectrometry and Allied Topics, ASMS 2017, Indianapolis, Indiana, United States.

327. **Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.** / Krolewski, Andrzej S; Skupien, Jan; Rossing, Peter et al.
In: Kidney International, Vol. 91, No. 6, 01.06.2017, p. 1300-1311.

328. **Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial.** / von Scholten, Bernt Johan; Persson, Frederik; Rosenlund, Signe et al.
In: Diabetes, Obesity and Metabolism, Vol. 19, No. 6, 01.06.2017, p. 901-905.

329. **Variability in response to albuminuria-lowering drugs: true or random?** / Petrykiv, Sergei I.; de Zeeuw, Dick; Persson, Frederik et al.
In: British Journal of Clinical Pharmacology, Vol. 83, No. 6, 01.06.2017, p. 1197-1204.

330. **Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.** / von Scholten, Bernt Johan; Davies, Melanie J; Persson, Frederik et al.
In: Journal of Diabetes and its Complications, Vol. 31, No. 7, 07.2017, p. 1164-1168.

331. **Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.** / Zobel, Emilie H; von Scholten, Bernt Johan; Reinhard, Henrik et al.
In: Cardiovascular Diabetology, Vol. 16, No. 1, 11.07.2017, p. e88.

332. **Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.** / Petrie, John R; Chaturvedi, Nishi; Ford, Ian et al.
In: The Lancet Diabetes and Endocrinology, Vol. 5, No. 8, 08.2017, p. 597-609.

333. **Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.** / Baigent, Colin; Herrington, William G; Coresh, Josef et al.
In: Kidney International, Vol. 92, No. 2, 08.2017, p. 297-305.

334. **A urinary proteome-based classifier for the early detection of decline in glomerular filtration.** / Pontillo, Claudia; Jacobs, Lotte; Staessen, Jan A et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 32, No. 9, 09.2017, p. 1510-1516.

335. **Diabetes and Hypertension: A Position Statement by the American Diabetes Association.** / de Boer, Ian H; Bangalore, Sripal; Benetos, Athanase et al.
In: Diabetes Care, Vol. 40, No. 9, 09.2017, p. 1273-1284.

336. **Higher plasma methylglyoxal levels are associated with incident cardiovascular disease in individuals with type 1 diabetes: a 12-year follow-up study.** / Hanssen, N. M. J.; Scheijen, J. L. J.; Jorsal, A. et al.
2017. S511 Abstract from 53rd Annual Meeting of the European Association for the study of Diabetes EASD, Lisabon, Portugal.

337. **GDF-15 and FGF-23 are associated with mortality in type 2 diabetic patients with microalbuminuria.** / Frimodt-Møller, Marie; von Scholten, Bernt Johan; Reinhard, Henrik et al.
2017. Abstract from 53rd Annual Meeting of the European Association for the study of Diabetes EASD, Lisabon, Portugal.

338. **Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, mortality and deterioration in kidney function in patients with type 2 diabetes.** / Hansen, Tine Wilum; Zobel, Emilie Hein; von Scholten, Bernt Johan et al.
2017. Abstract from 53rd Annual Meeting of the European Association for the study of Diabetes EASD, Lisabon, Portugal.

339. **Cluster analyses of patients with dysregulated type 2 diabetes based on routine clinical markers reveal cluster-specific prevalence of diabetes complications.** / Ali, Ashfaq; Safai, Narges; Rossing, Peter et al.
2017. Abstract from 53rd Annual Meeting of the European Association for the study of Diabetes EASD, Lisabon, Portugal.

340. **Reduced sublingual endothelial glycocalyx in type 1 diabetic patients with diabetic nephropathy.** / Winther, Signe Abitz; Frimodt-Møller, Marie; Zobel, Emilie Hein et al.
In: Diabetologia, Vol. 60, 1084, 13.09.2017, p. S499.

341. **Risk of heart failure in intensively treated patients with type 2 diabetes and microalbuminuria: 21 years follow-up in the multifactorial Steno-2 intervention.** / Øllgaard, Jens Christian; Gæde, Peter; Rørth, Rasmus et al.
2017. Abstract from 53rd Annual Meeting of the European Association for the study of Diabetes EASD, Lisabon, Portugal.

342. **Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.** / Zobel, Emilie H.; von Scholten, Bernt Johan; Reinhard, Henrik et al.
In: Diabetologia, Vol. 60, No. 10, 10.2017, p. 1883-1891.

343. **Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes.** / Jørgensen, Peter Godsk; Biering-Sørensen, Tor; Mogelvang, Rasmus et al.
In: European heart journal cardiovascular Imaging, 03.10.2017, p. 0-8.

344. **Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.** / Galsgaard, Julie; Persson, Frederik; Hansen, Tine Willum et al.
In: Kidney International, Vol. 92, No. 5, 11.2017, p. 1242-1248.

345. **Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.** / Pontillo, Claudia; Zhang, Zhen-Yu; Schanstra, Joost P et al.
In: Kidney International Reports, Vol. 2, No. 6, 11.2017, p. 1066-1075.

346. **Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.** / Lindhardt, Morten; Persson, Frederik Ivar; Zürbig, Petra et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 32, No. 11, 11.2017, p. 1866-1873.

347. **The Effect of Uric Acid Lowering on Albuminuria and Renal Function in Type 1 Diabetes: A Randomized Clinical Trial.** / Pilemann-Lyberg, Sascha ; Persson, Frederik; Frystyk, Jan et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

348. **A Novel Marker of Collagen Type VI Formation Is Prognostic for Cardiovascular Disease, All-Cause Mortality, and Deterioration of Kidney Function in Patients with Type 2 Diabetes with Microalbuminuria.** / Guldager, Daniel Kring Rasmussen; Hansen, Tine Wilum; Nielsen, Signe Holm et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

349. **Collagen Type III Degradation Is Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes with Microalbuminuria.** / Genovese, Federica; Hansen, Tine Wilum; Guldager, Daniel Kring Rasmussen et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

350. **GDF-15 and FGF-23 Are Associated with Mortality in Type 2 Diabetic Patients with Microalbuminuria.** / Frimodt-Møller, Marie; von Scholten, Bernt Johan; Reinhard, Henrik et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

351. **Is Urinary KIM-1 a Predictor of EGFR Decline, Incident Cardiovascular Disease, and All Cause Mortality?** / Eickhoff, Mie Klessen; von Scholten, Bernt Johan; Reinhard, Henrik et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

352. **Reduced Sublingual Endothelial Glycocalyx in Type 1 Diabetic Patients with Diabetic Nephropathy.** / Winther, Signe Abitz; Frimodt-Møller, Marie; Zobel, Emilie Hein et al.
In: Journal of the American Society of Nephrology, Vol. 28, FR-PO666, 03.11.2017, p. 575.

353. **Serum and Urine Markers of Collagen Type VI Formation (Pro-C6) and Type III Degradation (C3M) Reflect Renal Function in Type 1 Diabetes.** / Hansen, Tine Wilum; Guldager, Daniel Kring Rasmussen; Pilemann-Lyberg, Sascha et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

354. **Fasting Plasma Trimethylamine-N-Oxide as a Risk Marker of Poor Renal Outcomes, Cardiovascular Disease, and Mortality in Patients with Type 1 Diabetes with Diabetic Nephropathy.** / Winther, Signe Abitz; Øllgaard, Jens Christian; Parving, Hans-Henrik Dyring et al.
In: Journal of the American Society of Nephrology, Vol. 28, SA-OR113, 04.11.2017, p. 102-103.

355. **Symmetric and Asymmetric Dimethylarginine as Risk Markers of Cardiovascular Disease, All-Cause Mortality, and Deterioration in Kidney Function in Patients with Type 2 Diabetes and Microalbuminuria.** / Persson, Frederik; Zobel, Emilie Hein; von Scholten, Bernt Johan et al.
2017. Abstract from ASN Kidney Week 2017, New Orleans, United States.

356. **Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.** / Petrykiv, Sergei I.; Laverman, Gozewijn Dirk; Persson, Frederik et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 12, No. 11, 07.11.2017, p. 1804-1813.

357. **Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.** / Siwy, Justyna; Zürbig, Petra; Argilés, Angel et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 12.2017.

358. **A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics.** / Eder, Susanne; Leierer, Johannes; Kerschbaum, Julia et al.
In: Kidney & blood pressure research, Vol. 43, No. 1, 2018, p. 181-190.

359. **Clinical Features and Natural Course of Diabetic Nephropathy.** / Rossing, Peter; Frimodt-Møller, Marie.
Diabetic Nephropathy: Pathophysiology and Clinical Aspects. ed. / Joris Roelof; Liffert Vogt. 1. ed. Springer International Publishing, 2018. p. 21-33.

360. **Effects of Dapagliflozin on Albuminuria, Renal Function, and Renin-Angiotensin-Aldosterone Hormones in Type 2 Diabetes.** / Eickhoff, Mie Klessen; Frimodt-Møller, Marie; Jørgensen, Niklas Rye et al.
In: Journal of the American Society of Nephrology, 2018, p. 770.

361. **Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study.** / Frimodt-Møller, Marie; von Scholten, Bernt Johan; Reinhard, Henrik et al.
In: P L o S One, Vol. 13, No. 4, 2018, p. e0196634.

362. **Plasma lipids are associated with diabetic kidney disease: a study of plasma lipidomics in type 1 diabetes.** / Tofte, Nete; Suvitaival, Tommi; Ahonen, Linda Linnéa et al.
In: Diabetologia, Vol. 61, No. suppl 1, 1011, 2018, p. S497-S497.

363. **Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients-the Thousand & 1 Study.** / Theilade, Simone; Rossing, Peter; Jensen, Jan S et al.
In: Acta Diabetologica, Vol. 55, No. 1, 01.2018, p. 21-29.

364. **Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort.** / Ferreira, Isabel; Hovind, Peter; Schalkwijk, Casper G et al.
In: Diabetologia, Vol. 61, No. 1, 01.2018, p. 231-241.

365. **Diagnosis of diabetic kidney disease: state of the art and future perspective.** / Persson, Frederik; Rossing, Peter.
In: Kidney International Supplements, Vol. 8, No. 1, 01.01.2018, p. 2-7.

366. **Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.** / Lindhardt, Morten; Persson, Frederik; Oxlund, Christina S et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 33, No. 2, 02.2018, p. 296–303.

367. **The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial.** / Pilemann-Lyberg, S; Persson, F; Frystyk, J et al.
In: Diabetic Medicine Online, Vol. 35, No. 3, 03.2018, p. 392-393.

368. **Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes.** / Peeters, S A; Engelen, L; Buijs, J et al.
In: Journal of Diabetes and its Complications, Vol. 32, No. 3, 01.03.2018, p. 325-329.

369. **Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives.** / Rossing, Peter; Persson, Frederik; Frimodt-Møller, Marie.
In: Nephrologie & Therapeutique, Vol. 14 Suppl 1, 04.2018, p. S31-S37.

370. **Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes.** / Pilemann-Lyberg, Sascha; Hansen, Tine Willum; Persson, Frederik et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 11.04.2018.

371. **Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes.** / Charmet, Romain; Duffy, Seamus; Keshavarzi, Sareh et al.
In: Cardiovascular Diabetology, Vol. 17, No. 1, 25.04.2018, p. 61.

372. **Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria-A Path for Improved Renoprotection?** / Rossing, Peter; Persson, Frederik.
In: Medecine/Sciences, Vol. 355, No. 5, 05.2018, p. 407-408.

373. **Altered levels of plasma lipids are associated with diabetic kidney disease: a cross-sectional study of plasma lipidomics in type 1 diabetes.** / Tofte, Nete; Suvitaival, Tommi; Ahonen, Linda Linnéa et al.
In: Nephrology Dialysis Transplantation, Vol. 33, No. Suppl 1, SP420 , 05.2018.

374. **Subclassification of diabetes based on quantitative traits.** / Rossing, Peter.
In: Nature Reviews Nephrology, Vol. 14, 05.2018, p. 355-356.

375. **COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.** / Frimodt-Moller, Marie; Genovese, Federica; Hansen, Tine et al.
In: Nephrology Dialysis Transplantation, Vol. 33, No. 1, SP418, 01.05.2018.

376. **Decreases in weight with bardoxolone methyl in obese patients with chronic kidney disease stage 4 and type 2 diabetes - post-hoc analyses from beacon.** / Rossing, Peter; Appel, Gerald; Block, Geoffrey et al.
In: Nephrology Dialysis Transplantation, Vol. 33, No. 1, SP104, 01.05.2018.

377. **Effect of bardoxolone methyl treatment on urinary albumin in patients with type 2 diabetes and chronic kidney disease - post-hoc analysis from beam and beacon.** / Rossing, Peter; Block, Geoffrey; Chertow, Glenn et al.
In: Nephrology Dialysis Transplantation, Vol. 33, No. 1, FP152, 01.05.2018.

378. **Effect of dapagliflozin on albuminuria and the renin-angiotensin system when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy.** / Eickhoff, Mie; Frimodt-Moller, Marie; Jorgensen, Niklas Rye et al.
In: Nephrology Dialysis Transplantation, Vol. 33, No. 1, SP417 , 01.05.2018.

379. **Prevalence of heart failure with preserved and reduced left ventricular ejection fraction and diagnostic value of MR-proANP in 803 outpatients with type 2 diabetes.** / Jensen, J.; Schou, M.; Kistorp, C. et al.
In: European Journal of Heart Failure, Vol. 20, No. S1, 01.05.2018, p. 432.

380. **Serum uric acid and progression of diabetic nephropathy in type 1 diabetes.** / Pilemann-Lyberg, S; Lindhardt, M; Persson, Frederik et al.
In: Journal of Diabetes and its Complications, Vol. 32, No. 5, 01.05.2018, p. 470-473.

381. **Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.** / Hansen, Tine Willum; Rasmussen, Daniel; Von Scholten, Bernt Johan et al.
2018. Abstract from The 31st Annual Meeting of the EDNSG will take place on 18th and 19th May 2018 in the University Medical Center Groningen, The Netherlands , Groningen, Netherlands.

382. **Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.** / Tofte, N; Lindhardt, M; Adamova, K et al.
In: Diabetic Medicine, Vol. 35, No. 10, 21.05.2018, p. 1375-1382.

383. **Altered somatosensory neurovascular response in patients with Becker muscular dystrophy.** / Lindberg, Ulrich; Kruuse, Christina; Witting, Nanna et al.
In: Brain and Behavior, Vol. 8, No. 6, 06.2018, p. e00985.

384. **Development and comparison of sample preparation methods for LC-MS based lipidomics on fecal samples.** / Ahonen, Linda Linnéa; Stanstrup, Jan; Mattila, Ismo et al.
2018. Abstract from 66th ASMS Conference on Mass Spectrometry and Allied Topics, San Diego, California, United States.

385. **Data Pipeline for Clinical Diabetes Metabolomics - From Targeted Mass-Spectra to Patient Stratification.** / Suvitaival, Tommi; Ahonen, Linda; Ali, Ashfaq et al.
2018. Abstract from Metabolomics 2018, Seattle, Washington, United States.

386. **A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.** / van Zuydam, Natalie R; Ahlqvist, Emma; Sandholm, Niina et al.
In: Diabetes, Vol. 67, No. 7, 07.2018, p. 1414-1427.

387. **Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.** / Rasmussen, Daniel G K; Hansen, Tine W; von Scholten, Bernt J et al.
In: Diabetes Care, Vol. 41, No. 7, 07.2018, p. 1493-1500.

388. **Stratification of type 2 diabetes based on routine clinical markers.** / Safai, Narges; Ali, Ashfaq; Rossing, Peter et al.
In: Diabetes Research and Clinical Practice, Vol. 141, 07.2018, p. 275-283.

389. **How Does Risk Screening for Kidney Disease Influence Diabetes Distress?** / Joensen, Lene Eide; Madsen, Kristoffer Panduro; Frimodt-Møller, Marie et al.
In: Diabetes, Vol. 67, No. Supplement 1, 01.07.2018.

390. **Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study.** / Oellgaard, Jens; Gæde, Peter; Rossing, Peter et al.
In: Diabetologia, Vol. 61, No. 8, 08.2018, p. 1724-1733.

391. **Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes.** / Hansen, Tine Willum; Zobel, Emilie Hein; Hasbak, Philip et al.
In: Journal of Hypertension, Vol. 36, No. e suppl 3, A3993, 20.09.2018, p. S531-S531 .

392. **Cardiac repolarization and depolarization in people with Type 1 diabetes with normal ejection fraction and without known heart disease: a case-control study.** / Isaksen, J L; Graff, C; Ellervik, C et al.
In: Diabetic Medicine Online, Vol. 35, No. 10, 10.2018, p. 1337-1344.

393. **Collagen Type III Degradation Is Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes with Microalbuminuria.** / Genovesa, Federica ; Hansen, Tine Willum; Rasmussen, Daniel Guldager Kring et al.
In: Diabetologia, Vol. 61, 1001, 10.2018, p. S492-S492.

394. **Efficacy of long-term remote ischaemic conditioning on vascular and neuronal function in type 2 diabetes patients with peripheral arterial disease.** / Hansen, Christian Stevns; Jørgensen, Marit Eika; Fleischer, Jesper et al.
In: Diabetologia, Vol. 61, No. Suppl 1, 973, 10.2018, p. S480-S480.

395. **Acute hyperoxia deteriorates nerve conduction velocity in type 1 diabetes: A possible effect on oxidative stress?** / Laursen, J. C.; Hansen, C. Stevns; Bordino, M. et al.
In: Diabetologia, Vol. 61, No. 1, 948, 01.10.2018, p. S467.

396. **Hjertesvigt er en hyppig komplikation i forbindelse med diabetes mellitus.** / Hangaard, Martin Høhrmann; Rossing, Peter; Jensen, Jan Skov et al.
In: Ugeskrift for Laeger, Vol. 180, No. 20A, V02170164 , 01.10.2018.

397. **Soluble urokinase plasminogen activator receptor predicts cardiovascular events, mortality and kidney function decline in patients with type 1 diabetes.** / Curovic, V. Rotbain; Theilade, S.; Winther, S. A. et al.
In: Diabetologia, Vol. 61, No. 1, 1183, 01.10.2018, p. S577-S578.

398. **Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus.** / Jørgensen, Peter Godsk; Jensen, Magnus Thorsten; Biering-Sørensen, Tor et al.
In: Journal of the American Heart Association, Vol. 7, No. 19, 02.10.2018, p. e008856.

399. **Markers of collagen formation and degradation reflect renal function and predict adverse outcome in type 1 diabetes.** / Pilemann-Lyberg, Sascha ; Hansen, Tine Willum; Tofte, Nete et al.
In: Diabetologia, Vol. 61, No. S1, 999, 02.10.2018, p. S491.

400. **Effect of dapagliflozin on renal and cardiac function in patients with type 2 diabetes and albuminuria: a randomised study.** / Eickhoff, Mie Klessen; Olsen, Flemming Javier; Frimodt-Møller, Marie et al.
In: Diabetologia, Vol. 61, No. Suppl 1, 619, 04.10.2018, p. S299-S300 .

401. **Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and progression in diabetic kidney disease in patients with type 1 diabetes.** / Hansen, Tine Willum; Frimodt-Møller, Marie; Theilade, Simone et al.
In: Diabetologia, Vol. 61, No. Suppl 1, 1123, 04.10.2018, p. S548-S548.

402. **The REMOVAL Trial: Metformin reduces progression of carotid intima media thickness in never smokers with type 1 diabetes.** / Petrie, John R; Chaturvedi, Nish; Ford, Ian et al.
In: Diabetologia, Vol. 61, No. Suppl1, 1138, 04.10.2018, p. S555.

403. **Trajectories of estimated GFR in patients with and without albuminuria.** / Jørgensen, Marit Eika; Vistisen, Dorte; Andersen, Gregers Stig et al.
In: Diabetologia, Vol. 61, No. Suppl1, 181, 04.10.2018, p. S92.

404. **Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes.** / Hansen, Tine Willum; Frimodt-Møller, Marie; Theilade, Simone et al. 2018. Abstract from ARTERY 18 Guimarães, Portugal, from Thursday 18th – Saturday 20th October 2018., Portugal.

405. **Reduction in Albuminuria Is Associated with Cardiorenal Protection Independent of Baseline Albuminuria – A Post-Hoc Analysis of the LEADER Trial.** / Persson, Frederik; Rossing, Peter; Bain, Stephen C et al.
In: Journal of the American Society of Nephrology, Vol. 29, TH-OR034, 25.10.2018, p. 9.

406. **Cathepsin D: A Potential Biomarker for Diabetic Kidney Disease.** / Drel, Viktor; Natarajan, Loki; Hoofnagle, Andrew et al.
In: Journal of the American Society of Nephrology, 26.10.2018.

407. **Exome Wide Association Study Identifies a Rare Coding Variant in Cubilin Gene and Suggestive Variants in Additional Genes Associated with Albuminuria Among 33,985 Europeans with and Without Diabetes.** / Ahluwalia, Tarunveer Singh; Bredslund, Ivan; Christensen, Cramer Kjeldahl et al.
In: Journal of the American Society of Nephrology, 26.10.2018.

408. **Increasing Baseline Albuminuria Is Associated with a Continuously Increased Risk of Cardiovascular (CV) and Renal Outcomes in the LEADER Trial.** / mosenzon, ofri; Raz, Itamar; Bain, Stephen C et al.
In: Journal of the American Society of Nephrology, 26.10.2018.

409. **Myocardial Flow Reserve Assessed by Cardiac 82Rb PET/CT Is Associated with Albumin Excretion in Patients with Type 1 Diabetes.** / Zobel, Emilie Hein; Winther, Signe Abitz; Von Scholten, Bernt Johan et al.
In: Journal of the American Society of Nephrology, 26.10.2018.

410. **Plasma lipids are associated with diabetic kidney disease: a study of plasma lipidomics in type 1 diabetes.** / Tofte, Nete; Suvitaival, Tommi; Ahonen, Linda Linnéa et al.
In: Journal of the American Society of Nephrology, Vol. 29, FR-PO445, 26.10.2018, p. 535.

411. **Plasma metabolomics identifies markers of impaired kidney function: A meta-analyses of 1,984 Europeans with type 2 diabetes.** / Tofte, Nete; Ahluwalia, Tarunveer Singh; Vogelzangs, Nicole et al.
In: Journal of the American Society of Nephrology, Vol. 29, FR-PO446, 26.10.2018, p. 535.

412. **Pulse Wave Velocity Is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes.** / Frimodt-Møller, Marie; Theilade, Simone; Winther, Signe Abitz et al.
In: Journal of the American Society of Nephrology, Vol. 29, No. 1, FR-PO430, 26.10.2018.

413. **Soluble Urokinase Plasminogen Activator Receptor Predicts Kidney Function Decline and Mortality in Patients with Type 1 Diabetes.** / Rotbain Curovic, Viktor; Theilade, Simone; Winther, Signe Abitz et al.
In: Journal of the American Society of Nephrology, Vol. 29, FR-PO453, 26.10.2018, p. 537.

414. **Uric acid is an independent risk factor for mortality, cardiovascular event and decline in kidney function in patients with type 1 diabetes.** / Pilemann-Lyberg, Sascha ; Hansen, Tine Willum; Tofte, Nete et al.
In: Journal of the American Society of Nephrology, Vol. 29, FR-PO454, 26.10.2018, p. 537.

415. **Urine Metabolites Predict Kidney Function Decline in Type I Diabetic Subjects.** / Darshi, Manjula; Groop, Per-Henrik; Natarajan, Loki et al.
In: Journal of the American Society of Nephrology, 26.10.2018.

416. **Acute Hyperoxia and Slow Deep Breathing Improve Baroreflex Sensitivity in Long-Duration Type 1 Diabetes Irrespective of Macroalbuminuria.** / Laursen, Jens Christian ; Hansen, Christian Stevns; Bordino, Marco et al.
In: Journal of the American Society of Nephrology, Vol. 29, SA-PO158, 27.10.2018, p. 776.

417. **Effect of Dapagliflozin on Cardiac Function and Biomarkers in Patients with Type 2 Diabetes and Albuminuria – A Randomized Study.** / Eickhoff, Mie Klessen; Olsen, Flemming Javier; Frimodt-Møller, Marie et al.
In: Journal of the American Society of Nephrology, 27.10.2018, p. 770.

418. **Plasma Metabolomics Profiling in Auto-Antibody-Positive Individuals Progressing to Type 1 Diabetes.** / Suvitaival, Tommi; Wesley, Johnna D.; Ali, Ashfaq et al.
2018. Abstract from Immunology of Diabetes Society Congress 2018, London, United Kingdom.

419. **Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers.** / Lambers Heerspink, Hiddo Jan; Sjöström, David; Inzucchi, Silvio E et al.
In: Journal of the American Society of Nephrology, 27.10.2018.

420. **Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes.** / Hansen, C S; Theilade, S; Lajer, M et al.
In: Diabetic Medicine, Vol. 35, No. 11, 11.2018, p. 1596-1604.

421. **Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients.** / Rotbain Curovic, Viktor; Hansen, Tine W; Eickhoff, Mie K et al.
In: Acta Diabetologica, Vol. 55, No. 11, 11.2018, p. 1143-1150.

422. **Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study.** / Isaksen, Jonas L; Graff, Claus; Ellervik, Christina et al.
In: Journal of Electrocardiology, Vol. 51, No. 6, 01.11.2018, p. 72-77.

423. **Dyspnea With and Without Heart Failure and Prognosis in Out-Patients With Type 2 Diabetes.** / Jorgensen, Peter G.; Jensen, Magnus Thorsten; Schou, Morten et al.
In: Cirkulation, Vol. 138, No. 1, A11093, 06.11.2018.

424. **Epicardial Adipose Tissue is Associated With Measures of Diastolic Dysfunction in Type 2 Diabetes.** / Christensen, Regitse H.; Hansen, Christian S.; von Scholten, Bernt Johan et al.
In: Cirkulation, Vol. 138, No. 1, A11972, 06.11.2018.

425. **Predictive Value of Echocardiography is Modified by Sex in Type 2 Diabetes.** / Jorgensen, Peter G.; Jensen, Magnus Thorsten; Biering-Sorensen, Tor et al.
In: Cirkulation, Vol. 138, No. 1, A11089, 06.11.2018.

426. **Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; D'Alessio, David A; Fradkin, Judith et al.
In: Diabetologia, Vol. 61, No. 12, 12.2018, p. 2461-2498.

427. **Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; D'Alessio, David A; Fradkin, Judith et al.
In: Diabetes Care, Vol. 41, No. 12, 12.2018, p. 2669-2701.

428. **Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.** / Oellgaard, Jens; Gæde, Peter; Persson, Frederik et al.
In: Journal of Diabetes and its Complications, Vol. 32, No. 12, 01.12.2018, p. 1133-1140.

429. **Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.** / Chertow, Glenn M; Appel, Gerald B; Block, Geoffrey A et al.
In: Journal of Diabetes and its Complications, Vol. 32, No. 12, 01.12.2018, p. 1113-1117.

430. **Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.** / de Zeeuw, Dick; Renfurm, Ronny W; Bakris, George et al.
In: The Lancet Diabetes and Endocrinology, Vol. 6, No. 12, 01.12.2018, p. 925-933.

431. **Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.** / Currie, Gemma E; von Scholten, Bernt Johan; Mary, Sheon et al.
In: Cardiovascular Diabetology, Vol. 17, No. 50, 01.12.2018, p. 50.

432. **Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy.** / Hjortkjær, Henrik Øder; Jensen, Tonny; Hilsted, Jannik et al.
In: Diabetes and Vascular Disease Research, Vol. 16, No. 1, 01.2019, p. 98-102.

433. **Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries.** / Eder, Susanne; Leierer, Johannes; Kerschbaum, Julia et al.
In: Diabetes and Vascular Disease Research, Vol. 16, No. 1, 01.2019, p. 47-56.

434. **Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy.** / Skupien, Jan; Smiles, Adam M; Valo, Erkka et al.
In: Diabetes Care, Vol. 42, No. 1, 01.01.2019, p. 93-101.

435. **A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria.** / Ahluwalia, Tarunveer S; Schulz, Christina-Alexandra; Waage, Johannes et al.
In: Diabetologia, Vol. 62, No. 2, 01.02.2019, p. 292-305.

436. **Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy.** / Hjortkjær, Henrik Ø; Jensen, Tonny; Hilsted, Jannik et al.
In: Journal of Diabetes and its Complications, Vol. 33, No. 2, 01.02.2019, p. 171-177.

437. **Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes.** / Jensen, Jesper; Schou, Morten; Kistorp, Caroline et al.
In: Diabetes, Obesity and Metabolism, Vol. 21, No. 3, 03.2019, p. 736-740.

438. **Urinary proteomics and precision medicine for chronic kidney disease: Current status and future perspectives.** / Persson, Frederik; Rossing, Peter.
In: Proteomics - Clinical Applications, Vol. 13, No. 2, 1800176, 03.2019.

439. **Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder.** / Rossing, Peter; Frimodt-Møller, Marie; Persson, Frederik.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 73, No. 3, 01.03.2019, p. 293-296.

440. **Reduction in Albuminuria With Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers.** / Heerspink, Hiddo J L; Sjöström, C David; Inzucchi, Silvio E et al.
In: Diabetes, Obesity and Metabolism, Vol. 21, No. 3, 01.03.2019, p. 720-725.

441. **Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; D'Alessio, David A; Fradkin, Judith et al.
In: Diabetologia, Vol. 62, No. 5, 05.2019, p. 873.

442. **MR-proANP effectively risk stratifies patients with type 2 diabetes regardless of presence of heart failure.** / Jensen, J; Schou, M; Kistorp, C et al.
In: European Journal of Heart Failure, Vol. 21, No. Suppl 1, P964, 05.2019, p. 223.

443. **Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: individual effects of treatment.** / Zobel, Emilie H; von Scholten, Bernt Johan; Goldman, Bryan et al.
In: Diabetes, Obesity and Metabolism, Vol. 21, No. 5, 05.2019, p. 1261-1265.

444. **Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population.** / Hjortkjær, Henrik Ø; Jensen, Tonny; Hilsted, Jannik et al.
In: Diabetes and Vascular Disease Research, Vol. 16, No. 3, 01.05.2019, p. 289-296.

445. **Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.** / SONAR Committees and Investigators.
In: The Lancet, Vol. 393, No. 10184, 11.05.2019, p. 1937-1947.

446. **Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy.** / Eickhoff, Mie Klessen; Frimodt-Møller, Marie; Mischak, Harald et al.
2019. Abstract from European Diabetic Nephropathy Study Group 32nd Annual Meeting, EDNSG, Paris, France.

447. **Identification of serum metabolites associated with renal impairment: A metabolomics study in Type 1 Diabetes.** / Tofte, Nete; Suvitaival, Tommi; Trošt, Kajetan et al.
2019. Abstract from European Diabetic Nephropathy Study Group 32nd Annual Meeting, EDNSG, Paris, France.

448. **Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes.** / Hansen, Tine Willum; Frimodt-Møller, Marie; Theilade, Simone et al.
2019. Abstract from European Diabetic Nephropathy Study Group 32nd Annual Meeting, EDNSG, Paris, France.

449. **Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes.** / Curovic, Viktor Rotbain; Theilade, Simone; Winther, Signe Abitz et al.
2019. Abstract from European Diabetic Nephropathy Study Group 32nd Annual Meeting, EDNSG, Paris, France.

450. **The utility of plasma concentration of Trimethylamine-N-Oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes.** / Winther, Signe Abitz; Øllgaard, Jens Christian; Tofte, Nete et al.
2019. Abstract from European Diabetic Nephropathy Study Group 32nd Annual Meeting, EDNSG, Paris, France.

451. **Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors.** / Eickhoff, Mie K; Dekkers, Claire C J; Kramers, Bart J et al.
In: Journal of Clinical Medicine, Vol. 8, No. 6, 31.05.2019.

452. **A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes.** / Frimodt-Møller, Marie; Hansen, Tine W; Rasmussen, Daniel G K et al.
In: Acta Diabetologica, Vol. 56, No. 6, 06.2019, p. 711-712.

453. **Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy.** / Eickhoff, Mie Klessen; Frimodt-Møller, Marie; Mischak, Harald et al.
In: Diabetes, Vol. 68, No. Suppl 1, 526-P, 06.2019.

454. **Effects of semaglutide and liraglutide on urinary albumin-to-creatinine ration (UACR) -A pooled analysis of sustain 6 and leader.** / Perkovic, Vlado; Bain, Stephen C; Bakris, George L et al.
In: Nephrology Dialysis Transplantation, Vol. 34, No. Suppl 1, FP483, 06.2019, p. 205.

455. **Effects of the glucogon-like peptide-1 (GLP-1) analogues semaglutide and liragutide on renal outcomes - A pooled analysis of the sustain 6 and leader trials.** / Perkovic, Vlado; Bain, Stephen C; Bakris, George L et al.
In: Nephrology Dialysis Transplantation, Vol. 34, No. Suppl 1, SaO010, 06.2019, p. 388.

456. **EGFR loss with glucagon-like-peptide-1 (GLP-1) analouge treatment: Data from sustain 6 and leader.** / Perkovic, Vlado; Bain, Stephen C; Bakris, George L et al.
In: Nephrology Dialysis Transplantation, Vol. 34, No. Suppl 1, FP482 , 06.2019.

457. **Obesity remains a major risk factor associated with vascular stiffening in type 2 diabetes.** / Currie, Gemma; Flynn, J; Rossing, Peter et al.
In: Journal of Hypertension, Vol. 37, No. Suppl 1, 06.2019, p. 65.

458. **Predictive value of echocardiography in Type 2 diabetes.** / Jørgensen, Peter G; Biering-Sørensen, Tor; Mogelvang, Rasmus et al.
In: European heart journal cardiovascular Imaging, Vol. 20, No. 6, 06.2019, p. 687-693.

459. **A catalog of genetic loci associated with kidney function from analyses of a million individuals.** / LifeLines Cohort Study.
In: Nature Genetics, Vol. 51, No. 6, 01.06.2019, p. 957-972.

460. **Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.** / Pollock, Carol; Stefánsson, Bergur; Reyner, Daniel et al.
In: The Lancet Diabetes and Endocrinology, Vol. 7, No. 6, 01.06.2019, p. 429-441.

461. **Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes.** / Zobel, Emilie H; Hasbak, Philip; Winther, Signe A et al.
In: Diabetes, Vol. 68, No. 6, 01.06.2019, p. 1277-1286.

462. **Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin.** / Rossing, Peter; Persson, Frederik; Frimodt-Møller, Marie.
In: Kidney International, Vol. 95, No. 6, 01.06.2019, p. 1287-1288.

463. **Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.** / Rotbain Curovic, Viktor; Theilade, Simone; Winther, Signe A et al.
In: Diabetes Care, Vol. 42, No. 6, 01.06.2019, p. 1112-1119.

464. **Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes.** / Pilemann-Lyberg, Sascha; Hansen, Tine Willum; Tofte, Nete et al.
In: Diabetes Care, Vol. 42, No. 6, 01.06.2019, p. 1088-1094.

465. **Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.** / PIONEER 5 Investigators.
In: The Lancet Diabetes and Endocrinology, Vol. 7, No. 7, 01.07.2019, p. 515-527.

466. **Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes.** / Zobel, Emilie H; Winther, Signe A; Hasbak, Philip et al.
In: European heart journal cardiovascular Imaging, Vol. 20, No. 7, jey174, 01.07.2019, p. 796-803.

467. **Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease.** / Hansen, Christian S; Jørgensen, Marit E; Fleischer, Jesper et al.
In: Journal of the American Heart Association, Vol. 8, No. 13, e011779, 02.07.2019, p. 1-17.

468. **Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.** / Winther, Signe A; Øllgaard, Jens C; Tofte, Nete et al.
In: Diabetes Care, Vol. 42, No. 8, 08.2019, p. 1512-1520.

469. **Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes.** / Christensen, Regitse H; Hansen, Christian S; von Scholten, Bernt Johan et al.
In: Diabetes, Obesity and Metabolism, Vol. 21, No. 8, 01.08.2019, p. 2006-2011.

470. **Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.** / PERL Study Group.
In: Diabetes Care, Vol. 42, No. 8, 01.08.2019, p. 1454-1463.

471. **An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes.** / Jørgensen, Peter G; Schou, Morten; Biering-Sørensen, Tor et al.
In: International Journal of Cardiology, Vol. 289, 15.08.2019, p. 119-124.

472. **Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes.** / Christensen, Regitse H; von Scholten, Bernt Johan; Hansen, Christian S et al.
In: Cardiovascular Diabetology, Vol. 18, No. 1, 114, 30.08.2019.

473. **Circulating metabolites are associated with present and future renal impairment in type 1 Diabetes.** / Tofte, Nete; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 57, 09.2019, p. 30.

474. **Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy: Barcelona, Spain, 16 - 20 September 2019.** / Eickhoff, Mie Klessen; Frimodt-Møller, Marie; Mischak, Harald et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 77, 09.2019, p. 40.

475. **Estimated GFR (eGFR) loss with glucagon like peptide 1 (GLP1) analogue treatment: Data from Sustain 6 and LEADER.** / Perkovic, Vlado; Bain, Stephen C; Bakris, George L et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 998, 09.2019, p. 484.

476. **Plasma metabolomics identifies markers of kidney function in 3,064 Europeans with type 2 diabetes: Barcelona, Spain, 16 - 20 September 2019.** / Ahluwalia, Tarunveer Singh; Tofte, Nete; Vogelzangs, Nicole et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 937, 09.2019, p. 456.

477. **Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock?** / Laursen, Jens Christian ; Hansen, Christian Stevns; Bordino, Marco et al.
2019. Abstract from The 29th annual meeting of the diabetic neuropathy study group of the EASD, Barcelona, Spain.

478. **Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock? Barcelona, Spain, 16 - 20 September 2019.** / Laursen, Jens Christian ; Hansen, Christian Stevns; Bordino, Marco et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 98, 09.2019, p. 52.

479. **Renal function dominates the landscape of the metabolome in type 1 diabetes.** / Suvitaival, Tommi; Tofte, Nete; Mattila, Ismo et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 936, 09.2019, p. 455.

480. **Role of gastrointestinal inflammation in diabetic kidney disease.** / Mannerla, Miia; Winther, Signe Abitz; Frimodt-Møller, Marie et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 991, 09.2019, p. 480.

481. **The utility of plasma concentration of Trimethylamine-N-Oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes.** / Winther, Signe Abitz; Øllgaard, Jens Christian; Tofte, Nete et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 60, 09.2019, p. 32.

482. **Visit-to-visit variability of HbA1c and systolic BP as risk markers for cardiovascular events, end stage renal disease, renal function decline and mortality in type 1 diabetes.** / Curovic, Viktor Rotbain; Theilade, Simone; Winther, Signe Abitz et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 1181, 09.2019, p. 568.

483. **Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study.** / Gæde, Peter; Oellgaard, Jens; Kruuse, Christina et al.
In: Diabetologia, Vol. 62, No. 9, 01.09.2019, p. 1575-1580.

484. **Cell populations and molecular biomarkers in blood and urine characterise nephropathy in type 1 diabetes.** / Henriksen, Peter; Kyluik-Price, Dana; Winther, Signe Abitz et al.
In: Diabetologia, Vol. 62, No. Suppl 1, 986, 01.09.2019, p. 478.

485. **Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes.** / Pilemann-Lyberg, Sascha; Rasmussen, Daniel Guldager Kring; Hansen, Tine Willum et al.
In: Diabetes Care, Vol. 42, No. 9, 01.09.2019, p. 1760-1768.

486. **Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients.** / Ahonen, Linda; Jäntti, Sirkku; Suvitaival, Tommi et al.
In: Metabolites, Vol. 9, No. 9, 184, 14.09.2019.

487. **Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study.** / BIRTH-GENE (BIG) Study Working Group.
In: JAMA network open, Vol. 2, No. 9, e1910915, 20.09.2019.

488. **Editorial: Novel Biomarkers for Type 2 Diabetes.** / Ahluwalia, Tarunveer S.; Kilpeläinen, Tuomas O.; Singh, Sandeep et al.
In: Frontiers in Endocrinology, Vol. 10, 649, 27.09.2019.

489. **Assessment of the Sublingual Microcirculation with the GlycoCheck System: Reproducibility and Examination Conditions.** / Frimodt-Møller, Marie; Eickhoff, Mie Klessen; Winther, Signe Abitz et al.
In: Journal of the American Society of Nephrology, Vol. 30, SA-PO331, 10.2019, p. 849.

490. **Hypoxia in individuals with type 1 diabetes and macroalbuminuria is associated with autonomic dysfunction.** / Laursen, Jens Christian ; Clemmensen, Kim Katrine Bjerring; Hansen, Christian Stevns et al.
In: Journal of the American Society of Nephrology, Vol. 30, TH-PO92, 10.2019, p. 361.

491. **Impact of Binge Drinking on Hepatic Lipid Metabolism: Lipidome Analysis of Liver Vein and Peripheral Blood During Acute Alcohol Intoxication.** / Bastrup Israelsen, Mads; Trošt, Kajetan; Stæhr Madsen, Bjørn et al.
In: Hepatology, Vol. 70, No. Suppl 1, 267, 10.2019, p. 172A-173A.

492. **Individual Effects of Liraglutide on Cardiorenal Risk Markers: Results from the LEADER Trial.** / Persson, Frederik; Zobel, Emilie Hein; Hansen, Tine et al.
In: Journal of the American Society of Nephrology, Vol. 30, PUB071, 10.2019, p. 1096.

493. **Lipoprotein(a) and Decline in Renal Function, Incidence of Cardiovascular Disease, and Mortality in Individuals with Type 2 Diabetes and Microalbuminuria.** / S. Heinrich, Niels ; von Scholten, Bernt Johan; Persson, Frederik et al.
In: Journal of the American Society of Nephrology, Vol. 30, PUB081, 10.2019, p. 1094.

494. **Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.** / Tofte, Nete; Lindhardt, Morten Kofod; Currie, Gemma et al.
In: Journal of the American Society of Nephrology, Vol. 30, FR-OR113 , 10.2019, p. 1.

495. **Polyols and Branched Chained Amino Acids Are Associated with Present and Future Renal Impairment in Type 1 Diabetes.** / Tofte, Nete; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Journal of the American Society of Nephrology, Vol. 30, TH-PO934, 10.2019, p. 362.

496. **Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock?** / Laursen, Jens Christian ; Hansen, Christian Stevns; Bordino, Marco et al.
2019. Abstract from DDA Training Day 2019, Boston, United States.

497. **Spironolactone for the prevention of microalbuminuria in high risk type 2 diabetes: Results from the multicenter randomized double-blind controlled study "PRIORITY".** / Lindhardt, Morten Kofod; Tofte, Nete; Frimodt-Møller, Marie et al.
In: Journal of the American Society of Nephrology, Vol. 30, FR-PO247, 10.2019, p. 498.

498. **The association between vitamin D level and microvascular complications in persons with type 2 diabetes.** / Tougaard, Ninna Hahn; Hansen, Tine Willum; Rossing, Peter.
In: Journal of the American Society of Nephrology, Vol. 30, SA-PO557, 10.2019, p. 905.

499. **Trimethylamine-N-Oxide and Renal Complications, Cardiovascular Disease, and Mortality in Individuals with Type 2 Diabetes and Microalbuminuria.** / Winther, Signe Abitz; Øllgaard, Jens Christian; Hansen, Tine Willum et al.
In: Journal of the American Society of Nephrology, Vol. 30, SA-PO551, 10.2019, p. 904.

500. **Urinary Glycolic Acid Predicts Kidney Function Decline in Type 1 Diabetic Subjects.** / Darshi, Manjula; Kim, Jiwan John; Ahluwalia, Tarunveer Singh et al.
In: Journal of the American Society of Nephrology, Vol. 30, TH-PO919, 10.2019, p. 358.

501. **Visit-to-Visit Variability of Albuminuria and eGFR as Risk Markers for Renal Complications, Cardiovascular Events, and Mortality in Type 1 Diabetes.** / Curovic, Viktor Rotbain; Theilade, Simone; Winther, Signe Abitz et al.
In: Journal of the American Society of Nephrology, Vol. 30, SA-PO552, 10.2019, p. 904.

502. **Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.** / Rossing, Peter; Block, Geoffrey A; Chin, Melanie P et al.
In: Kidney International, Vol. 96, No. 4, 01.10.2019, p. 1030-1036.

503. **Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen.** / SUMMIT Consortium, DCCT/EDIC Research Group, GENIE Consortium.
In: Journal of the American Society of Nephrology, Vol. 30, No. 10, 01.10.2019, p. 2000-2016.

504. **Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease.** / Persson, Frederik; Frimodt-Møller, Marie; Rossing, Peter.
In: Kidney International Reports, Vol. 4, No. 10, 01.10.2019, p. 1362-1365.

505. **Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes.** / Lassen, Mats Christian Højbjerg; Jensen, Magnus T; Biering-Sørensen, Tor et al.
In: European heart journal cardiovascular Imaging, Vol. 20, No. 10, 01.10.2019, p. 1171-1178.

506. **Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function - even without albuminuria.** / Vistisen, Dorte; Andersen, Gregers Stig; Hulman, Adam et al.
In: Diabetes Care, Vol. 42, No. 10, 01.10.2019, p. 1886-1894.

507. **Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes.** / Tofte, Nete; Suvitaival, Tommi; Ahonen, Linda et al.
In: Scientific Reports, Vol. 9, No. 1, 16398, 08.11.2019.

508. **Genome wide association study of apparent treatment resistant hypertension in the CHARGE consortium: The CHARGE Pharmacogenetics Working Group.** / VA Million Veteran Program and the CHARGE Pharmacogenetics Working group.
In: American Journal of Hypertension, Vol. 32, No. 12, 15.11.2019, p. 1146-1153.

509. **Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes.** / Tofte, Nete; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Frontiers in Endocrinology, Vol. 10, 818, 22.11.2019, p. 1-11.

510. **Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).** / Jürgens, Mikkel; Schou, Morten; Hasbak, Philip et al.
In: BMJ Open, Vol. 9, No. 11, e029098, 27.11.2019.

511. **Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study.** / Jensen, Magnus T; Sogaard, Peter; Gustafsson, Ida et al.
In: Diabetologia, Vol. 62, No. 12, 12.2019, p. 2354-2364.

512. **Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes.** / Pilemann-Lyberg, Sascha; Hansen, Tine Willum; Rossing, Peter.
In: Diabetes Care, Vol. 42, No. 12, 12.2019, p. e188.

513. **The effect of needle tenotomy on hammer, mallet and claw toe deformities in patients with diabetes, a retrospective study.** / Hedegaard Andersen, Jonas; Rasmussen, Anne; Frimodt-Møller, Marie et al.
In: Journal of Clinical and Translational Endocrinology, Vol. 18, 100208, 01.12.2019.

514. **Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining.** / Kirk, Isa Kristina; Simon, Christian; Banasik, Karina et al.
In: eLife, Vol. 8, e44941, 10.12.2019.

515. **Liraglutide and vascular inflammation in type 2 diabetes as assessed by FDG-PET/CT: The LiraFlame study.** / Ripa, Rasmus Sejersten; Zobel, Emilie Hein; Von Scholten, Bernt Johan et al.
2020.

516. **Long term effects of flexor tenotomies.** / Andersen, Jonas Hedegaard; Rasmussen, Anne; Kirketerp-Møller, Klaus et al.
2020. Abstract from Diabetic Foot Study Group 2020, 16th meeting.

517. **Long term effects of flexor tenotomies.** / Andersen, Jonas Hedegaard; Rasmussen, Anne; Kirketerp-Møller, Klaus et al.
2020. Abstract from Diabetic Foot Study Group 2020, 16th meeting.

518. **Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy.** / Siwy, Justyna; Ahonen, Linda; Magalhães, Pedro et al.
DIABETIC NEPHROPATHY: METHODS AND PROTOCOLS. ed. / Luigi Gnudi; David A. Long. Vol. 2067 2020. p. 287-306 (Methods in molecular biology).

519. **The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER trial.** / Zobel, Emilie Hein; Hansen, Tine Willum; Persson, Frederik et al.
2020.

520. **Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study.** / Joensen, Lene Eide; Madsen, Kristoffer Panduro; Frimodt-Møller, Marie et al.
In: Journal of Diabetes and its Complications, Vol. 34, No. 1, 107467, 01.01.2020.

521. **Mitigating risk of aldosterone in diabetic kidney disease.** / Frimodt-Møller, Marie; Persson, Frederik; Rossing, Peter.
In: Current opinion in nephrology and hypertension, Vol. 29, No. 1, 01.01.2020, p. 145-151.

522. **The History of Prevention and Treatment of Diabetic Nephropathy.** / Rossing, Peter; Parving, Hans-Henrik Dyring.
Unveiling Diabetes - Historical Milestones in Diabetology.. ed. / Victor Jörgens; Massimo Porta. Vol. 29 Basel: Karger, 2020. p. 242-256.

523. **Carotid-femoral pulse wave velocity is a risk marker for complications in persons with type 1 diabetes.** / Tougaard, Ninna Hahn; Theilade, Simone; Winther, Signe Abitz et al.
2020. Abstract from Dansk Endokrinologisk Selskabs årsmøde 2020.

524. **Describing the fecal metabolome in cryogenically collected samples from healthy participants.** / Trošt, Kajetan; Ahonen, Linda; Suvitaival, Tommi et al.
In: Scientific Reports, Vol. 10, No. 1, 885, 21.01.2020.

525. **2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Buse, John B; Wexler, Deborah J; Tsapas, Apostolos et al.
In: Diabetes Care, Vol. 43, No. 2, 02.2020, p. 487-493.

526. **2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Buse, John B; Wexler, Deborah J; Tsapas, Apostolos et al.
In: Diabetologia, Vol. 63, No. 2, 02.2020, p. 221-228.

527. **Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.** / DAPA-CKD Investigators .
In: Nephrology Dialysis Transplantation, Vol. 35, No. 2, 07.02.2020, p. 274-282.

528. **Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes.** / Zobel, Emilie H; Christensen, Regitse Højgaard; Winther, Signe A et al.
In: Cardiovascular Diabetology, Vol. 19, No. 1, 16, 10.02.2020.

529. **Sex differences in the association between myocardial function and outcome in type 1 diabetes without known heart disease.** / Lassen, Mats Hojbjerg; Biering-Sorensen, Tor; Jorgensen, Peter et al.
In: Journal of the American College of Cardiology, Vol. 75, No. 11, 1, 1065-07, 24.03.2020, p. 1576.

530. **Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.** / PRIORITY investigators.
In: The Lancet Diabetes and Endocrinology, Vol. 8, No. 4, 01.04.2020, p. 301-312.

531. **Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients.** / Holt, C B; Hoffmann-Petersen, I T; Hansen, T K et al.
In: Immunobiology, Vol. 225, No. 3, 151939, 05.2020, p. 151939.

532. **Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The thousand & 1 study.** / Rørth, Rasmus; Jørgensen, Peter Godsk; Andersen, Henrik Ullits et al.
In: European Journal of Endocrinology, Vol. 182, No. 5, 05.2020, p. 481-488.

533. **Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?** / Christensen, Regitse Højgaard; von Scholten, Bernt Johan; Lehrskov, Louise Lang et al.
In: Therapeutic Advances in Endocrinology and Metabolism, Vol. 11, 05.2020, p. 2042018820928824.

534. **Post-Systolic Shortening by Speckle Tracking Echocardiography Predicts Cardiac Events in Type 2 Diabetes.** / Brainin, Philip; Jensen, Magnus T; Biering-Sørensen, Tor et al.
In: JACC. Cardiovascular imaging, Vol. 13, No. 5, 05.2020, p. 1289-1291.

535. **2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.** / Cosentino, Francesco; Grant, Peter J.; Aboyans, Victor et al.
In: Revista Espanola de Cardiologia (Online), Vol. 73, No. 5, 01.05.2020, p. 404.e1-404.e59.

536. **Metformin and cardiorenal outcomes in diabetes: a reappraisal.** / Petrie, John R; Rossing, Peter; Campbell, Ian W.
In: Diabetes, Obesity and Metabolism, Vol. 22, No. 6, 06.2020, p. 904-915.

537. **Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump–Treated Type 1 Diabetes.** / Rosenlund, Signe Vestergaard; Hansen, Tine Willum; Rossing, Peter et al.
2020.

538. **Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.** / PERL Study Group.
In: The New England journal of medicine, Vol. 382, No. 26, 25.06.2020, p. 2493-2503.

539. **Erratum. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (Diabetes Care, (2020) 43, (487-493), 10.2337/dci19-0066).** / Buse, John B; Wexler, Deborah J; Tsapas, Apostolos et al.
In: Diabetes Care, Vol. 43, No. 7, 07.2020, p. 1670.

540. **Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria.** / Heinrich, Niels Sondergaard; von Scholten, Bernt Johan; Reinhard, Henrik et al.
In: Journal of Diabetes and its Complications, Vol. 34, No. 7, 107593, 07.2020, p. 107593.

541. **Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood.** / Zheng, Yan; Huang, Tao; Wang, Tiange et al.
In: European Journal of Epidemiology, Vol. 35, No. 7, 07.2020, p. 685-697.

542. **Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial.** / Eickhoff, Mie K.; Olsen, Flemming J.; Frimodt-Møller, Marie et al.
In: Journal of Diabetes and its Complications, Vol. 34, No. 7, 107590, 01.07.2020.

543. **Plasma metabolomics identifies markers of impaired renal function: A meta-analysis of 3,089 persons with type 2 diabetes.** / Tofte, Nete; Vogelzangs, Nicole; Mook-Kanamori, Dennis et al.
In: The Journal of clinical endocrinology and metabolism, Vol. 105, No. 7, dgaa173, 01.07.2020, p. 2275-2287.

544. **Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes.** / Jain, Ruchi; Özgümüş, Türküler; Jensen, Troels Mygind et al.
In: Scientific Reports, Vol. 10, No. 1, 11561, 14.07.2020, p. 11561.

545. **Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) (Diabetologia, (2020), 63, 2, (221-228), 10.1007/s00125-019-05039-w).** / Buse, John B; Wexler, Deborah J; Tsapas, Apostolos et al.
In: Diabetologia, Vol. 63, No. 8, 08.2020, p. 1667.

546. **SGLT 2 inhibitors in Type 1 diabetes.** / Stougaard, Elisabeth Buur; Amadid, Hanan; Søndergaard, Esben et al.
In: Ugeskrift for Laeger, Vol. 182, No. 35, 24.08.2020.

547. **Major decreases in the lipidome following liraglutide treatment: 21-25 September 2020.** / Wretlind, Asger; Zobel, Emilie Hein; Ripa, Rasmus Sejersten et al.
In: Diabetologia, Vol. 63, No. Suppl 1, 525, 25.08.2020, p. S252.

548. **Metabolites of the mitochondrial energy production are associated with future cardiovascular morbidity and mortality in type 1 diabetes.** / Tofte, Nete; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Diabetologia, Vol. 63, No. Suppl 1, 940, 25.08.2020, p. S447.

549. **Profiling of gut microbiota and plasma metabolites in persons with type 1 diabetes and kidney disease.** / Henriksen, Peter; Winther, Signe Abitz; Vogt, Josef Korbinian et al.
In: Diabetologia, Vol. 63, No. Suppl 1, 795, 25.08.2020, p. S384.

550. **The circulating lipidome in diabetic retinopathy.** / Suvitaival, Tommi; Curovic, Viktor Rotbain; Ahonen, Linda Linnéa et al.
In: Diabetologia, Vol. 63, No. Suppl 1, 820, 25.08.2020, p. S395.

551. **Hyperoxia improves autonomic function in individuals with long-duration type 1 diabetes and macroalbuminuria.** / Laursen, J C; Hansen, C S; Bordino, M et al.
In: Diabetic Medicine, Vol. 37, No. 9, 09.2020, p. 1561-1568.

552. **Performance of Indexed and Nonindexed Estimated GFR.** / Titan, Silvia; Miao, Shiyuan; Tighiouart, Hocine et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 76, No. 3, 09.2020, p. 446-449.

553. **Uncarboxylated Matrix Gla-Protein: A Biomarker of Vitamin K Status and Cardiovascular Risk.** / Jespersen, Torkild; Møllehave, Line Tang; Thuesen, Betina Heinsbæk et al.
In: Clinical Biochemistry, Vol. 83, 09.2020, p. 49-56.

554. **Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus.** / Tougaard, Ninna Hahn; Theilade, Simone; Winther, Signe Abitz et al.
In: Journal of the American Heart Association, Vol. 9, No. 19, 21.09.2020, p. e017165.

555. **Non invasive assessment of changes in cardiac microvascular function in persons with type 2 diabetes.** / Rasmussen, Ida Kirstine Bull; Hasbak, Philip; von Scholten, Bernt Johan et al.
2020.

556. **A prediction model for end-stage kidney disease in type 1 diabetes in the presence of competing risk of death.** / Vistisen, Dorte; Andersen, Gregers Stig; Hulman, Adam et al.
2020. Abstract from 56th EASD Annual Meeting of the European Association for the Study of Diabetes.

557. **Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes.** / Curovic, Viktor Rotbain; Suvitaival, Tommi; Mattila, Ismo et al.
In: Diabetes, Vol. 69, No. 10, 10.2020, p. 2217-2226.

558. **Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.** / de Boer, Ian H; Caramori, M Luiza; Chan, Juliana C N et al.
In: Kidney International, Vol. 98, No. 4, 10.2020, p. 839-848.

559. **KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.** / Rossing, Peter.
In: Kidney International Supplements, Vol. 98, No. 4, 10.2020, p. S1-S115.

560. **Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?** / Tofte, Nete; Persson, Frederik; Rossing, Peter.
In: Journal of Nephrology, Vol. 33, No. 5, 10.2020, p. 931-948.

561. **A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes.** / Limonte, Christine P; Valo, Erkka; Montemayor, Daniel et al.
In: American Journal of Nephrology, Vol. 51, No. 10, 01.10.2020, p. 839-848.

562. **The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.** / Wheeler, David C.; Stefansson, Bergur V.; Batiushin, Mikhail et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, No. 10, 01.10.2020, p. 1700-1711.

563. **Dapagliflozin in Patients with Chronic Kidney Disease.** / Heerspink, Hiddo J L; Stefánsson, Bergur V; Correa-Rotter, Ricardo et al.
In: The New England journal of medicine, Vol. 383, No. 15, 08.10.2020, p. 1436-1446.

564. **MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction.** / Jensen, Jesper; Schou, Morten; Kistorp, Caroline et al.
In: Cardiovascular Diabetology, Vol. 19, No. 1, 180, 16.10.2020, p. 180.

565. **Changes in cardiac microvascular function in persons with type 2 diabetes in relation to kidney function.** / Rasmussen, Ida Kirstine Bull; Hasbak, Philip; von Scholten, Bernt Johan et al.
2020.

566. **Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality.** / Copur, Sidar; Onal, Emine M; Afsar, Baris et al.
In: Journal of Diabetes and its Complications, Vol. 34, No. 11, 107707, 11.2020, p. 107707.

567. **Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes.** / Ranjan, Ajenthen G; Rosenlund, Signe V; Hansen, Tine W et al.
In: Diabetes Care, Vol. 43, No. 11, 11.2020, p. 2882-2885.

568. **Cardiovascular and renal outcomes by baseline albuminuria status and renal function - results from the LEADER randomized trial.** / LEADER Trial Investigators.
In: Diabetes, Obesity and Metabolism, Vol. 22, No. 11, 01.11.2020, p. 2077-2088.

569. **Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.** / Mann, Johannes F E; Hansen, Thomas; Idorn, Thomas et al.
In: The Lancet Diabetes and Endocrinology, Vol. 8, No. 11, 01.11.2020, p. 880-893.

570. **Concomitant diabetes with atrial fibrillation and anticoagulation management considerations.** / Kreutz, Reinhold; Camm, A John; Rossing, Peter.
In: European heart journal supplements : journal of the European Society of Cardiology, Vol. 22, No. Suppl O, 12.2020, p. O78-O86.

571. **Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria.** / Winther, Signe A; Henriksen, Peter; Vogt, Josef K et al.
In: Diabetologia, Vol. 63, No. 12, 12.2020, p. 2713-2724.

572. **Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.** / FIDELIO-DKD and FIGARO-DKD Investigators; Krarup, Thue (Member of author group).
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 12.2020.

573. **TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?** / Winther, Signe Abitz; Rossing, Peter.
In: The Journal of clinical endocrinology and metabolism, Vol. 105, No. 12, 01.12.2020.

574. **Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.** / Bakris, George L; Agarwal, Rajiv; Anker, Stefan D et al.
In: The New England journal of medicine, Vol. 383, No. 23, 03.12.2020, p. 2219-2229.

575. **Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease.** / Rossing, Peter.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 15, No. 12, 07.12.2020, p. 1696-1698.

576. **Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions.** / Eickhoff, Mie Klessen; Winther, Signe Abitz; Hansen, Tine Willum et al.
In: PLoS One, Vol. 15, No. 12, 23.12.2020, p. e0243737.

577. **Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.** / DAPA-CKD Trial Committees and Investigators.
In: The Lancet Diabetes and Endocrinology, Vol. 9, No. 1, 01.2021, p. 22-31.

578. **Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture.** / Rossing, Peter; Persson, Frederik; Frimodt-Møller, Marie et al.
In: Diabetes, Vol. 70, No. 1, 01.2021, p. 39-50.

579. **Relationship between Peripheral Neuropathy, Diastolic Function, and Adverse Cardiovascular Outcome in Individuals with Type 1 Diabetes Mellitus without Known Cardiovascular Disease: Results from The Thousand & 1 Study.** / Hansen, Gorm Mørk; Jørgensen, Peter Godsk; Andersen, Henrik U et al.
In: Diabetes, Obesity and Metabolism, Vol. 23, No. 1, 14209, 01.2021, p. 158-165.

580. **Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker.** / Copur, Sidar; Siriopol, Dimitrie; Afsar, Baris et al.
In: Acta Diabetologica, Vol. 58, No. 1, 01.2021, p. 81-91.

581. **SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.** / Tuttle, Katherine R; Brosius, Frank C; Cavender, Matthew A et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 77, No. 1, 01.2021, p. 94-109.

582. **SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.** / Tuttle, Katherine R; Brosius, Frank C; Cavender, Matthew A et al.
1 ed. 2021. 16 p. (Diabetes).

583. **Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus.** / Antikainen, Anni A V; Sandholm, Niina; Trëgouet, David-Alexandre et al.
In: Cardiovascular Research, Vol. 117, No. 2, cvaa045, 21.01.2021, p. 600-612.

584. **Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes.** / Tofte, Nete; Theilade, Simone; Winther, Signe A et al.
In: Diabetes Care, Vol. 44, No. 2, 02.2021, p. 595-603.

585. **Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes.** / Brainin, Philip; Biering-Sørensen, Tor; Jensen, Magnus T et al.
In: Journal of the American Society of Echocardiography, Vol. 34, No. 2, 02.2021, p. 127-135.

586. **Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.** / McMurray, John J V; Wheeler, David C; Stefánsson, Bergur V et al.
In: Circulation, Vol. 143, No. 5, 02.02.2021, p. 438-448.

587. **Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes.** / FIDELIO-DKD Investigators.
In: Circulation, Vol. 143, No. 6, 09.02.2021, p. 540-552.

588. **A primer on metabolic memory: why existing diabesity treatments fail.** / Copur, Sidar; Rossing, Peter; Afsar, Baris et al.
In: Clinical kidney journal, Vol. 14, No. 3, 03.2021, p. 756-767.

589. **Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.** / Navaneethan, Sankar D; Zoungas, Sophia; Caramori, M Luiza et al.
In: Annals of Internal Medicine, Vol. 174, 03.2021, p. 385-394.

590. **Genome-Wide Association Study of Circulating Interleukin 6 Levels Identifies Novel Loci.** / Ahluwalia, Tarunveer S; Prins, Bram P; Abdollahi, Mohammadreza et al.
In: Human Molecular Genetics, Vol. 30, No. 5, 03.2021, p. 393-409.

591. **Major adverse renal events (MARE): A proposal to unifying renal endpoints.** / Prischl, Friedrich C; Rossing, Peter; Bakris, George et al.
In: Nephrology Dialysis Transplantation, Vol. 36, No. 3, 03.2021, p. 491-497.

592. **Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria.** / Winther, Signe Abitz; Øllgaard, Jens Christian; Hansen, Tine Willum et al.
In: PLoS One, Vol. 16, No. 3, e0244402, 03.2021, p. e0244402.

593. **Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.** / Heerspink, Hiddo J L; Sjöström, C David; Jongs, Niels et al.
In: European Heart Journal, Vol. 42, No. 13, 31.03.2021, p. 1216-1227.

594. **A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.** / Persson, Frederik; Borg, Rikke; Rossing, Peter.
In: Annals of Translational Medicine, Vol. 9, No. 8, 04.2021, p. 716.

595. **A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes.** / Vistisen, Dorte; Andersen, Gregers S; Hulman, Adam et al.
In: Diabetes Care, Vol. 44, No. 4, 04.2021, p. 901-907.

596. **Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.** / Persson, Frederik; Bain, Stephen C; Mosenzon, Ofri et al.
In: Diabetes Care, Vol. 44, No. 4, 04.2021, p. 1020-1026.

597. **Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?** / Vlahou, Antonia; Hallinan, Dara; Apweiler, Rolf et al.
In: Hypertension, Vol. 77, No. 4, 04.2021, p. 1029-1035.

598. **Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline.** / Gorski, Mathias; Jung, Bettina; Li, Yong et al.
In: Kidney International, Vol. 99, No. 4, 01.04.2021, p. 926-939.

599. **A New Panel-Estimated GFR, Including beta(2)-Microglobulin and beta-Trace Protein and Not Including Race, Developed in a Diverse Population.** / CKD-EPI GFR Collaborators.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 77, No. 5, 05.2021, p. 673-683.e1.

600. **Biomarkers for early detection of kidney disease: a call for pathophysiological relevance.** / Siwy, Justyna; Mischak, Harald; Beige, Joachim et al.
In: Kidney International, Vol. 99, No. 5, 05.2021, p. 1240-1241.

601. **Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes.** / Rotbain Curovic, Viktor; Theilade, Simone; Winther, Signe Abitz et al.
In: Diabetic Medicine Online, Vol. 38, No. 5, e14459, 05.2021, p. e14459.

602. **The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes.** / Sivalingam, Suvanjaa; Larsen, Emil List; van Raalte, Daniel H et al.
In: Scientific Reports, Vol. 11, No. 1, 10624, 19.05.2021, p. 10624.

603. **Cardiovascular Autonomic Neuropathy in Type 1 Diabetes is Associated with Several Metabolic Pathways – New Risk Markers on the Horizon.** / Hansen, Christian Stevns; Suvitaival, Tommi; Theilade, Simone et al.
bioRxiv, 2021.

604. **Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions.** / Laursen, Jens Christian; Clemmensen, Kim Katrine Bjerring; Hansen, Christian Stevns et al.
In: BMJ Open Diabetes Research and Care, Vol. 9, No. 1, e001944, 31.05.2021.

605. **Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial.** / REMOVAL Study Group.
In: Diabetes, Obesity and Metabolism, Vol. 23, No. 6, 06.2021, p. 1371-1378.

606. **Non-invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls.** / Rasmussen, Ida K B; Hasbak, Philip; von Scholten, Bernt J et al.
In: Diabetic Medicine, Vol. 38, No. 6, 06.2021, p. e14517.

607. **Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907.** / Vistisen, Dorte; Andersen, Gregers S; Hulman, Adam et al.
In: Diabetes Care, Vol. 44, No. 6, 06.2021.

608. **Practice guidelines chronic kidney disease in diabetes: Guidelines from KDIGO.** / Khunti, Kamlesh; de Boer, Ian H.; Rossing, Peter.
In: American Family Physician, Vol. 103, No. 11, 01.06.2021, p. 698-700.

609. **Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study.** / Slieker, Roderick C; Donnelly, Louise A; Fitipaldi, Hugo et al.
In: Diabetologia, Vol. 64, 10.06.2021, p. 1982–1989.

610. **Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial.** / Laursen, Jens Christian; Søndergaard-Heinrich, Niels; de Melo, Joana Mendes Lopes et al.
In: EClinicalMedicine, Vol. 37, 100895, 07.2021, p. 100895.

611. **A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.** / DAPA-CKD Trial Committees and Investigators.
In: Kidney International, Vol. 100, No. 1, 07.2021, p. 215-224.

612. **Effect of Liraglutide on Arterial Inflammation Assessed as [F-18]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial: A Randomized, Double-Blind, Placebo-Controlled Trial.** / Ripa, Rasmus S; Zobel, Emilie H; von Scholten, Bernt J et al.
In: Circulation. Cardiovascular Imaging, Vol. 14, No. 7, e012174, 07.2021, p. e012174.

613. **Successful glucose lowering therapy triumphs in heart failure.** / Rossing, Peter.
In: EClinicalMedicine, Vol. 37, 100996, 07.2021, p. 100996.

614. **What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?** / Rossing, Peter; Persson, Frederik.
In: Advances in Chronic Kidney Disease, Vol. 28, No. 4, 07.2021, p. 290-297.

615. **Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.** / Filippatos, Gerasimos; Bakris, George L; Pitt, Bertram et al.
In: Journal of the American College of Cardiology, Vol. 78, No. 2, 13.07.2021, p. 142-152.

616. **Association of the Liver and Plasma Lipidomes with the Histological Stage of Alcohol-Related Liver Disease.** / Thiele, Maja; Suvitaival, Tommi; Trošt, Kajetan et al.
medRxiv, 2021.

617. **Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy.** / Winther, Signe Abitz; Mannerla, Miia Maininki; Frimodt-Møller, Marie et al.
In: Scientific Reports, Vol. 11, No. 1, 15208, 26.07.2021, p. 15208.

618. **Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes.** / Stougaard, Elisabeth Buur; Winther, Signe Abitz; Amadid, Hanan et al.
In: PLoS One, Vol. 16, No. 7, e0254859, 30.07.2021, p. e0254859.

619. **Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation.** / Ertuglu, Lale A; Porrini, Esteban; Hornum, Mads et al.
In: Transplant international : official journal of the European Society for Organ Transplantation, Vol. 34, No. 8, 08.2021, p. 1341-1359.

620. **Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.** / DAPA-CKD Trial Committees and Investigators.
In: Diabetes Care, Vol. 44, No. 8, 01.08.2021, p. 1894-1897.

621. **Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.** / Jürgens, Mikkel; Schou, Morten; Hasbak, Philip et al.
In: Journal of the American Heart Association, Vol. 10, No. 15, e020418, 03.08.2021, p. e020418.

622. **Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE.** / Zobel, Emilie H; Ripa, Rasmus S; von Scholten, Bernt J et al.
In: Diagnostics, Vol. 11, No. 8, 1431, 08.08.2021.

623. **Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.** / Zobel, Emilie H; Wretlind, Asger; Ripa, Rasmus S et al.
In: BMJ open diabetes research & care, Vol. 9, No. 1, e002395, 09.2021.

624. **Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes.** / Afshinnia, Farsad; Rajendiran, Thekkelnaycke M; He, Chenchen et al.
In: Diabetes Care, Vol. 44, No. 9, 09.2021, p. 2098-2106.

625. **Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.** / Chertow, Glenn; Vart, Priya; Jongs, Niels et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 32, No. 9, 09.2021, p. 2352-2361.

626. **Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.** / Piazza, M.; Hanssen, N. M.J.; Persson, F. et al.
In: Diabetic Medicine, Vol. 38, No. 9, e14405, 09.2021, p. e14405.

627. **Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes.** / Busch, Nikolaj; Jensen, Magnus T; Goetze, Jens P et al.
In: Journal of Diabetes, Vol. 13, No. 9, 09.2021, p. 754-763.

628. **Sex differences in the association between myocardial function and prognosis in type 1 diabetes without known heart disease: the Thousand & 1 Study.** / Lassen, Mats Christian Højbjerg; Biering-Sørensen, Tor; Jørgensen, Peter Godsk et al.
In: European heart journal cardiovascular Imaging, Vol. 22, No. 9, jeaa227, 09.2021, p. 1017-1025.

629. **Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials.** / DIRECT Programme Study Group.
In: Diabetic Medicine, Vol. 38, No. 9, e14634, 09.2021, p. e14634.

630. **Circulating sphingomyelin: A causal risk-factor of chronic kidney disease?** / Suvitaival, Tommi; Rossing, Peter; Legido-Quigley, Cristina .
In: Diabetologia, Vol. 64, No. Suppl 1, 617, 01.09.2021, p. S324.

631. **Metabolomic risk predictors of diabetic foot ulcers.** / Andersen, Jonas Hedegaard; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Diabetologia, Vol. 64, No. Suppl 1, 193, 01.09.2021, p. S102.

632. **Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.** / Zobel, Emilie H; Ripa, Rasmus S; von Scholten, Bernt J et al.
In: Scientific Reports, Vol. 11, No. 1, 18522, 17.09.2021, p. 18522.

633. **Metabolomic Risk Predictors of Diabetic Foot Ulcers.** / Andersen, Jonas Hedegaard; Suvitaival, Tommi; Frimodt-Møller, Marie et al.
2021. Abstract from Diabetic Foot Study Group 2021.

634. **Novel Topical Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell treatment of Hard to Heal Diabetic Foot Ulcers.** / Rasmussen, Anne; Frimodt-Møller, Marie; Kirketerp-Møller, Klaus et al.
2021. Poster session presented at Diabetic Foot Study Group 2021.

635. **Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes.** / Mychaleckyj, Josyf; Valo, Erkka; Ichimura, Takaharu et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 32, No. 10, 10.2021, p. 2634-2651.

636. **The low-expression variant of FABP4 is associated with cardiovascular disease in type 1 diabetes.** / FinnDiane Study Group.
In: Diabetes, Vol. 70, No. 10, 10.2021, p. 2391-2401.

637. **A Machine Learning Approach to Predict 5-year Risk for Complications in Type 1 Diabetes.** / Al-Sari, Naba ; Kutuzova, Svetlana; Suvitaival, Tommi et al.
medRxiv, 2021.

638. **Association of the Liver and Plasma Lipidomes with the Histological Severity Stage of Alcohol-Related Liver Disease.** / GALAXY and MicrobLiver consortia.
2021. Abstract from NNF Challenge Symposium, Hellerup, Denmark.

639. **Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes.** / Bjerre-Christensen, Theis; Winther, Signe A; Tofte, Nete et al.
In: BMJ open diabetes research & care, Vol. 9, No. 1, e002289, 13.10.2021.

640. **Distinct Molecular Signatures of Clinical Clusters in People with Type 2 Diabetes: an IMI-RHAPSODY Study.** / Slieker, Roderick C; Donnelly, Louise A; Fitipaldi, Hugo et al.
In: Diabetes, Vol. 70, No. 11, 11.2021, p. 2683-2693.

641. **Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.** / Heerspink, Hiddo; Xie, Di; Bakris, George et al.
In: Journal of the American Society of Nephrology, Vol. 32, No. 11, 11.2021, p. 2900-2911.

642. **Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.** / DAPA-CKD Trial Committees and Investigators.
In: The Lancet Diabetes and Endocrinology, Vol. 9, No. 11, 11.2021, p. 743-754.

643. **Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.** / DAPA-CKD Trial Committees and Investigators.
In: The Lancet Diabetes and Endocrinology, Vol. 9, No. 11, 11.2021, p. 755-766.

644. **Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.** / McMurray, John J V; Wheeler, David C; Stefánsson, Bergur V et al.
In: JACC. Heart failure, Vol. 9, No. 11, 11.2021, p. 807-820.

645. **Essential Branched-Chain Amino Acids and Ribonic Acid Are Associated with Cardiorenal Events in Type 1 Diabetes.** / Ferreira-Divino, Luis Felipe; Suvitaival, Tommi; Curovic, Viktor Rotbain et al.
In: Journal of the American Society of Nephrology, Vol. 32, SA-OR30, 11.2021, p. 48.

646. **New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.** / Chronic Kidney Disease Epidemiology Collaboration.
In: The New England journal of medicine, Vol. 385, No. 19, 04.11.2021, p. 1737-1749.

647. **Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [Cu-64]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial: Results from the LIRAFLAME Trial.** / Jensen, Jacob K; Zobel, Emilie H; von Scholten, Bernt J et al.
In: Frontiers in Endocrinology, Vol. 12, 790405, 30.11.2021, p. 790405.

648. **Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.** / Rasmussen, Ida K B; Zobel, Emilie H; Ripa, Rasmus S et al.
In: Diabetes, Obesity and Metabolism, Vol. 23, No. 12, 12.2021, p. 2651-2659.

649. **Sodium-Glucose Cotransporter 2 Inhibitors for Diabetes Mellitus Control After Kidney Transplantation: Review of the Current Evidence.** / Kanbay, Mehmet; Demiray, Atalay; Afsar, Baris et al.
In: Nephrology, Vol. 26, No. 12, 12.2021, p. 1007-1017.

650. **Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial.** / Rossing, Peter; Strand, Jorma; Avogaro, Angelo et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 36, No. 12, 02.12.2021, p. 2263-2273.

651. **Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.** / Fauchier, Laurent; Boriani, Giuseppe; de Groot, Joris R et al.
In: EP Europace, Vol. 23, No. 12, 07.12.2021, p. 1873-1891.

652. **Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.** / Pitt, Bertram; Filippatos, Gerasimos; Agarwal, Rajiv et al.
In: The New England journal of medicine, Vol. 385, No. 24, 2110956, 09.12.2021, p. 2252-2263.

653. **The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls.** / Laursen, Jens Christian; Rasmussen, Ida Kirstine B; Zobel, Emilie H et al.
In: Frontiers in Endocrinology, Vol. 12, 780679, 13.12.2021, p. 780679.

654. **Development in eGFR Trajectories in People With Diabetic Nephropathy.** / Poulsen, Christina Gjerlev ; Jesse, Kristin; Carstensen, Bendix et al.
2022. Abstract from ASN Kidney Week 2022, Orlando, Florida, United States.

655. **Effect of Spironolactone Wash-Out on Albuminuria After Long-Term Treatment: The AFTER-PRIORITY Study.** / on the behalf of the PRIORITY Study Group.
In: Journal of the American Society of Nephrology, Vol. 33, SA-PO272 P, 2022, p. 677.

656. **Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial.** / Wretlind, Asger; Zobel, Emilie Hein; de Zawadzki, Andressa et al.
In: Frontiers in Clinical Diabetes and Healthcare, Vol. 3, 856485, 2022, p. 856485.

657. **Ny kvalitetsrapport om diabetesbehandling er lidt af en fuser.** / Thybo, Tanja; Rossing, Peter; Sjøgren, Kristian Peter.
In: Dagens Medicin, Vol. 2022, No. 2, 2022, p. 22-23.

658. **The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.** / von Scholten, Bernt Johan; Kreiner, Frederik Flindt; Rasmussen, Søren et al.
In: Therapeutic Advances in Endocrinology and Metabolism, Vol. 13, 2022, p. 20420188221112490.

659. **A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.** / Heerspink, Hiddo Jl; Cherney, David; Postmus, Douwe et al.
In: Kidney International, Vol. 101, No. 1, 01.2022, p. 174-184.

660. **Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes.** / Heinrich, Niels S; Theilade, Simone; Winther, Signe A et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, No. 1, 01.2022, p. 100-107.

661. **Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.** / Rossing, Peter; Inzucchi, Silvio E; Vart, Priya et al.
In: The Lancet Diabetes and Endocrinology, Vol. 10, No. 1, 01.2022, p. 24-34.

662. **Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.** / Rossing, Peter; Agarwal, Rajiv; Anker, Stefan D et al.
In: Diabetes, Obesity and Metabolism, Vol. 24, No. 1, 01.2022, p. 125-134.

663. **Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.** / FIDELIO-DKD Investigators; Krarup, Thue (Member of author group).
In: Kidney International Reports, Vol. 7, No. 1, 01.2022, p. 36-45.

664. **Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.** / FIDELIO-DKD Investigators; Krarup, Thue.
In: Journal of the American Society of Nephrology, Vol. 33, No. 1, 01.2022, p. 225-237.

665. **The authors reply: KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.** / Caramori, M Luiza; Tuttle, Katherine R; Tandon, Nikhil et al.
In: Kidney International, Vol. 101, No. 2, 02.2022, p. 420-421.

666. **The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.** / Zobel, Emilie H.; Von Scholten, Bernt Johan ; Hansen, Tine W. et al.
In: Diabetes, Obesity and Metabolism, Vol. 24, No. 2, 02.2022, p. 281-288.

667. **Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial.** / FIGARO-DKD Investigators.
In: Circulation, Vol. 145, No. 6, 08.02.2022, p. 437-447.

668. **Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators ; Krarup, Thure (Member of author group).
In: European Heart Journal, Vol. 43, No. 6, 10.02.2022, p. 474-484.

669. **Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.** / Shaman, Ahmed M; Bain, Stephen C; Bakris, George L et al.
In: Circulation, Vol. 145, No. 8, 22.02.2022, p. 575-585.

670. **Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial.** / Ersbøll, Mads; Jürgens, Mikkel; Hasbak, Philip et al.
In: The international journal of cardiovascular imaging, Vol. 38, No. 3, 03.2022, p. 579-587.

671. **The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.** / DAPA-CKD Trial Committees and Investigators.
In: Kidney International Reports, Vol. 7, No. 3, 03.2022, p. 436-443.

672. **Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.** / Rossing, Peter.
In: Kidney International Supplements, Vol. 12, No. 1, 04.2022, p. 27-35.

673. **Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.** / Vart, Priya; Correa-Rotter, Ricardo; Hou, Fan Fan et al.
In: Kidney International Reports, Vol. 7, No. 4, 04.2022, p. 699-707.

674. **Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.** / FIDELIO-DKD Investigators; Krarup, Thue (Member of author group); Madsbad, Sten.
In: Diabetes Care, Vol. 45, No. 4, 01.04.2022, p. 888-897.

675. **Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial.** / Wolsk, Emil; Jürgens, Mikkel; Schou, Morten et al.
In: Diabetes, Vol. 71, No. 4, 01.04.2022, p. 812-820.

676. **Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With Disturbances in TCA, Lipid, and Glucose Metabolism.** / Hansen, Christian S; Suvitaival, Tommi; Theilade, Simone et al.
In: Frontiers in Endocrinology, Vol. 13, 831793, 14.04.2022, p. 831793.

677. **Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.** / Rotbain Curovic, Viktor; Houlind, Morten B; Hansen, Tine W et al.
In: Frontiers in Pharmacology, Vol. 13, 799915, 27.04.2022, p. 1-7.

678. **BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE.** / Perkovic, Vlado; Baeres, Florian; Bakris, George et al.
In: Nephrology Dialysis Transplantation, Vol. 37, No. Suppl 3, FC 123, 05.2022, p. I893-I894.

679. **FINERENONE AND CANAGLIFLOZIN IN THE TREATMENT OF CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF FIDELIO-DKD AND CREDENCE.** / Cherney, David; Folkerts, Kerstin; Mernagh, Paul et al.
In: Nephrology Dialysis Transplantation, Vol. 37, No. Suppl 3, FC083, 05.2022, p. I848-I849.

680. **Microalbuminuria constitutes a Clinical Action Item for Clinicians in 2021.** / Rossing, Peter; Epstein, Murray.
In: The American Journal of Medicine, Vol. 135, No. 5, 05.2022, p. 576-580.

681. **OUTCOMES WITH FINERENONE IN PATIENTS WITH STAGE 4 CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY SUBGROUP ANALYSIS.** / Sarafidis, Pantelis; Ruilope, Luis; Anker, Stefan D. et al.
In: Nephrology Dialysis Transplantation, Vol. 37, No. Suppl 3, MO 198, 05.2022, p. I134-I135.

682. **Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.** / Chertow, Glenn M; Vart, Priya; Jongs, Niels et al.
In: Diabetes, Obesity and Metabolism, Vol. 24, No. 5, 05.2022, p. 827-837.

683. **HEPATIC STEATOSIS IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE.** / Adrian, Therese; Hornum, Mads; Knop, Filip K. et al.
In: Nephrology Dialysis Transplantation, Vol. 37, No. Suppl 3, MO 408, 03.05.2022, p. I294-I294.

684. **INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.** / Dunger, David B.; Bruggraber, Sylvaine F.A.; Mander, Adrian P. et al.
In: Trials, Vol. 23, No. 1, 414, 18.05.2022.

685. **Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial.** / Pratley, Richard E.; Baeres, Florian M. M.; Bakris, George et al.
In: Diabetes, Vol. 71, No. Suppl 1, 747-P, 06.2022.

686. **Effects of Finerenone in Patients with CKD and T2D Are Independent of HbA1c at Baseline, HbA1c Variability, and Duration of Diabetes.** / FIDELIO-DKD and FIGARO-DKD Investigators ; Rossing, Peter.
In: Diabetes, Vol. 71, No. Suppl 1, 16-LB, 06.2022.

687. **Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study.** / Persson, Frederik; Rossing, Peter; Jongs, Niels et al.
In: Diabetes, Vol. 71, No. Suppl 1, 866-P, 06.2022.

688. **Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use.** / Rossing, Peter; Anker, Stefan; Filippatos, Gerasimos et al.
In: Diabetes, Vol. 71, No. Supplement_1, 06.2022.

689. **Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.** / FIDELIO-DKD Investigators; Krarup, Thue (Member of author group).
In: European Journal of Heart Failure, Vol. 24, No. 6, 06.2022, p. 996-1005.

690. **Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology.** / Waijer, Simke W.; Provenzano, Michele; Mulder, Skander et al.
In: Diabetes, Obesity and Metabolism, Vol. 24, No. 6, 06.2022, p. 983-990.

691. **Normalizing Glomerular Filtration Rate (GFR) Using Extracellular Volume (ECV) Instead of Body Surface Area (BSA) : Results from an Analysis of the Preventing Early Renal Loss (PERL) Trial.** / Lovblom, Leif Erik; Lanctot, Sebastien O.; Maahs, David M. et al.
In: Diabetes, Vol. 71, No. Supplement_1, 391-P, 06.2022.

692. **Optimization of Albuminuria Lowering Treatment by Crossover Rotation to Four Different Drug Classes.** / Curovic, Viktor Rotbain; Kroonen, Marjolein Y. A.; Jongs, Niels et al.
In: Diabetes, Vol. 71, No. Suppl 1, 21-OR, 06.2022.

693. **Precision diagnostic approach to predict 5-year risk for microvascular complications in type 1 diabetes.** / Al-Sari, Naba; Kutuzova, Svetlana; Suvitaival, Tommi et al.
In: EBioMedicine, Vol. 80, 104032, 06.2022, p. 104032.

694. **Real-Life Evaluation of Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes.** / Stougaard, Elisabeth Buur; Kristensen, Peter L.; Kielgast, Urd et al.
In: Diabetes, Vol. 71, No. Suppl 1, 369-P, 06.2022.

695. **Baseline Risk Markers and Visit-to-Visit Variability in Relation to Kidney Outcomes: A Post Hoc Analysis of the PERL Study.** / CUROVIC, VIKTOR ROTBAIN; ROY, NEIL; HANSEN, TINE W. et al.
In: Diabetes, Vol. 71, No. Supplement_1, 394-P, 01.06.2022.

696. **Effect of Finerenone on Occurrence of Vision-Threatening Events in Patients with DR.** / ROSSING, PETER; ANKER, STEFAN; GARWEG, JUSTUS G. et al.
In: Diabetes, Vol. 71, No. Supplement_1, 826-P, 01.06.2022.

697. **Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Trial.** / Tougaard, Ninna Hahn; Frimodt-Møller, Marie; Salmenkari, Hanne et al.
In: Diabetes, Vol. Volume 71, No. Issue Supplement_1, 406-P, 01.06.2022.

698. **Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes.** / Kidney Precision Medicine Project.
In: Diabetes Care, Vol. 45, No. 6, 02.06.2022, p. 1416-1427.

699. **Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals.** / LifeLines Cohort Study.
In: Communications biology, Vol. 5, No. 1, 580, 13.06.2022, p. 580.

700. **Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.** / Tougaard, Ninna Hahn; Frimodt-Møller, Marie; Salmenkari, Hanne et al.
In: Journal of Clinical Medicine, Vol. 11, No. 13, 3573, 21.06.2022.

701. **Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.** / FIDELIO-DKD Investigators; Krarup, Thue.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, No. 7, 23.06.2022, p. 1261-1269.

702. **Novel topical allogeneic bone-marrow-derived mesenchymal stem cell treatment of hard-to-heal diabetic foot ulcers: a proof of concept study.** / Askø Andersen, Jonas; Rasmussen, Anne; Frimodt-Møller, Marie et al.
In: Stem Cell Research & Therapy, Vol. 13, No. 1, 280, 28.06.2022, p. 280.

703. **Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes.** / Safi, Mostafa; Borup, Anna; Stevns Hansen, Christian et al.
In: Diabetes Research and Clinical Practice, Vol. 189, 109943, 07.2022.

704. **Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.** / Waijer, Simke W; Vart, Priya; Cherney, David Z I et al.
In: Diabetologia, Vol. 65, No. 7, 07.2022, p. 1085-1097.

705. **Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria.** / McGill, Janet B; Haller, Hermann; Roy-Chaudhury, Prabir et al.
In: BMJ open diabetes research & care, Vol. 10, No. 4, e002806, 07.2022.

706. **Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines.** / Stougaard, Elisabeth B; Rossing, Peter; Cherney, David et al.
In: Journal of Diabetes and its Complications, Vol. 36, No. 8, 108257, 08.2022, p. 108257.

707. **The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.** / Sivalingam, Suvanjaa; Hein Zobel, Emilie; Hansen, Christian S et al.
In: Diabetes, Obesity and Metabolism, Vol. 24, No. 8, 08.2022, p. 1638-1642.

708. **Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.** / Wheeler, David C; Jongs, Niels; Stefansson, Bergur V et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, No. 9, 22.08.2022, p. 1647-1656.

709. **Circulating metabolites associated with diabetic sensorimotor peripheral neuropathy among individuals with type 1 diabetes.** / Sørland, Brede Aksdal; Hansen, Christian Stevns; Sulek, Karolina et al.
In: Diabetologia, Vol. 65, No. Suppl 1, SO59-719, 09.2022.

710. **Development in eGFR trajectories in people with diabetic nephropathy.** / Poulsen, Christina Gjerlev ; Jesse, Kristin; Carstensen, Bendix et al.
In: Diabetologia, Vol. 65, No. Suppl 1, 09.2022.

711. **Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies.** / LifeLines Cohort Study.
In: Kidney International, Vol. 102, No. 3, 09.2022, p. 624-639.

712. **Genome wide association study of Diabetic Foot Ulcers.** / Altintas, Sule; Andersen, Jonas Askø; Hansen, Christian Stevns et al.
In: Diabetologia, Vol. 65, No. Suppl 1, OP04-20, 09.2022.

713. **Non-dipping and higher nocturnal blood pressure are associated with risk of mortality and development of kidney disease in type 1 diabetes.** / Hjortkjær, Henrik Ø; Persson, Frederik; Theilade, Simone et al.
In: Journal of Diabetes and its Complications, Vol. 36, No. 9, 108270, 09.2022, p. 108270.

714. **Preconception Antidiabetic Drugs in Men and Birth Defects in Offspring Response.** / Rossing, Peter; Gwilt, Michael.
In: Annals of Internal Medicine, Vol. 175, No. 9, 01.09.2022, p. W106.

715. **Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and renal disease as assessed by Steno Risk Engines in adults with type 1 diabetes.** / Stougaard, E. B.; Rossing, P.; Vistisen, D. et al.
In: Diabetologia, Vol. 65, No. SUPPL 1, 1, SI, 01.09.2022, p. S47.

716. **Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: JAMA network open, Vol. 5, No. 10, 03.10.2022, p. e2236123.

717. **Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.** / Stougaard, Elisabeth B; Kristensen, Peter L; Kielgast, Urd et al.
In: Diabetes and Vascular Disease Research, Vol. 19, No. 5, 21.10.2022, p. 14791641221130043.

718. **Baseline risk markers and visit-to-visit variability in relation to kidney outcomes - A post-hoc analysis of the PERL study.** / PERL Study Group.
In: Diabetes Research and Clinical Practice, Vol. 193, 110119, 11.2022, p. 110119.

719. **Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.** / DAPA-CKD Trial Committees and Investigators.
In: Journal of the American Society of Nephrology, Vol. 33, No. 11, 11.2022, p. 2094-2107.

720. **Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).** / de Boer, Ian H; Khunti, Kamlesh; Sadusky, Tami et al.
In: Kidney International, Vol. 102, No. 5, 11.2022, p. 974-989.

721. **Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria.** / DAPA-CKD Trial Committee and Investigators.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 17, No. 11, 11.2022, p. 1665-1668.

722. **Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.** / Rossing, Peter; Caramori, M Luiza; Chan, Juliana C N et al.
In: Kidney International, Vol. 102, No. 5, 11.2022, p. 990-999.

723. **Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.** / Filippatos, Gerasimos; Anker, Stefan D; Pitt, Bertram et al.
In: JACC. Heart failure, Vol. 10, No. 11, 11.2022, p. 860-870.

724. **KDIGO 2022 CLINICAL PRACTICE GUIDELINE FOR DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE.** / KDIGO Diabetes Work Group.
In: Kidney International, Vol. 102, No. 5, 11.2022, p. S1-S127.

725. **Kidney oxygenation, perfusion and blood flow in people with and without type 1 diabetes.** / Laursen, Jens Christian; Søndergaard-Heinrich, Niels; Haddock, Bryan et al.
In: Clinical kidney journal, Vol. 15, No. 11, 11.2022, p. 2072-2080.

726. **Organic anion transporter gene variants associated with plasma exposure and long-term response to atrasentan in patients with diabetic kidney disease.** / Smeijer, J David; Koomen, Jeroen V; Kohan, Donald E et al.
In: Clinical Pharmacology and Therapeutics, Vol. 112, No. 5, 11.2022, p. 1098-1107.

727. **Dapagliflozin Improves the Urinary Proteomic Kidney-Risk Classifier CKD273 in Type 2 Diabetes with Albuminuria - a Randomized Clinical Trial.** / Curovic, Rotbain Viktor; Eickhoff, Mie Klessen; Rönkkö, Teemu et al.
In: Diabetes Care, Vol. 45, No. 11, 01.11.2022, p. 2662-2668.

728. **Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort.** / Tougaard, Ninna Hahn; Møller, Alexandra Louise; Rønn, Pernille Falberg et al.
In: Diabetes Care, Vol. 45, No. 11, 01.11.2022, p. 2746-2748.

729. **Flexor Tendon Tenotomy Treatment of the Diabetic Foot: A Multicenter Randomized Controlled Trial.** / Andersen, Jonas Askø; Rasmussen, Anne; Engberg, Susanne et al.
In: Diabetes Care, Vol. 45, No. 11, 01.11.2022, p. 2492-2500.

730. **Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; Aroda, Vanita R; Collins, Billy S et al.
In: Diabetes Care, Vol. 45, No. 11, 01.11.2022, p. 2753-2786.

731. **The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus.** / Puig-Jové, Carlos; Julve, Josep; Castelblanco, Esmeralda et al.
In: Cardiovascular Diabetology, Vol. 21, No. 1, 257, 24.11.2022, p. 257.

732. **Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes.** / Ferreira-Divino, Luis F; Suvitaival, Tommi; Rotbain Curovic, Viktor et al.
In: Cardiovascular Diabetology, Vol. 21, No. 1, 135, 12.2022, p. 135.

733. **Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes.** / Gregers, Mads C T; Schou, Morten; Jensen, Magnus T et al.
In: Scandinavian Cardiovascular Journal, Vol. 56, No. 1, 2095435, 12.2022, p. 256-263.

734. **Distal symmetrical polyneuropathy is present in all individuals with diabetes and foot ulcers - and does not associate with healing time.** / Mizrak, Hatice Isik; Hansen, Tine Willum; Andersen, Jonas Askø et al.
In: Journal of Diabetes and its Complications, Vol. 36, No. 12, 108353, 12.2022, p. 108353.

735. **Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.** / Rossing, Peter; Anker, Stefan D; Filippatos, Gerasimos et al.
In: Diabetes Care, Vol. 45, No. 12, 12.2022, p. 2991-2998.

736. **Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; Aroda, Vanita R; Collins, Billy S et al.
12 ed. 2022. 41 p. (Diabetologia).

737. **Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.** / Schnell, Oliver; Battelino, Tadej; Bergenstal, Richard et al.
In: Cardiovascular Diabetology, Vol. 21, No. 1, 50, 12.2022, p. 50.

738. **Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.** / FIDELIO-DKD Investigators; Krarup, Thue (Member of author group).
In: Hypertension, Vol. 79, No. 12, 01.12.2022, p. 2685-2695.

739. **Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).** / de Boer, Ian H; Khunti, Kamlesh; Sadusky, Tami et al.
In: Diabetes Care, Vol. 45, No. 12, 01.12.2022, p. 3075-3090.

740. **Multiomics signatures of type 1 diabetes with and without albuminuria.** / Clos-Garcia, Marc; Ahluwalia, Tarunveer S.; Winther, Signe A. et al.
In: Frontiers in Endocrinology, Vol. 13, 1015557, 02.12.2022.

741. **Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.** / Filippatos, Gerasimos; Anker, Stefan D; Pitt, Bertram et al.
In: European heart journal. Cardiovascular pharmacotherapy, Vol. 9, No. 1, 15.12.2022, p. 85-93.

742. **Increased mitochondrial proton leak and glycolysis in peripheral blood mononuclear cells in type-1-diabetes.** / Lopes de Melo, Joana Mendes; Laursen, Jens Christian; Søndergaard-Heinrich, Niels et al.
In: Heliyon, Vol. 8, No. 12, e12304, 20.12.2022.

743. **Aldosterone Synthase Inhibition with or Without Background Sodium Glucose Cotransporter 2 Inhibition in CKD: A Phase II Clinical Trial.** / Tuttle, Katherine R.; Hauske, Sibylle J; Cronin, Lisa et al.
In: Journal of the American Society of Nephrology, 2023.

744. **Associations Between Albuminuria and Clinical Outcomes in Patients with CKD with and Without Diabetes: New Insights from DAPA-CKD.** / van Mil, Dominique; Vart, Priya; Schechter, Meir et al.
In: Journal of the American Society of Nephrology, 2023.

745. **Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?** / Bomholt, Tobias; Kofod, Dea; Nørgaard, Kirsten et al.
In: Nephron, Vol. 147, No. 2, 2023, p. 91-96.

746. **Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.** / FIDELIO-DKD Investigators.
In: American Journal of Nephrology, Vol. 54, No. 9-10, 2023, p. 370-378.

747. **Comparative effectiveness of GLP-1 receptor agonists vs DPP-4 inhibitors in patients with type 2 diabetes and moderate/severe chronic kidney disease.** / Tuttle, Katherine R.; Fioretto, Paola; Clark, Alice Jessie et al.
In: Diabetologia, Vol. 66, No. Suppl 1, 664, 2023, p. 335.

748. **Effect of albuminuria on atherosclerotic phenotype in type 2 diabetes without known cardiovascular disease.** / Rasmussen, Ida Kirstine Bull; Skriver-Møller, Anne-Cathrine; Ripa, Rasmus Sejersten et al.
2023. Abstract from European Diabetic Nephropathy Study Group (EDNSG) 35th Annual meeting, Nantes, France.

749. **Effects of Probiotics and Fibers on Markers of Nephropathy and Endothelial Dysfunction in Persons with Type 1 Diabetes and Albuminuria.** / Stougaard, Elisabeth Buur; Tougaard, Ninna Hahn; Curovic, Viktor Rotbain et al.
In: Journal of the American Society of Nephrology, 2023.

750. **Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort.** / Møller, Alexandra Louise; Tougaard, Ninna Hahn; Rasmussen, Daniel Guldager Kring et al.
In: Frontiers in molecular biosciences, Vol. 10, 1229579, 2023, p. 1229579.

751. **ESKD-Free Survival Time in Patients with CKD and Type 2 Diabetes (TD2) in FIDELITY.** / Singh, Ajay K; Anker, Stefan D; Filippatos, Gerasimos et al.
In: Journal of the American Society of Nephrology, Vol. 34, SA-PO476, 2023.

752. **Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.** / Rossing, Peter; Groehl, Franziska; Mernagh, Paul et al.
In: Journal of Medical Economics, Vol. 26, No. 1, 2023, p. 935-943.

753. **FIGARO-BM, a Biomarker Study of FIGARO-DKD, Reveals New Insights into the Mode of Action of Finerenone.** / Berger, Mario ; Christopher, Lydia J ; Goea, Laura et al.
In: Journal of the American Society of Nephrology, 2023.

754. **Four missense genetic variants in CUBN are associated with higher levels of eGFR in non-diabetes but not in diabetes mellitus or its subtypes: A genetic association study in Europeans.** / Uglebjerg, Nicoline; Ahmadizar, Fariba; Aly, Dina M et al.
In: Frontiers in Endocrinology, Vol. 14, 1081741, 2023, p. 1081741.

755. **Hepatic Fibrosis Evaluated in Patients with Type 2 Diabetes with and without Chronic Kidney Disease.** / Adrian, Therese; Hornum, Mads; Knop, Filip Krag et al.
In: Nephron, Vol. 147, No. 11, 2023, p. 673-684.

756. **Impact of Finerenone-Induced Albuminuria Reduction on CKD Outcomes in Type 2 Diabetes: A Causal Mediation Analysis.** / Agarwal, Rajiv; Tu, Wanzu; Farjat, Alfredo et al.
In: Journal of the American Society of Nephrology, 2023.

757. **Increased Coronary Artery Pathology in Type 2 Diabetes Without Cardiovascular Disease but with Albuminuria.** / Hansen, Tine Willum; Rasmussen, Ida Kirstine Bull; Skriver-Møller, Anne-Cathrine et al.
In: Journal of the American Society of Nephrology, Vol. 34, FR-OR97, 2023, p. 56.

758. **Insulin Resistance, Kidney Outcomes, and Effects of the Endothelin Receptor Antagonist Atrasentan in Patients with Type 2 Diabetes and CKD.** / Smeier, Johannes D; Kohan, Donald E; Rossing, Peter et al.
In: Journal of the American Society of Nephrology, 2023.

759. **Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria.** / Poulsen, Christina Gjerlev; Rasmussen, Daniel G K; Genovese, Federica et al.
In: PLoS One, Vol. 18, No. 3, e0283296, 2023.

760. **Mediators of the Kidney Protective Effects of Dapagliflozin in Patients with CKD with or Without Type 2 Diabetes.** / Schechter, Meir; Jongs, Niels; Chertow, Glenn M et al.
In: Journal of the American Society of Nephrology, 2023.

761. **Metabolomic and Transcriptomic Reveal Signature of Citrate Homeostasis in Diabetic Kidney Disease.** / Maity, soumya; Limonte, Christine P; Valo, Erkka et al.
In: Journal of the American Society of Nephrology, 2023.

762. **Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease.** / Adrian, Therese; Hornum, Mads; Knop, Filip Krag et al.
In: Nephron, Vol. 147, No. 6, 2023, p. 317-328.

763. **Oral ketone esters acutely improve myocardial contractility in post-hospitalized COVID-19 patients: A randomized placebo-controlled double-blind crossover study.** / Wodschow, Helena Zander; Davidovski, Filip Søskov; Christensen, Jacob et al.
In: Frontiers in nutrition, Vol. 10, 1131192, 2023, p. 1131192.

764. **Overall and Interindividual Effect of Four Different Drug Classes on Soluble Urokinase Plasminogen Activator Receptor in Albuminuric Type 1 and Type 2 Diabetes.** / Curovic, Viktor Rotbain; Houlind, Morten Baltzer; Kroonen, Marjolein Y. A. et al.
In: Journal of the American Society of Nephrology, Vol. 34, SA-PO478, 2023.

765. **Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy.** / Vestergaard, Mark B; Laursen, Jens Christian; Heinrich, Niels Søndergaard et al.
In: Frontiers in Neuroscience, Vol. 17, 1229509, 2023, p. 1229509.

766. **PRO-C3 as a risk marker for kidney disease progression and mortality in type 1 diabetes.** / Rygg, Marte Opseth; Møller, Alexandra Louise; Curovic, Viktor Rotbain et al.
In: Journal of the American Society of Nephrology, 2023.

767. **Progression to ESKD in Type 1 Diabetes by Histological Findings.** / Jensen, Karina Haar; Persson, Frederik; Bressendorff, Iain et al.
In: Journal of the American Society of Nephrology, 2023.

768. **Progression to ESKD in Type 2 Diabetes by Histological Findings: A Retrospective Cohort Study.** / Jensen, Karina Haar; Persson, Frederik; Bressendorff, Iain et al.
In: Journal of the American Society of Nephrology, 2023.

769. **Rationale and Design of a Phase 3 Registration Trial Investigating Finerenone in Participants with CKD and Type 1 Diabetes Using a Urine Albumin-Creatinine Ratio (UACR) End Point (FINE-ONE).** / Lambers Heerspink, Hiddo J; Rossing, Peter; Groop, Per-Henrik et al.
In: Journal of the American Society of Nephrology, 2023.

770. **Renal Effects of Empagliflozin Alone or in Combination with Semaglutide in Albuminuric Type 2 Diabetes: A Randomized, Placebo-Controlled Trial.** / Persson, Frederik; Sivalingam, Suvanjaa; Wasehuus, Victor et al.
In: Journal of the American Society of Nephrology, 2023.

771. **The Influence of Bone on Kidney Disease Progression in Persons with Type 1 Diabetes.** / Hauge, Sabina Chaudhary; Hjortkjær, Henrik Øder ; Persson, Frederik et al.
In: Journal of the American Society of Nephrology, 2023.

772. **A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.** / FIDELIO-DKD and FIGARO-DKD Investigators; Krarup, Thue (Member of author group).
In: Kidney International, Vol. 103, No. 1, 01.2023, p. 196-206.

773. **Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD.** / Schechter, Meir; Jongs, Niels; Chertow, Glenn M et al.
In: Annals of Internal Medicine, Vol. 176, No. 1, 01.2023, p. 59-66.

774. **In vivo molecular imaging of cardiac angiogenesis in persons with and without type 2 diabetes: a cross-sectional 68 Ga-RGD-PET study.** / Laursen, Jens Christian; Rasmussen, Ida Kirstine Bull; Zobel, Emilie Hein et al.
In: Diabetic medicine : a journal of the British Diabetic Association, Vol. 40, No. 1, e14960, 01.2023.

775. **Lower blood oxygen saturation is associated with microvascular complications in individuals with type 1 diabetes.** / Laursen, Jens Christian; Mizrak, Hatice Isik; Kufaishi, Huda et al.
In: The Journal of clinical endocrinology and metabolism, Vol. 108, No. 1, 01.2023, p. 99-106.

776. **HbA1c and beyond.** / Rossing, Peter.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, No. 1, 23.01.2023, p. 34-40.

777. **A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.** / Agarwal, Rajiv; Pitt, Bertram; Palmer, Biff F et al.
In: Clinical kidney journal, Vol. 16, No. 2, 02.2023, p. 293-302.

778. **Effects of Two- and Twelve-Weeks Sodium-Glucose Cotransporter 2 Inhibition on DNA and RNA Oxidation: Two Randomized, Placebo-Controlled Trials.** / Larsen, Emil L; Andersen, Andreas; Kjaer, Laura K et al.
In: Free Radical Research, Vol. 57, No. 2, 02.2023, p. 140-151.

779. **Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 2, 02.2023, p. 407-416.

780. **Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.** / Agarwal, Rajiv; Ruilope, Luis M.; Ruiz-Hurtado, Gema et al.
In: Journal of Hypertension, Vol. 41, No. 2, 01.02.2023, p. 295-302.

781. **Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: the DECODE-CKD trial.** / Bartholdy, Katja Vu; Johansen, Niklas Dyrby; Landler, Nino et al.
In: Kidney360, Vol. 4, No. 2, 01.02.2023, p. 143-149.

782. **Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.** / Filippatos, Gerasimos; Anker, Stefan D; August, Phyllis et al.
In: European heart journal. Cardiovascular pharmacotherapy, Vol. 9, No. 2, 02.02.2023, p. 183-191.

783. **Kidney outcomes with finerenone: An analysis from the FIGARO-DKD study.** / Ruilope, Luis M; Pitt, Bertram; Anker, Stefan D et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, No. 2, 13.02.2023, p. 372-383.

784. **Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes.** / Khurana, Ishant; Kaipananickal, Harikrishnan; Maxwell, Scott et al.
In: The Journal of clinical investigation, Vol. 133, No. 4, e160959, 15.02.2023.

785. **Clinical implications and guidelines for CKD in type 2 diabetes.** / Zhang, Rong M; Persson, Frederik; McGill, Janet B et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, No. 3, 03.2023, p. 542-550.

786. **Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.** / Navaneethan, Sankar D; Zoungas, Sophia; Caramori, M Luiza et al.
In: Annals of Internal Medicine, Vol. 176, No. 3, 03.2023, p. 381-387.

787. **Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR).** / Rossing, Peter; Garweg, Justus G; Anker, Stefan D et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 3, 03.2023, p. 894-898.

788. **Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.** / Beernink, Jelle M; Persson, Frederik; Jongs, Niels et al.
In: Diabetes Care, Vol. 46, No. 3, 03.2023, p. 602-607.

789. **Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: a sub-study from the SIMPLE randomized clinical trial.** / Brandt-Jacobsen, Niels H; Jürgens, Mikkel; Hasbak, Philip et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 3, 03.2023, p. 844-855.

790. **Efficacy and safety of finerenone by age and sex subgroups in patients with chronic kidney disease and type 2 diabetes.** / Bansal, S.; Anker, S.; Bakris, G. et al.
In: Diabetes Research and Clinical Practice, Vol. 197, No. 1, IDF2022-1255, 01.03.2023.

791. **Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.** / Curovic, Viktor Rotbain; Jongs, Niels; Kroonen, Marjolein Y A M et al.
In: Diabetes Care, Vol. 46, No. 3, 01.03.2023, p. 593-601.

792. **CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.** / Schnell, Oliver; Battelino, Tadej; Bergenstal, Richard et al.
In: Cardiovascular Diabetology, Vol. 22, No. 1, 59, 16.03.2023, p. 59.

793. **Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).** / Green, Jennifer B; Mottl, Amy K; Bakris, George et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, No. 4, 31.03.2023, p. 894-903.

794. **Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial.** / on the behalf of the PRIORITY Study Group.
In: Journal of Diabetes and its Complications, Vol. 37, No. 4, 108433, 04.2023, p. 108433.

795. **Differential Methylation of Telomere-Related Genes Is Associated with Kidney Disease in Individuals with Type 1 Diabetes.** / Hill, Claire; Duffy, Seamus; Kettyle, Laura M et al.
In: Genes, Vol. 14, No. 5, 1029, 30.04.2023.

796. **Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 18, No. 5, 05.2023, p. 602-612.

797. **Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.** / McEwan, Phil; Boyce, Rebecca; Sanchez, Juan Jose Garcia et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, No. 5, 01.05.2023, p. 1260-1270.

798. **Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.** / DAPA-CKD Trial Committees and Investigators.
In: Journal of the American Heart Association, Vol. 12, No. 9, e028739, 02.05.2023, p. e028739.

799. **Identification of biomarkers for glycaemic deterioration in type 2 diabetes.** / Slieker, Roderick C; Donnelly, Louise A; Akalestou, Elina et al.
In: Nature Communications, Vol. 14, No. 1, 2533, 03.05.2023, p. 2533.

800. **Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.** / Koshino, Akihiko; Schechter, Meir; Chertow, Glenn M et al.
In: NEJM evidence, Vol. 2, No. 6, 06.2023, p. EVIDoa2300049.

801. **Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 6, 06.2023, p. 1512-1522.

802. **Sphingolipids are depleted in alcohol-related liver fibrosis.** / Thiele, Maja; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Gastroenterology, Vol. 164, No. 7, 06.2023, p. 1248-1260.

803. **The association between blood oxygen saturation and baroreflex sensitivity in adults with type 1 diabetes with and without albuminuria.** / Laursen, Jens Christian; Hansen, Christian Stevns; Bordino, Marco et al.
In: Journal of Diabetes and its Complications, Vol. 37, No. 6, 108473, 06.2023, p. 108473.

804. **Circulating biomarkers of collagen remodeling as markers for development ofmicroalbuminuria in type 2 diabetes: the priority trial.** / Moller, Alexandra Louise; Curovic, Viktor Rotbain; Rasmussen, Daniel G. K. et al.
In: Nephrology Dialysis Transplantation, Vol. 38, No. 1, #5482, 01.06.2023, p. I462.

805. **Effect of dapagliflozin in patients with CKD across the spectrum of age and by sex.** / Yu, Margaret; Vart, Priya; Heerspink, Hiddo Lambers et al.
In: Nephrology Dialysis Transplantation, Vol. 38, No. 1, #3669, 01.06.2023, p. I638-I639.

806. **Higher mortality risk with chronic kidney disease in type 2 diabetes in younger ages: a danish nationwide cohort study 2014-2018.** / Nyeland, Martin; Rorth, Rasmus; Carstensen, Bendix et al.
In: Nephrology Dialysis Transplantation, Vol. 38, No. 1, #2789, 01.06.2023, p. I502-I503.

807. **Phase ii dose-selection, randomised double-blind trial of the asi, bi 690517, alone and in combination with empa in people with ckd.** / Tuttle, Katherine; Rossing, Peter; Cronin, Lisa et al.
In: Nephrology Dialysis Transplantation, Vol. 38, No. 1, #3318, 01.06.2023, p. I652.

808. **Reasons for dialysis initiation and safety of dapagliflozin among dialysis participants: new insights from dapa-ckd.** / Heerspink, Hiddo Lambers; Wheeler, David C.; Jong, Niels et al.
In: Nephrology Dialysis Transplantation, Vol. 38, No. 1, #3382, 01.06.2023, p. i52-i53.

809. **Validation of a CKD progression risk prediction model in the fidelity trial population.** / Tangri, Navdeep; Ferguson, Thomas; Leon-Mantilla, Silvia et al.
In: Nephrology Dialysis Transplantation, Vol. 38, No. 1, #4486, 01.06.2023, p. I643-I644.

810. **Rationale and design of a prospective, clinical study of kidney biopsies in people with type 2 diabetes and severely increased albuminuria (the PRIMETIME 2 study).** / Møller, Marie; Borg, Rikke; Bressendorff, Iain et al.
In: BMJ Open, Vol. 13, No. 6, e072216, 06.06.2023, p. e072216.

811. **Collagen turnover is associated with cardiovascular autonomic and peripheral neuropathy in type 1 diabetes: novel pathophysiological mechanism?** / Hansen, Christian S; Rasmussen, Daniel G K; Hansen, Tine W et al.
In: Cardiovascular Diabetology, Vol. 22, No. 1, 158, 29.06.2023.

812. **Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.** / Stougaard, Elisabeth B; Rossing, Peter; Vistisen, Dorte et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 7, 07.2023, p. 1874-1882.

813. **Effect of finerenone on the incidence of hypokalemia in patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: European Journal of Heart Failure, Vol. 25 Suppl 2, No. 2, 01.07.2023, p. 415.

814. **Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials.** / Sen, Taha; Curovic, Viktor Rotbain; Jongs, Niels et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 8, 08.2023, p. 2413-2418.

815. **Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark.** / Schäfer, Zeinab; Mathisen, Andreas; Thomsen, Trine Rolighed et al.
In: Diabetes Research and Clinical Practice, Vol. 202, 110799, 08.2023, p. 110799.

816. **People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action.** / Heerspink, Hiddo Jl; Cherney, David Zi; Groop, Per-Henrik et al.
In: The Lancet Diabetes and Endocrinology, Vol. 11, No. 8, 08.2023, p. 536-540.

817. **Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.** / Agarwal, Rajiv; Pitt, Bertram; Rossing, Peter et al.
In: JAMA Cardiology, Vol. 8, No. 8, 09.08.2023, p. 732-741.

818. **Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.** / Rossing, Peter; Bain, Stephen C; Bosch-Traberg, Heidrun et al.
In: Cardiovascular Diabetology, Vol. 22, No. 1, 220, 24.08.2023, p. 220.

819. **Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease.** / Heinrich, Niels Søndergaard; Pedersen, Rune Ploegstra; Vestergaard, Mark Bitsch et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 9, 09.2023, p. 2605-2615.

820. **Alleviation of autonomic dysfunction measured as pressure pain sensitivity at the sternum improves empowerment and quality of life in type 2 diabetes: a randomised trial.** / Hecquet, S.; Ballegaard, S.; Eldrup, E. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S373.

821. **Blood oxygen saturation and associations with autonomic and peripheral neuropathy in diabetes.** / Brodsgaard, R. B.; Laursen, J. C.; Mizrak, H. I. et al.
In: Diabetologia, Vol. 66, No. Suppl 1, 906, 01.09.2023, p. S463-S464.

822. **Circulating metabolites with race free eGFR and risk of kidney disease in individuals with type 2 diabetes: insights from the UK Biobank study.** / Bjorgvinsdottir, A. H.; Persson, F.; Hansen, T. W. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 953, 01.09.2023, p. S487-S488.

823. **Comparative effectiveness of GLP-1 receptor agonists versus SGLT2 inhibitors in patients with type 2 diabetes and moderate chronic kidney disease.** / Rossing, Peter; Fioretto, Paola; Clark, Alice Jessie et al.
In: Diabetologia, Vol. 66, No. 1, 702, 01.09.2023.

824. **Effect of dapagliflozin on circulating biomarkers of extracellular matrix remodelling in type 2 diabetes with albuminuria: a randomised clinical trial.** / Wasehuus, V.; Curovic, V. R.; Eickhoff, M. K. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S453-S454.

825. **Finerenone increases the likelihood of improved KDIGO risk category in patients with type 2 diabetes and CKD: an analysis from FIDELITY.** / Inzucchi, S. E.; Filippatos, G.; Anker, S. D. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S354-S355.

826. **Overall gastrointestinal symptom burden is associated with diabetic autonomic neuropathy: a DANES cohort study.** / Kufaishi, H.; Mizrak, H. I.; Brock, B. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. 1-536.

827. **Persons with type 2 diabetes without cardiovascular disease but with albuminuria has increased coronary artery pathology.** / Rasmussen, I. K. B.; Ripa, R.; Skriver-Moller, A. -C. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S465.

828. **Prevalence of diabetic neuropathies in individuals with type 1 and type 2 diabetes in a tertiary outpatient clinic: the DANES cohort study.** / Mizrak, H.; Kufaishi, H.; Hecquet, S. K. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 203, 01.09.2023, p. S107-S108.

829. **Renal effects of empagliflozin alone or in combination with semaglutide in albuminuric type 2 diabetes: a randomised, placebo-controlled trial.** / Sivalingam, S.; Wasehuus, V. Soendergaard; Curovic, V. Rotbain et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S125.

830. **Soluble urokinase plaminogen activator receptor is associated with cardiovascular autonomic neuroapthy in type 1 diabetes.** / Hansen, C.; Theilade, S.; Eugen-Olsen, J. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 914, 01.09.2023, p. S468-S468.

831. **Surface swaps of diabetic foot ulcers carry a distinct protein biomarker profile compared with healing ulcers.** / Petkovic, M.; Raguz, J. A.; Kirketerp-Moller, K. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S461-S462.

832. **The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.** / Rossing, Peter; Baeres, Florian M M; Bakris, George et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, No. 9, 01.09.2023, p. 2041-2051.

833. **Time trends in the incidence of diabetic ketoacidosis among adults with type 1 diabetes: a nationwide Danish register study.** / Stougaard, E. Buur; Amadid, H.; Sondergaard, E. et al.
In: Diabetologia, Vol. 66, No. SUPPL 1, 1, 01.09.2023, p. S57-S58.

834. **Platelet aggregation and aspirin response in type 1 diabetes with and without albuminuria.** / Poulsen, Christina Gjerlev; Ferreira-Divino, Luis Felipe; Pedersen, Oliver et al.
2023. Abstract from 59th EASD Annual Meeting: EASD 2023, Hamborg, Hamburg, Germany.

835. **Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study.** / Jaimes Campos, Mayra Alejandra; Andújar, Iván; Keller, Felix et al.
In: Pharmaceuticals (Basel, Switzerland), Vol. 16, No. 9, 1298, 14.09.2023.

836. **Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.** / Smeijer, J David; Kohan, Donald E; Rossing, Peter et al.
In: Cardiovascular Diabetology, Vol. 22, No. 1, 251, 16.09.2023, p. 251.

837. **Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.** / Wretlind, Asger; Curovic, Viktor Rotbain; de Zawadzki, Andressa et al.
In: Lipids in Health and Disease, Vol. 22, No. 1, 160, 26.09.2023, p. 160.

838. **Discordance Between Creatinine-Based and Cystatin C-Based Estimated GFR: Interpretation According to Performance Compared to Measured GFR.** / Wang, Yeli; Adingwupu, Ogechi M; Shlipak, Michael G et al.
In: Kidney medicine, Vol. 5, No. 10, 100710, 10.2023, p. 100710.

839. **Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.** / Laursen, Jens Christian; Rotbain Curovic, Viktor; Kroonen, Marjolein Y A M et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 10.2023, p. 3064-3067.

840. **Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Kidney medicine, Vol. 5, No. 10, 100704, 10.2023, p. 100704.

841. **Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.** / Heerspink, Hiddo J L; Birkenfeld, Andreas L; Cherney, David Z I et al.
In: Diabetes Research and Clinical Practice, Vol. 204, 110908, 10.2023, p. 110908.

842. **The drivers of non-adherence to albuminuria testing guidelines and the clinical and economic impact of not identifying chronic kidney disease.** / Groehl, Franziska; Garreta-Rufas, Antonio; Meredith, Kimberley et al.
In: Clinical Nephrology, Vol. 100, No. 4, 10.2023, p. 145-156.

843. **The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes.** / Jürgens, Mikkel; Schou, Morten; Hasbak, Philip et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 10.2023, p. 2888-2896.

844. **The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.** / Rossing, Peter; Anker, Stefan D; Filippatos, Gerasimos et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 10.2023, p. 2989-2998.

845. **Vitamin D deficiency and development of complications in individuals with type 1 and type 2 diabetes: A cohort study.** / Tougaard, Ninna Hahn; Hansen, Tine Willum; Rossing, Peter.
In: Journal of Diabetes and its Complications, Vol. 37, No. 10, 108611, 10.2023, p. 108611.

846. **Ceramides as risk markers for future cardiovascular events and all-cause mortality in long-standing type 1 diabetes.** / Wretlind, Asger; Curovic, Viktor R; Suvitaival, Tommi et al.
In: Diabetes, Vol. 72, No. 10, 01.10.2023, p. 1493–1501.

847. **Evaluation of Extracellular Matrix Turnover Proteins as Risk Markers in Persons with Type 2 Diabetes and Microalbuminuria.** / Wasehuus, Victor; Skriver-Møller, Anne-Cathrine; Møller, Alexandra Louise et al.
In: Journal of the American Society of Nephrology, 13.10.2023, p. 136.

848. **Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?** / Rossing, Peter; Frimodt-Møller, Marie; Persson, Frederik.
In: Seminars in Nephrology, Vol. 43, No. 3, 151430, 18.10.2023, p. 151430.

849. **Albuminuria Is Associated with Higher Carotid Plaque Volume Quantified by Novel 3D Ultrasound in Type 1 Diabetes.** / Ferreira-Divino, Luis Felipe; Poulsen, Christina Gjerlev; Curovic, Viktor Rotbain et al.
In: Journal of the American Society of Nephrology, Vol. 34, No. Abstract Supplement 2023, 11.2023.

850. **Declining Incidence Rates of Distal Symmetric Polyneuropathy in People With Type 1 and Type 2 Diabetes in Denmark, With Indications of Distinct Patterns in Type 1 Diabetes.** / Mizrak, Hatice Isik; Hansen, Tine Willum; Rossing, Peter et al.
In: Diabetes Care, Vol. 46, No. 11, 11.2023, p. 1997-2003.

851. **Myocardial performance index improves prediction of major adverse cardiovascular events and heart failure in type 1 and type 2 diabetes without known heart disease: Thousand&1 and Thousand&2 study.** / Bahrami, Hashmat S. Z.; Jørgensen, Peter Godsk; Hove, Jens Dahlgaard et al.
In: European Heart Journal, 11.2023.

852. **Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.** / Rotbain Curovic, Viktor; Houlind, Morten B; Kroonen, Marjolein Y A M et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 11, 11.2023, p. 3152-3160.

853. **Time Trends in the Incidence of Diabetic Ketoacidosis Leading to Hospital Admission Among Adults With Type 1 Diabetes-A Nationwide Danish Register Study.** / Stougaard, Elisabeth B; Amadid, Hanan; Søndergaard, Esben et al.
In: Diabetes Care, Vol. 46, No. 11, 11.2023, p. 1897-1902.

854. **Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand&1 and Thousand&2 studies.** / Bahrami, Hashmat Sayed Zohori; Jørgensen, Peter Godsk; Hove, Jens Dahlgaard et al.
In: European Heart Journal Cardiovascular Imaging, Vol. 24, No. 11, 01.11.2023, p. 1555-1562.

855. **Design and methodology of the PRIMETIME 1 cohort study: PRecIsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy.** / Jensen, Karina Haar; Persson, Frederik; Hansen, Ditte et al.
In: Clinical kidney journal, Vol. 16, No. 12, 12.2023, p. 2482-2492.

856. **Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Kidney medicine, Vol. 5, No. 12, 100730, 12.2023, p. 100730.

857. **Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Annals of Internal Medicine, Vol. 176, No. 12, 12.2023, p. 1606-1616.

858. **The effect of diabetes and the diabetogenic TBC1D4 p.Arg684ter variant on kidney function in Inuit in Greenland.** / Overvad, Maria; Díaz, Lars Jorge; Bjerregaard, Peter et al.
In: International Journal of Circumpolar Health, Vol. 82, No. 1, 2191406, 12.2023, p. 2191406.

859. **CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in Adults.** / Inker, Lesley A; Tighiouart, Hocine; Adingwupu, Ogechi M et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 34, No. 12, 01.12.2023, p. 1953-1964.

860. **Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.** / Fletcher, Robert A; Jongs, Niels; Chertow, Glenn M et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 34, No. 12, 01.12.2023, p. 1965-1975.

861. **International Variability of Renal and Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus in Europe.** / Thöni, Stefanie; Keller, Felix; Denicolò, Sara et al.
In: Kidney & blood pressure research, Vol. 48, No. 1, 01.12.2023, p. 165-174.

862. **Birthweight and risk of chronic kidney disease after being diagnosed with type 2 diabetes.** / Hansen, Aleksander; Christiansen, C. F.; Brøns, Charlotte et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 285, 2024.

863. **Effects of Dapagliflozin in Patients with Membranous Nephropathy.** / Chertow, Glenn M; Heerspink, Hiddo Lambers; Mark, Patrick B et al.
In: Glomerular diseases, Vol. 4, No. 1, 2024, p. 137-145.

864. **Efficacy and safety of finerenone in patients with CKD and type 2 diabetes across the frailty spectrum: a FIDELITY post hoc analysis.** / Rossing, Peter; Birkenfeld, Andreas L; Fioretto, P et al.
In: Diabetologia, Vol. 67, No. Suppl.1, 892, 2024.

865. **Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5.** / Cheng, A. Y. ; Rossing, Peter; Benamar, M. et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 784, 2024.

866. **Elevated triglyceride levels correlate with a unique swap and plasma biomarker profile in diabetic foot ulcers.** / Petkovic, Marija; Raguz, J. A.; Rasmussen, Anne et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 262, 2024.

867. **Exploring biomarkers for diabetes neuropathy through comprehensive serum proteome analysis.** / Kaur, Gurjeet; Okdahl, Tina; Suvitaival, Tommi et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 933, 2024.

868. **Histological findings predict kidney failure in diabetes: a retrospective cohort study.** / Jensen, Karina Haar; Blond, Martin Bæk; Persson, Frederik et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 894, 2024.

869. **Impact of SGLT2 inhibition on glucosuria in MODY3.** / Maagensen, Henrik; Jensen, Johanne Skov; Høyerup, Stine Offersgaard et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 228, 2024.

870. **Incidence of diabetic foot complications in a type 1 and type 2 diabetes population: a Danish register-based cohort study.** / Akerkar, Abhilasha; Rønn, Pernille Falberg; Kosjerina, Vanja et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 338, 2024.

871. **Influence of sex and risk factors on myocardial microvascular function in individuals with type 2 diabetes free of overt cardiovascular disease: the DiaHeart study.** / Skriver-Møller, Anne-Cathrine; Rasmussen, Ida Kirstine Bull; Blond, Martin Bæk et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 982, 2024.

872. **Kidney, cardiovascular and all-cause mortality outcomes of semaglutide with and without baseline MRA use in type 2 diabetes and CKD: a FLOW trial analysis.** / FLOW Trial Committees and Investigators.
In: Diabetologia, Vol. 67, No. Suppl. 1, LBA 21, 2024.

873. **Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.** / Tuttle, Katherine R; Rossing, Peter; Hauske, Sibylle J et al.
In: American Journal of Nephrology, Vol. 55, No. 2, 2024, p. 262-272.

874. **New Diabetic Treatment by Alleviation of Autonomic Nervous System Dysfunction Measured as Periosteal Pressure Sensitivity at Sternum Improves Empowerment, Treatment Satisfaction, and Self-Reported Health of People with Type 2 Diabetes: A Randomized Trial.** / Hecquet, Sofie Korsgaard; Ballegaard, Søren; Eldrup, Ebbe et al.
In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 17, 2024, p. 2519-2531.

875. **Novel proteomic markers of diabetic foot ulcer healing time.** / Ahluwalia, Tarunveer Singh; Jain, S.; Petkovic, Marija et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 263, 2024.

876. **Periosteal pressure sensitivity a measure of autonomic neuropathy in comparison to other neuropathy measures in people with type 1 diabetes: a DANES cohort study.** / Hecquet, Sofie Korsgaard; Mizrak, Hatice Isik ; Kufaishi, Huda et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 945, 2024.

877. **Predicted Life Course of Individuals With Type 2 Diabetes and Nephropathy at Steno Diabetes Center Copenhagen from 2001 to 2020.** / Jesse, Kristin; Carstensen, Bendix; Poulsen, Christina Gjerlev et al.
2024. Abstract from 11th Nordic Conference of Epidemiology and Register-Based Health Research, Copenhagen, Denmark.

878. **Redefining the eGFR-albuminuria relationship using genetics: setting stage for precision monitoring.** / Naaman, Cilia Hanna; Hansen, Tine Willum; Persson, Frederik et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 157, 2024.

879. **Screening for type 2 diabetes is cost-effective: evidence from a pilot screening study in Denmark.** / Mateu, Nuri C.; Rossing, Peter; Neergaard, Kirsten et al.
In: Diabetologia, Vol. 67, No. Suppl. 1, 102, 2024.

880. **Techniques to assess the effect of sodium-glucose cotransporter 2 inhibitors on blood volume in patients with diabetic kidney disease.** / Vinje, Vårin; Bomholt, Tobias; Rossing, Peter et al.
In: Nephron, Vol. 148, No. 3, 2024, p. 137-142.

881. **Trends in first diabetic foot ulcer in a type-1 and type-2 diabetes population: A retrospective Danish register-based study.** / Akerkar, Abhilasha; Rønn, Pernille Falberg; Ahluwalia, Tarunveer Singh et al.
2024. Abstract from 11th Nordic Conference of Epidemiology and Register-Based Health Research, Copenhagen, Denmark.

882. **Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.** / Sivalingam, Suvanjaa; Wasehuus, Victor Soendergaard; Rotbain Curovic, Viktor et al.
In: Diabetes, Obesity and Metabolism, Vol. 26, No. 1, 01.2024, p. 54-64.

883. **Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.** / Sridhar, Vikas S; Limonte, Christine P; Groop, Per-Henrik et al.
In: Diabetologia, Vol. 67, No. 1, 01.2024, p. 3-18.

884. **Copenhagen Diabetes Consensus (CODIAC) 2021: User involvement in diabetes care, prevention and research.** / Bloch, Paul; Dadaczynski, Kevin; Grabowski, Dan et al.
In: Diabetic medicine : a journal of the British Diabetic Association, Vol. 41, No. 1, e15160, 01.2024, p. e15160.

885. **Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: Diabetes, Obesity and Metabolism, Vol. 26, No. 1, 01.2024, p. 191-200.

886. **Soluble urokinase plasminogen activator receptor, platelet aggregation, and carotid plaque thickness in diabetes: A cross-sectional analysis.** / Rotbain Curovic, Viktor; Tavenier, Juliette; Ferreira-Divino, Luis F et al.
In: Journal of Diabetes and its Complications, Vol. 38, No. 1, 108654, 01.2024.

887. **Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.** / Tuttle, Katherine R; Hauske, Sibylle J; Canziani, Maria Eugenia et al.
In: Lancet, Vol. 403, No. 10424, 27.01.2024, p. 379-390.

888. **Performance of GFR Estimating Equations in Young Adults.** / Inker, Lesley A; Tighiouart, Hocine; Adingwupu, Ogechi M et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 83, No. 2, 02.2024, p. 272-276.

889. **Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease.** / Ahluwalia, Tarunveer S; Rönkkö, Teemu K E; Eickhoff, Mie K et al.
In: Kidney International Reports, Vol. 9, No. 2, 02.2024, p. 334-346.

890. **Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.** / McEwan, Phil; Davis, Jason A; Gabb, Peter D et al.
In: Clinical kidney journal, Vol. 17, No. 2, sfae025, 01.02.2024, p. fae025.

891. **Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease across the Spectrum of Frailty.** / Vart, Priya; Butt, Jawad H; Jongs, Niels et al.
In: The journals of gerontology. Series A, Biological sciences and medical sciences, Vol. 79, No. 2, 181, 01.02.2024.

892. **Ratio of transmitral early filling velocity to diastolic strain rate and prognosis in type-1 diabetes.** / Lassen, Mats Christian Højbjerg; Biering-Sørensen, Tor; Jørgensen, Peter Godsk et al.
In: International Journal of Cardiology, Vol. 397, 131653, 15.02.2024, p. 131653.

893. **Increased sub-clinical coronary artery pathology in type 2 diabetes with albuminuria.** / Rasmussen, Ida Kirstine Bull; Skriver-Moeller, Anne-Cathrine; Ripa, Rasmus Sejersten et al.
In: Diabetes, Vol. 73, No. 3, 01.03.2024, p. 490-496.

894. **Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance.** / Ebert, Thomas; Anker, Stefan D; Ruilope, Luis M et al.
In: Diabetes Care, Vol. 47, No. 3, 01.03.2024, p. 362-370.

895. **CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.** / Schnell, Oliver; Barnard-Kelly, Katharine; Battelino, Tadej et al.
In: Cardiovascular Diabetology, Vol. 23, No. 1, 104, 19.03.2024, p. 104.

896. **Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.** / Bansal, Shweta; Canziani, Maria E F; Birne, Rita et al.
In: BMJ Open, Vol. 14, No. 3, e076444, 19.03.2024, p. e076444.

897. **Ambient heat exposure and kidney function in patients with chronic kidney disease: a post-hoc analysis of the DAPA-CKD trial.** / Zhang, Zhiyan; Heerspink, Hiddo J L; Chertow, Glenn M et al.
In: The Lancet. Planetary health, Vol. 8, No. 4, 04.2024, p. e225-e233.

898. **Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.** / Heerspink, Hiddo Jl; Provenzano, Michele; Vart, Priya et al.
In: American Heart Journal, Vol. 270, 04.2024, p. 125-135.

899. **Effectiveness of finerenone in slowing ckd progression after hospitalization for heart failure: a fidelity subgroup analysis.** / Shafi, Tariq; Anker, Stefan D.; Pitt, Bertram et al.
In: American Journal of Kidney Diseases, Vol. 83, No. 4, 2, 229, 01.04.2024, p. S69-S70.

900. **Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population.** / Tangri, Navdeep; Ferguson, Thomas; Leon, Silvia J et al.
In: Clinical kidney journal, Vol. 17, No. 4, sfae052, 01.04.2024, p. fae052.

901. **Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes.** / Rotbain Curovic, Viktor; Sørland, Brede A; Hansen, Tine W et al.
In: BMJ open diabetes research & care, Vol. 12, No. 2, e003973, 11.04.2024.

902. **Urinary peptide analysis to predict the response to blood pressure medication.** / Jaimes Campos, Mayra Alejandra; Mavrogeorgis, Emmanouil; Latosinska, Agnieszka et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 39, No. 5, 26.04.2024, p. 873-883.

903. **Association of carpal tunnel syndrome with incident diabetes.** / Jacobsen, Jeppe Ravn; Westergaard, Lucas Malta; Fosbøl, Emil L et al.
In: Diabetes, Obesity and Metabolism, Vol. 26, No. 5, 05.2024, p. 1976-1979.

904. **Effect of dapagliflozin on collectins and complement activation in plasma from patients with type 2 diabetes and albuminuria: Data from the DapKid cohort.** / Jensen, Mia; Eickhoff, Mie K; Persson, Frederik et al.
In: Immunobiology, Vol. 229, No. 3, 152797, 05.2024, p. 152797.

905. **Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.** / Yu, Margaret K; Vart, Priya; Jongs, Niels et al.
In: Journal of General Internal Medicine, Vol. 39, No. 6, 05.2024, p. 921-930.

906. **Gastrointestinal symptom burden in diabetic autonomic and peripheral neuropathy - A Danes cohort study.** / Kufaishi, Huda; Mizrak, Hatice Isik; Brock, Birgitte et al.
In: Journal of Diabetes and its Complications, Vol. 38, No. 5, 108745, 05.2024, p. 108745.

907. **CKD-PC risk model for CKD progression: validation and association with outcomes in the FIDELITY population.** / Shafi, Tariq; Anker, Stefan D.; Filippatos, Gerasimos et al.
In: Nephrology Dialysis Transplantation, Vol. 39, No. 1, 2546, 01.05.2024, p. I1037-I1038.

908. **Phase II dose-selection, randomised, controlled trial of ASi BI 690517 with and without EMPA in CKD: subgroup analysis by T2D status.** / Tuttle, Katherine R.; Rossing, Peter; Hauske, Sibylle et al.
In: Nephrology Dialysis Transplantation, Vol. 39, No. 1, Meeting Abstract 1418, 01.05.2024, p. I279-I280.

909. **Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.** / Bornstein, Stefan R; de Zeeuw, Dick; Heerspink, Hiddo J L et al.
In: Diabetes, Obesity and Metabolism, Vol. 26, No. 6, 06.2024, p. 2128-2138.

910. **Contemporary prevalence of diabetic neuropathies in individuals with type 1 and type 2 diabetes in a Danish tertiary outpatient clinic.** / Mizrak, Hatice Isik; Kufaishi, Huda; Hecquet, Sofie Korsgaard et al.
In: Journal of Diabetes and its Complications, Vol. 38, No. 6, 108761, 06.2024, p. 108761.

911. **Extracellular matrix turnover proteins as risk markers in people with type 2 diabetes and microalbuminuria.** / Skriver-Møller, Anne-Cathrine; Møller, Alexandra L; Blond, Martin B et al.
In: Journal of Diabetes and its Complications, Vol. 38, No. 6, 108765, 06.2024.

912. **Increased Triglyceride Levels Are Associated with a Distinct Lipid-Associated Protein Biomarker Profile of Diabetic Foot Ulcers.** / Petkovic, Marija; Raguz, Jana A; Rasmussen, Anne et al.
In: Diabetes, Vol. 73, No. Supplement 1, 129-OR, 06.2024.

913. **Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.** / Iversen, Esben; Christensen, Katrine McLain; Walls, Anne Byriel et al.
In: Diabetes, Obesity and Metabolism, Vol. 26, No. 6, 06.2024, p. 2501-2504.

914. **Detection of Type 2 Diabetes-Evidence from a Pilot Screening Study in Denmark.** / Mateu, Nuria Cayuelas; Rossing, Peter; Neergaard, Kirsten P. et al.
In: Diabetes, Vol. 73, No. 1, 01.06.2024.

915. **Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Basal Insulin in Individuals with Type 2 Diabetes by Kidney Function-ONWARDS 1-5.** / Rossing, Peter; Benamar, Malik; Cheng, Alice Y. Y. et al.
In: Diabetes, Vol. 73, No. 1, 826-P, 01.06.2024.

916. **Proteomic Predictors of Diabetic Foot Ulcer Healing Time.** / Ahluwalia, Tarunveer Singh; Jain, Siddhi; Petkovic, Marija et al.
In: Diabetes, Vol. 73, No. 1, 523-P, 01.06.2024.

917. **Combination therapy for kidney disease in people with diabetes mellitus.** / van Raalte, Daniël H; Bjornstad, Petter; Cherney, David Z I et al.
In: Nature Reviews Nephrology, Vol. 20, No. 7, 07.2024, p. 433-446.

918. **Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.** / Perkovic, Vlado; Tuttle, Katherine R; Rossing, Peter et al.
In: The New England journal of medicine, Vol. 391, No. 2, 11.07.2024, p. 109-121.

919. **The validity of pathology codes for biopsy-confirmed kidney disease in the Danish National Patobank.** / Møller, Marie; Bressendorff, Iain; Borg, Rikke et al.
In: Clinical kidney journal, Vol. 17, No. 8, sfae203, 08.2024.

920. **Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology.** / Mavrogeorgis, Emmanouil; Kondyli, Margarita; Mischak, Harald et al.
In: Journal of Hypertension, Vol. 42, No. 8, 01.08.2024, p. 1331-1339.

921. **Phase ii dose-selection, randomised, controlled trial of asi bi 690517 with and without empag-liflozin in chronic kidney disease: subgroup analysis by type 2 diabetes status.** / Tang, Francesca; Rossing, Peter; Hauske, Sibylle et al.
In: Nephrology, Vol. 29, No. 1, 01.08.2024, p. 72-73.

922. **Prevalence of Chronic Kidney Disease in Type 1 Diabetes Among Adults in the U.S.** / Rossing, Peter; Groop, Per-Henrik; Singh, Rakesh et al.
In: Diabetes Care, Vol. 47, No. 8, 01.08.2024, p. 1395-1399.

923. **Association of Multiple Sclerosis with incident Diabetes: A nationwide cohort study.** / Jacobsen, Jeppe R; Kristensen, Søren L; Fosbøl, Emil L et al.
In: Diabetes & Metabolism, Vol. 50, No. 5, 101551, 09.2024.

924. **Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison.** / Cherney, David; Folkerts, Kerstin; Mernagh, Paul et al.
In: Journal of market access & health policy, Vol. 12, No. 3, 09.2024, p. 169-180.

925. **Summary of Research: Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease-The FIDELITY Pooled Analysis.** / Humle, Karin; Klanger, Boris; Kolkhof, Peter et al.
In: Diabetes Therapy, Vol. 15, No. 9, 09.2024, p. 1861-1864.

926. **The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases.** / Genovese, Federica; Bager, Cecilie; Frederiksen, Peder et al.
In: Matrix biology : journal of the International Society for Matrix Biology, Vol. 132, 09.2024, p. 1-9.

927. **Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetes.** / Okdahl, Tina; Kufaishi, Huda; Kornum, Ditte et al.
In: Scientific Reports, Vol. 14, No. 1, 21042, 09.09.2024, p. 21042.

928. **Cohort profile: the PRIMETIME 1 (PReclsion MEdicine based on kidney TIssue Molecular interrogation in diabetic nEphropathy) cohort - a longitudinal Danish nationwide study of individuals with diabetes and a performed kidney biopsy.** / Jensen, Karina Haar; Kosjerina, Vanja; Hansen, Ditte et al.
In: BMJ Open, Vol. 14, No. 9, e086086, 20.09.2024, p. e086086.

929. **Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.** / Mann, Johannes F E; Rossing, Peter; Bakris, George et al.
In: Nature Medicine, Vol. 30, No. 10, 10.2024, p. 2849-2856.

930. **Influence of Sex and Other Risk Factors, Including Kidney Function, on Myocardial Microvascular Function in Individuals with Type 2 Diabetes Free of Overt Cardiovascular Disease: The DiaHeart Study.** / Skriver-Moller, Anne-Cathrine; Hasbak, Philip; Rasmussen, Ida Kirstine Bull et al.
In: Journal of the American Society of Nephrology, Vol. 35, No. 10S, FR-PO335, 10.2024.

931. **Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.** / Lundgaard, Agnete T; Westergaard, David; Röder, Timo et al.
In: Diabetologia, Vol. 67, No. 10, 10.2024, p. 2289-2303.

932. **Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.** / Rossing, Peter.
In: Journal of the American Society of Nephrology : JASN, Vol. 35, No. 10, 01.10.2024, p. 1438-1441.

933. **Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.** / Pratley, Richard E; Tuttle, Katherine R; Rossing, Peter et al.
In: Journal of the American College of Cardiology, Vol. 84, No. 17, 22.10.2024, p. 1615-1628.

934. **Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study.** / Alhakak, A.; Kober, L.; Petrie, M. C. et al.
In: European Heart Journal, Vol. 45, No. 1, SI, ehae666.3317, 28.10.2024.

935. **Interleukin-6 and suPAR are associated with diastolic function in type 1 diabetes: The Thousand & 1 Study.** / Bahrami, H.S.Z.; Jorgensen, P. G.; Hove, J. D. et al.
In: European Heart Journal, Vol. 45, No. 1, SI, ehae666.953, 28.10.2024.

936. **Interleukin-6 and suPAR improves prediction of all-cause mortality in type 1 diabetes - the Thousand & 1 Study.** / Bahrami, H.; Jorgensen, P. G.; Hove, J. D. et al.
In: European Heart Journal, Vol. 45, No. 1, SI, ehae666.2909, 28.10.2024.

937. **Systolic plood pressure response to ASi BI 690517 with and without empagliflozin in CKD.** / Rossing, P.; Hauske, S. J.; Cronin, L. et al.
In: European Heart Journal, Vol. 45, No. 1, SI, ehae666.2580, 28.10.2024.

938. **Cardiovascular and non-renal complications of chronic kidney disease: Managing risk.** / Rossing, Peter; Hansen, Tine Willum; Kümler, Thomas.
In: Diabetes, Obesity and Metabolism, Vol. 26, No. S6, 11.2024, p. 13-21.

939. **Circulating Levels of the Pro-Fibrotic Collagen Hormone Endotrophin are Associated with the Risk of Experiencing Major Adverse Cardiovascular Events in Individuals with Type 2 Diabetes – The Thousand&2 Study.** / Laursen, Clara; Bahrami, Hashmat S. Z.; Martin, Emily et al.
In: Circulation, 11.2024.

940. **Endothelial dysfunction markers syndecan-1 and thrombomodulin are associated with higher albuminuria levels in type 2 diabetes with no history of clinical cardiovascular disease.** / Ferreira-Divino, Luis F; Poulsen, Christina G; Rotbain Curovic, Viktor et al.
In: Journal of Diabetes and its Complications, Vol. 38, No. 11, 108879, 11.2024, p. 108879.

941. **Estimating glomerular filtration rate in kidney transplant recipients: Considerations for Selecting Equations.** / Agarwal, Krishna A; Adingwupu, Ogechi M; Tighiouart, Hocine et al.
In: Kidney International, Vol. 106, No. 5, 11.2024, p. 991-995.

942. **The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.** / McEwan, Phil; Gabb, Peter D; Davis, Jason A et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 39, No. 12, 27.11.2024, p. 2040-2047.

943. **Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes(Nature Medicine, 10.1038/s41591-024-03264-4).** / Vaduganathan, Muthiah; Filippatos, Gerasimos; Claggett, Brian L et al.
In: Nature Medicine, Vol. 30, No. 12, 12.2024, p. 3778.

944. **Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetes.** / Wolsk, Emil; Jürgens, Mikkel; Schou, Morten et al.
In: ESC Heart Failure, Vol. 11, No. 6, 12.2024, p. 3551-3558.

945. **Effects of probiotics and fibers on markers of nephropathy, inflammation, intestinal barrier dysfunction and endothelial dysfunction in individuals with type 1 diabetes and albuminuria. The ProFOS Study.** / Stougaard, Elisabeth B; Tougaard, Ninna Hahn; Sivalingam, Suvanjaa et al.
In: Journal of Diabetes and its Complications, Vol. 38, No. 12, 108892, 12.2024, p. 108892.

946. **Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.** / Vaduganathan, Muthiah; Filippatos, Gerasimos; Claggett, Brian L et al.
In: Nature Medicine, Vol. 30, No. 12, e008789, 12.2024, p. 3758-3764.

947. **Prognosis for Type 1 Diabetes with Diabetic Nephropathy between 2000 and 2020 - Changes in Kidney Function Decline Over Time and Development of Cardiovascular Disease, Kidney Failure, and Mortality.** / Poulsen, Christina G; Jesse, Kristin; Carstensen, Bendix et al.
In: Kidney International Reports, Vol. 9, No. 12, 12.2024, p. 3403-3413.

948. **Baseline, Early Changes, and Residual Albuminuria: Post Hoc Analysis of a Randomized Clinical Trial of Dapagliflozin in Chronic Kidney Disease.** / van Mil, Dominique; Vart, Priya; Chertow, Glenn M et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 19, No. 12, 10, 01.12.2024, p. 1574-1584.

949. **Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.** / Heerspink, Hiddo J L; Perkovic, Vlado; Tuttle, Katherine R et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 35, No. 12, 01.12.2024, p. 1726-1736.

950. **Effect of flexor tendon tenotomy of the diabetic hammertoe on plantar pressure: a randomized controlled trial.** / Askø Andersen, Jonas; Rasmussen, Anne; Engberg, Susanne et al.
In: BMJ open diabetes research & care, Vol. 12, No. 6, e004398, 03.12.2024.

951. **Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.** / Wada, Takashi; Anker, Stefan D; Liu, Zhihong et al.
In: Kidney diseases (Basel, Switzerland), Vol. 11, No. 1, 2025, p. 402-415.

952. **Evaluating the long-term risk of major adverse cardiovascular events in type 1 diabetes: the role of albuminuria and diastolic impairment.** / Frimodt-Moeller, Katrine Emilie ; Bahrami, Hashmat S. Z.; Kolahi Azar, Ava et al.
In: Diabetologia, Vol. 68, No. Suppl 1, 1160, 2025, p. S592.

953. **Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity.** / Huang, Yan; Sulek, Karolina; Stinson, S E et al.
In: Obesity Facts, Vol. 18, No. suppl1, AD14.01, 2025.

954. **Novel proteomic markers associated with diabetic foot ulcer healing time.** / Ahluwalia, Tarunveer Singh; Jain, Siddhi Y; Petkovic, Marija et al.
2025. 8-8 Abstract from 20th meeting of the Diabetic Foot Study Group, Prague, Czech Republic.

955. **Personalised medicine in diabetes: Immense possibilities, but what is the patient's perspective?** / Curovic, Viktor Rotbain; Theilade, Simone; Rossing, Peter.
In: Diabetologia, Vol. 68, No. Suppl 1, 837, 2025, p. S428.

956. **Albuminuria and Rapid Kidney Function Decline as Selection Criteria for Kidney Clinical Trials in Type 1 Diabetes Mellitus.** / Keum, Youngshin; Caramori, Maria Luiza; Cherney, David Z et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 20, No. 1, 01.2025, p. 62-71.

957. **Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.** / Wasehuus, Victor; Rotbain Curovic, Viktor; Tofte, Nete et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 1, 01.2025, p. 387-393.

958. **Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.** / Badve, Sunil V; Bilal, Anika; Lee, Matthew M Y et al.
In: The Lancet Diabetes and Endocrinology, Vol. 13, No. 1, 01.2025, p. 15-28.

959. **Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity.** / Huang, Yun; Sulek, Karolina; Stinson, Sara E et al.
In: Nature Medicine, Vol. 31, No. 1, 985, 01.2025, p. 294-305.

960. **Possible Glycemic Effects of Vagus Nerve Stimulation Evaluated by Continuous Glucose Monitoring in People with Diabetes and Autonomic Neuropathy: A Randomized, Sham-Controlled Trial.** / Kufaishi, Huda; Bertoli, Davide; Kornum, Ditte Smed et al.
In: Diabetes Technology & Therapeutics, Vol. 27, No. 1, 01.2025, p. 52-59.

961. **The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.** / Friis Bryde Nielsen, Camilla; Møller Thysen, Sanne; Bach Kampmann, Freja et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 1, 01.2025, p. 348-356.

962. **Hyperkalemia Risk And The Effect Of Finerenone In Patients With Diabetes And Chronic Kidney Disease: An Analysis From Fidelity.** / Ferreira, Joao pedro p.; Anker, Stefan; Palmer, Biff f et al.
In: Journal of Cardiac Failure, Vol. 31, No. 1, 015, 01.01.2025.

963. **Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone - a FIDELITY analysis.** / Pitt, Bertram; Agarwal, Rajiv; Anker, Stefan D et al.
In: European heart journal. Cardiovascular pharmacotherapy, Vol. 11, No. 1, pvae074, 01.01.2025, p. 10-19.

964. **Long Term Outcomes After Flexor Tendon Tenotomy of the Diabetic Foot.** / Andersen, Jonas Askø; Rasmussen, Anne; Frimodt-Møller, Marie et al.
In: Clinical medicine insights. Endocrinology and diabetes, Vol. 18, 01.01.2025, p. 11795514251314787.

965. **Executive Summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An Update Based on New Evidence.** / Rossing, Peter; Caramori, M. L.; Chan, Juliana C. N. et al.
In: DIABETOLOGIE UND STOFFWECHSEL, Vol. 20, No. 01, 27.01.2025, p. 47-58.

966. **Bone mineral density and the risk of kidney disease in patients with type 1 diabetes.** / Hauge, Sabina Chaudhary; Hjortkjær, Henrik Øder; Persson, Frederik et al.
In: Journal of Diabetes and its Complications, Vol. 39, No. 2, 108927, 02.2025.

967. **Data sharing restrictions are hampering precision health in the European Union.** / Legido-Quigley, Cristina; Wewer Albrechtsen, Nicolai J; Bæk Blond, Martin et al.
In: Nature Medicine, Vol. 31, No. 2, 02.2025, p. 360-361.

968. **Effect of Dapagliflozin on Measured vs. Panel-Estimated Glomerular Filtration Rate.** / Iversen, Esben; Nielsen, Line Juel; Curovic, Viktor Rotbain et al.
In: Clinical Pharmacology and Therapeutics, Vol. 117, No. 2, 02.2025, p. 515-522.

969. **Effect of finerenone treatment discontinuation on kidney and cv outcomes in patients with ckd and t2d: a fidelity subanalysis.** / Anker, Stefan; Pitt, Bertram; Rossing, Peter et al.
In: Kidney International Reports, Vol. 10, No. Suppl 2, 02.2025, p. S126.

970. **Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes.** / FIDELIO-DKD and FIGARO-DKD Investigators.
In: ESC Heart Failure, Vol. 12, No. 1, 02.2025, p. 185-188.

971. **Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY.** / Singh, Ajay K; James, Glen; Anker, Stefan D et al.
In: JACC: Advances, Vol. 4, No. 2, 101524, 02.2025, p. 101524.

972. **Genetic factors shaping the plasma lipidome and the relations to cardiometabolic risk in children and adolescents.** / Huang, Yun; Stinson, Sara Elizabeth; Thodberg, Malte et al.
In: EBioMedicine, Vol. 112, 105537, 02.2025, p. 105537.

973. **Kidney fat by magnetic resonance spectroscopy in type 2 diabetes with chronic kidney disease.** / Heinrich, Niels Sondergaard; Pedersen, Rune Ploegstra; Vestergaard, Mark Bitsch et al.
In: Journal of Diabetes and its Complications, Vol. 39, No. 2, 108923, 02.2025.

974. **The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.** / Smeijer, Johannes David; Gomez, Maria F; Rossing, Peter et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 2, 02.2025, p. 511-518.

975. **Wcn25-662 efficacy and safety of finerenone in patients with nephrectomy: a fidelity subanal-ysis.** / Mendoza, Jair Munoz; Weir, Matthew; Anker, Stefan D. et al.
In: Kidney International Reports, Vol. 10, No. 2, 02.2025, p. S265.

976. **Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6.** / Apperloo, Ellen M; Cherney, David Z I; Kuhlman, Anja Birk et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 40, No. 2, gfae150, 01.02.2025, p. 352-359.

977. **The era of combination of nephroprotective agents in CKD is there.** / Jadoul, Michel; Rossing, Peter.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 40, No. Supplement_1, 05.02.2025, p. i1-i2.

978. **Characterization of Anti-Insulin Antibodies in Type 1 and Type 2 Diabetes Mellitus: Clinical Relevance.** / Toft-Hansen, Henrik; Aniol-Nielsen, Christina; Elias, Daniel et al.
In: International Journal of Molecular Sciences, Vol. 26, No. 4, 1730, 18.02.2025.

979. **Barriers and new opportunities in developing effective therapies for diabetic neuropathy: International expert consensus recommendations.** / Brock, C; Andersen, H; Alibegovic, A C et al.
In: Diabetes Research and Clinical Practice, Vol. 221, 112010, 03.2025, p. 112010.

980. **Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.** / Mahaffey, Kenneth W; Tuttle, Katherine R; Arici, Mustafa et al.
In: European Heart Journal, Vol. 46, No. 12, ehae613, 21.03.2025, p. 1096-1108.

981. **Association between interleukin-6, suPAR, and hsCRP with subclinical left ventricular dysfunction in type 1 diabetes: The Thousand & 1 study.** / Bahrami, Hashmat Sayed Zohori; Jørgensen, Peter Godsk; Hove, Jens Dahlgaard et al.
In: Diabetes Research and Clinical Practice, Vol. 222, 112071, 04.2025, p. 112071.

982. **Birthweight and risk of chronic kidney disease after a type 2 diabetes diagnosis in the DD2 cohort.** / Hansen, Aleksander L; Christiansen, Christian F; Brøns, Charlotte et al.
In: Diabetologia, Vol. 68, No. 4, 04.2025, p. 778-791.

983. **Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study.** / Akerkar, Abhilasha; Rønn, Pernille F; Kosjerina, Vanja et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 4, 04.2025, p. 2284-2287.

984. **Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials.** / Rossing, Peter; Benamar, Malik; Cheng, Alice Y Y et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 4, 04.2025, p. 2259-2270.

985. **Incept: The Intensive Care Platform Trial-Design and protocol.** / Granholm, Anders; Møller, Morten Hylander; Kaas-Hansen, Benjamin Skov et al.
In: Acta Anaesthesiologica Scandinavica, Vol. 69, No. 4, e70023, 04.2025, p. e70023.

986. **Efficacy and safety of finerenone in patients with cancer: a fidelity subgroup analysis.** / Mandayam, Sreedhar A.; Workeneh, Biruh T.; Anker, Markus S. et al.
In: American Journal of Kidney Diseases, Vol. 85, No. 4, 1, G-301, 01.04.2025, p. S93-S94.

987. **Phase II dose-selection, randomised, controlled trial of ASi Vicadrostat (BI 690517) with and without EMPA in CKD: Subgroup analysis by T2D status.** / Lucas, Tina; Heilmann, Clemens; Rossing, Peter et al.
In: INNERE MEDIZIN, Vol. 66, No. Suppl 1, P23-02, 01.04.2025, p. S146-S147.

988. **SGLT-2 inhibitors and nephrolithiasis risk: a meta-analysis.** / Kanbay, Mehmet; Brinza, Crischentian; Copur, Sidar et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 40, No. 4, gfae179, 01.04.2025, p. 671-678.

989. **Sex differences in myocardial flow reserve among individuals with type 2 diabetes: insights from the DiaHeart study.** / Skriver-Møller, Anne-Cathrine; Hasbak, Philip; Rasmussen, Ida K B et al.
In: Cardiovascular Diabetology, Vol. 24, No. 1, 172, 18.04.2025, p. 172.

990. **Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme.** / Ferreira, João Pedro; Anker, Stefan D; Palmer, Biff F et al.
In: European Heart Journal, 22.04.2025.

991. **Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis.** / Mentz, Robert J; Anker, Stefan D; Pitt, Bertram et al.
In: European Journal of Heart Failure, Vol. 27, No. 5, 05.2025, p. 764-774.

992. **GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.** / de Boer, Ian H; Caramori, M Luiza; Chan, Juliana C N et al.
In: Kidney International, Vol. 107, No. 5, 05.2025, p. 767-771.

993. **GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?** / Kosjerina, Vanja; Rossing, Peter.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 85, No. 5, 05.2025, p. 537-539.

994. **Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.** / Ostrominski, John W; Claggett, Brian L; Miao, Zi Michael et al.
In: Diabetes Care, Vol. 48, No. 5, 01.05.2025, p. 745-755.

995. **Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis.** / Pabon, Maria A; Filippatos, Gerasimos; Claggett, Brian L et al.
In: Journal of the American College of Cardiology, Vol. 85, No. 17, 06.05.2025, p. 1649-1660.

996. **Adherence to Chronic Kidney Disease Screening Guidelines in Type 1 and Type 2 Diabetes.** / Lee, Christina J-Y.; Kosjerina, Vanja; Gerds, Thomas A. et al.
In: Diabetes, Vol. 74, No. Suppl 1, 06.2025.

997. **Baseline Characteristics for FINE-ONE-A Randomized Phase III Trial Assessing Finerenone in People with T1D and CKD.** / Heerspink, Hiddo L.; Birkenfeld, Andreas L.; Cherney, David et al.
In: Diabetes, Vol. 74, No. suppl 1, 06.2025.

998. **Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD-Data from the FLOW Trial.** / Mann, Johannes F. E.; Tuttle, Katherine R.; Pratley, Richard E. et al.
In: Diabetes, Vol. 74, No. Suppl 1, 06.2025.

999. **Once-Weekly Semaglutide vs. Placebo for the Treatment of Type 2 Diabetes and Chronic Kidney Disease in Denmark-A Long-Term Cost-Effectiveness Analysis Based on Flow.** / Rossing, Peter; Lindhardt, Morten; Tikkanen, Christian K. et al.
In: Diabetes, Vol. 74, No. Suppl 1, 06.2025.

1000. **The Confidence Trial-Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes.** / Agarwal, Rajiv; Green, Jennifer B.; Heerspink, Hiddo L. et al.
In: Diabetes, Vol. 74, No. Suppl 1, 06.2025.

1001. **The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.** / Judge, Parminder K; Tuttle, Katherine R; Staplin, Natalie et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 40, No. 6, gfae263, 01.06.2025, p. 1175-1186.

1002. **Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis.** / Navaneethan, Sankar D; Anker, Stefan D; Filippatos, Gerasimos et al.
In: Kidney International, Vol. 108, No. 1, 07.2025, p. 136-144.

1003. **Cumulative Effects of Vicadrostat (BI 690517) and Empagliflozin on Albuminuria in People with Chronic Kidney Disease.** / Rossing, Peter; Hauske, Sibylle J.; Cronin, Lisa et al.
In: Metabolism, Vol. 168, No. S, 156218, 01.07.2025.

1004. **Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.** / Rossing, Peter; Birkenfeld, Andreas L; Fioretto, Paola et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 20, No. 7, 01.07.2025, p. 968-977.

1005. **Indexing GFR Using Extracellular Volume versus Body Surface Area in a Population with Type 1 Diabetes and Diabetic Kidney Disease.** / Sridhar, Vikas S; Kugathasan, Luxcia; Lovblom, Leif Erik et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 36, No. 7, 01.07.2025, p. 1414-1416.

1006. **Trends in use of cardiorenal protective medication among people with type 2 diabetes and chronic kidney disease in Denmark.** / Rørth, Rasmus; Gerds, Thomas A.; Kosjerina, Vanja et al.
In: Diabetes Epidemiology and Management, Vol. 19-20, 100286, 01.07.2025.

1007. **Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.** / Wasehuus, Victor; Smeijer, J David; Ambery, Phil et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 8, 08.2025, p. 4311-4319.

1008. **Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis.** / Ostrominski, John W; Filippatos, Gerasimos; Claggett, Brian L et al.
In: JACC. Heart failure, Vol. 13, No. 8, 102497, 08.2025, p. 102497.

1009. **Polypeptides synthesized by common bacteria in the human gut improve rodent metabolism.** / Fan, Yong; Lyu, Liwei; Vazquez-Uribe, Ruben et al.
In: Nature Microbiology, Vol. 10, No. 8, 08.2025, p. 1918-1939.

1010. **COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics.** / Agarwal, Rajiv; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 40, No. 8, 01.08.2025, p. 1559-1569.

1011. **Effects of Vicadrostat with and Without Empagliflozin in People With Chronic Kidney Disease by Baseline Body Mass Index.** / Rossing, Peter; Hauske, Sibylle; Cronin, Lisa et al.
In: Nephrology, Vol. 40, No. Suppl 3, #3201, 01.08.2025.

1012. **Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.** / Agarwal, Rajiv; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: The New England journal of medicine, Vol. 393, No. 6, 07.08.2025, p. 533-543.

1013. **Discovery of novel autoantibodies associated with protection from vascular complications using large scale proteomics in long-standing type 1 diabetes.** / Trinh, X; Hernansanz Biel, Jorge; Kaur, Simranjeet et al.
In: Diabetologia, Vol. 68, No. Supp 1, 275, 09.2025, p. S151.

1014. **Genome-wide association study meta-analysis identifies new locus associated with increased risk of diabetic neuropathy in European ancestry individuals with diabetes.** / Armirola-Ricaurte, C; Veluchamy, Abirami; Lemmellä, S et al.
In: Diabetologia, Vol. 68, No. Supp 1, 102, 09.2025, p. S57.

1015. **Heritability and genome-wide association study of arterial stiffness in type 1 diabetes.** / Tynjälä, A; Antikainen, Anni A V; Syreeni, A et al.
In: Diabetologia, Vol. 68, No. Supp 1, 238, 09.2025, p. S131.

1016. **Psychological and emotional aspects in people with diabetic foot disease: A systematic scoping review.** / Cardon, Alice; Andersen, Tue Helms; Akerkar, Abhilasha et al.
2025. 57-57 Abstract from 20th meeting of the Diabetic Foot Study Group, Prague, Czech Republic.

1017. **Serum lipidomics profiling unveiling biomarkers for diabetes neuropathy in type 1 diabetes patients.** / Muk, Tik; Okdahl, Tina; Kokla, Marietta et al.
In: Diabetologia, Vol. 68, No. Supp 1, 97, 09.2025, p. S55.

1018. **Soluble urokinase plasminogen activator receptor and interleukin-6 improves prediction of all-cause mortality and major adverse cardiovascular events in Type 1 diabetes.** / Bahrami, Hashmat Sayed Zohori; Jørgensen, Peter Godsk; Hove, Jens Dahlgaard et al.
In: Journal of Internal Medicine, Vol. 298, No. 3, 09.2025, p. 188-199.

1019. **Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes.** / Maagensen, Henrik; Jensen, Johanne S; Høyerup, Stine O et al.
In: Diabetes Care, Vol. 48, No. 9, 01.09.2025, p. 1536-1544.

1020. **The polymicrobial metaproteomic signature impact on host defences of diabetic foot ulcers.** / Petkovic, Marija; M.K.Nielsen, Marcus; Rasmussen, Anne et al.
In: Diabetologia, Vol. 68, No. Supp 1, 59, 04.09.2025, p. 35-36.

1021. **Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial.** / Berger, Mario; MacNamara, Aidan; Ferreira, João Pedro et al.
In: European Heart Journal, Vol. 46, No. 34, 07.09.2025, p. 3382-3386.

1022. **Adherence to diabetes screening in high-risk women after gestational diabetes in Denmark: Vienna, Austria, 15 - 19 September 2025.** / Hædersdal, Sofie; Jacobsen, Katja Kemp; Foghsgaard, Signe et al.
In: Diabetologia, Vol. 68, No. Suppl 1 , LBA 11, 10.2025, p. S649.

1023. **Burden and progression of arterial calcification in type 1 diabetes predicts future cardiovascular disease.** / Hjortkjær, Henrik Ø.; Rossing, Peter; Kofoed, Klaus F.
In: Journal of Diabetes and its Complications, Vol. 39, No. 10, 109152, 10.2025.

1024. **Busting a Myth: Sodium-Glucose Cotransporter-2 Inhibitors do not Cause Postoperative Acute Kidney Injury.** / Rossing, Peter.
In: Kidney International Reports, Vol. 10, No. 10, 10.2025, p. 3308-3310.

1025. **CONFIDENCE Asia: effect of simultaneous initiation of finerenone and empagliflozin on urinary albumin-to-creatinine ratio in Asian participants from the CONFIDENCE trial: Vienna, Austria, 15 - 19 September 2025.** / Agarwal, Ridhi; Green, Jennifer B; Heerspink, Hiddo J.L. et al.
In: Diabetologia, Vol. 68, No. Suppl 1, LBA 74, 10.2025, p. S684.

1026. **Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone on insulin resistance and markers of inflammation.** / Wasehuus, Victor; Smeijer, Johannes David; Sayer, M et al.
In: Diabetologia, Vol. 68, No. Suppl 1, 514, 10.2025, p. S266.

1027. **Increased endotrophin levels are associated with the risk of MACE in individuals with type 2 diabetes: the Thousand&2 study.** / Laursen, C F G ; Bahrami, Hashmat S. Z.; Martin, Emily et al.
In: Diabetologia, Vol. 68, No. Suppl 1, 1174, 10.2025, p. S600.

1028. **Re-evaluating the albuminuria-eGFR relationship using genetics for precision monitoring: the READ-GEN study.** / Ahluwalia, Tarunveer Singh; Naaman, Cilia Hanna; Rossing, Peter et al.
In: Diabetologia, Vol. 68, No. Suppl 1, 959, 10.2025, p. S493.

1029. **Semaglutide and risk reduction of major adverse limb events in diabetes: a pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials.** / Verma, S.; Bonaca, Marc P; Nordanstig, Joakim et al.
In: Diabetologia, Vol. 68, No. Suppl 1, LBA 21, 10.2025, p. S654.

1030. **Simultaneous initiation of finerenone and empagliflozin by baseline glucagon-like peptide-1 receptor agonist use: a prespecified analysis of CONFIDENCE: Vienna, Austria, 15 - 19 September 2025.** / Agarwal, Ridhi; Green, J; Heerspink, Hiddo J.L. et al.
In: Diabetologia, Vol. 68, No. Suppl 1, LBA 33, 10.2025, p. S662.

1031. **The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.** / Stougaard, Elisabeth B.; Andersen, Mads R.; Bagger, Jonatan I. et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 10, 10.2025, p. 5432-5443.

1032. **An application of urinary peptidomics and in silico methods to guide multifactorial intervention in chronic kidney disease.** / Latosinska, Agnieszka; Keller, Felix; Mayer, Gert et al.
In: Nephrology Dialysis Transplantation, Vol. 40, No. Suppl 3, #1817, 01.10.2025.

1033. **Effects of vicadrostat with and without empagliflozin in people with chronic kidney disease by baseline BMI.** / Rossing, Peter; Hauske, Sibylle; Cronin, Lisa et al.
In: Nephrology Dialysis Transplantation, Vol. 40, No. Suppl 3, 01.10.2025.

1034. **Genome-Wide Association Study of Quantitative Kidney Function in 52,531 Individuals with Diabetes Identifies Five Diabetes-Specific Loci.** / Cole, Joanne B; Dahlström, Emma H; Fermin, Damian et al.
In: Journal of the American Society of Nephrology : JASN, Vol. 36, No. 10, 10.1681/ASN.0000000718, 01.10.2025, p. 1939-1953.

1035. **Vicadrostat with and without empagliflozin reduces albuminuria across KDIGO risk class in chronic kidney disease.** / Tuttle, Katherine R.; Hauske, Sibylle; Cronin, Lisa et al.
In: Nephrology Dialysis Transplantation, Vol. 40, No. Suppl 3, #3315, 01.10.2025.

1036. **Current advances in diabetic neuropathy: Proteins as therapeutic targets.** / Kaur, Gurjeet; Ali, Salaha Osman; Santos, Alberto et al.
In: iScience, Vol. 28, No. 10, 113466, 17.10.2025.

1037. **Research kidney biopsies in type 2 diabetes: clinical and laboratory parameters alone are not enough to identify candidates for kidney biopsy.** / Jakobsen, Signe Kjaergaard; Moller, Marie; Borg, Rikke et al.
In: Nephrology Dialysis Transplantation, Vol. 40, No. Suppl 3, #2685 , 21.10.2025.

1038. **Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes.** / Bitsch Poulsen, Maria; Okdahl, Tina; Buciek, Jens Hove et al.
In: BMJ Open, Vol. 15, No. 10, e101074, 23.10.2025, p. e101074.

1039. **Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.** / Agarwal, Rajiv; Rossing, Peter; Mann, Johannes F E.
In: The New England journal of medicine, Vol. 393, No. 17, 30.10.2025, p. 1755.

1040. **Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.** / Bartholdy, Katja Vu; Johansen, Niklas Dyrby; Skaarup, Kristoffer Grundtvig et al.
In: NEJM Evidence, Vol. 4, No. 11, 11.2025, p. EVIDoa2500158.

1041. **Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.** / James, Stefan; Christoffersen, Andreas Dyreborg; David, Jens-Peter et al.
In: American Heart Journal, Vol. 289, 11.2025, p. 17-27.

1042. **Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes.** / Andersen, Jonas A; Suvitaival, Tommi; Trošt, Kajetan et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 11, 11.2025, p. 6167-6177.

1043. **Response to the letter to the editor entitled "Semaglutide and kidney function: direct kidney protection or an artifact?".** / Perkovic, Vlado; Tuttle, Katherine R; Rossing, Peter et al.
In: Kidney International, Vol. 108, No. 5, 11.2025, p. 948-950.

1044. **Targeting visceral and ectopic adiposity: Pharmacological and surgical interventions beyond global weight loss.** / Guldan, Mustafa; Ozbek, Lasin; Abdel-Rahman, Sama M et al.
In: Diabetes, Obesity and Metabolism, Vol. 27, No. 11, 11.2025, p. 6116-6138.

1045. **Effects of Dapagliflozin on Progression of Chronic Kidney Disease According to Different Rates of Pre-Trial Progression.** / Heerspink, Hiddo J L; Chertow, Glenn M; Rossing, Peter et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 20, No. 11, 10.2215/CJN.0000000810, 01.11.2025, p. 1527-1535.

1046. **Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.** / Rossing, Peter; Bakris, George; Perkovic, Vlado et al.
In: Diabetes Care, Vol. 48, No. 11, 01.11.2025, p. 1878-1887.

1047. **Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial).** / Agarwal, Rajiv; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Diabetes Care, Vol. 48, No. 11, 01.11.2025, p. 1904-1913.

1048. **Inflammatory biomarkers suPAR, IL-6, and hsCRP and 13-year risk of mortality and MACE in type 2 diabetes: a prospective cohort study.** / Bahrami, H. S. Z.; Jorgensen, P. G.; Rasmussen, L. J. H. et al.
In: European Heart Journal, Vol. 46, No. 1, SI, 01.11.2025.

1049. **Long-term risk of major adverse cardiovascular events in individuals with type 1 diabetes, albuminuria, and cardiac impairment.** / Frimodt-Moeller, E.; Bahrami, H. S. Z.; Azar, A. K. et al.
In: European Heart Journal, Vol. 46, No. 1, SI, 01.11.2025.

1050. **Trends in nephrology: From "diabetic kidney disease" to "CKD with risk factor diabetes".** / Speeckaert, Marijn M; Rossing, Peter.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 40, No. 11, 01.11.2025, p. 2004-2007.

1051. **Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk: Insights from the FIDELITY Program.** / Ostrominski, John; Neuen, Brendon; Claggett, Brian et al.
In: Cirkulation, Vol. 152, No. SUPPL3, 3, SI, 04.11.2025.

1052. **Estimated Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Patients with Type 2 Diabetes and Chronic Kidney Disease.** / Ostrominski, John; Neuen, Brendon; Claggett, Brian et al.
In: Cirkulation, Vol. 152, No. SUPPL3, 3, SI, 4369294, 04.11.2025.

1053. **Finerenone Reduces Loop Diuretic Requirement in Patients with Type 2 Diabetes and CKD: Participant-Level Pooled Analysis of FIDELIO-DKD and FIGARO-DKD.** / Chatur, Safia; Vaduganathan, Muthiah; Claggett, Brian et al.
In: Cirkulation, Vol. 152, No. SUPPL3, 3, SI, 4369612, 04.11.2025.

1054. **Finerenone Reduces Sudden Death across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis.** / Foa', Alberto; Pabon, Maria; Filippatos, Gerasimos et al.
In: Cirkulation, Vol. 152, No. SUPPL3, 3, SI, 4365801:, 04.11.2025.

1055. **Major Adverse Cardiovascular Events across the Spectrum of Cardio-Kidney-Metabolic Syndrome: A FINE-HEART Pooled Analysis.** / Siqueira, Sara; Pabon, Maria; Makuvire, Tracy et al.
In: Cirkulation, Vol. 152, No. SUPPL3, 3, SI, 4366287, 04.11.2025.

1056. **The HFpEF-ABA Algorithm and Finerenone in Chronic Kidney Disease with Type 2 Diabetes: A FINE-HEART Analysis.** / Inciardi, Riccardo; Ostrominski, John; Claggett, Brian et al.
In: Cirkulation, Vol. 152, No. SUPPL3, 3, SI, 4366042, 04.11.2025.

1057. **Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.** / Delic, Denis; Gashaw, Isabella; Duran-Fernandez, Ileana et al.
In: International Journal of Molecular Sciences, Vol. 26, No. 22, 10810, 07.11.2025.

1058. **Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.** / Ostrominski, John W; Harrington, Josephine; Claggett, Brian L et al.
In: Journal of the American College of Cardiology, Vol. 86, No. 20, 18.11.2025, p. 1781-1801.

1059. **Infective endocarditis and relationship with diabetes mellitus - Patient characteristics, microbial etiology and mortality.** / Jensen, Andreas Dalsgaard; Østergaard, Lauge; Graversen, Peter Laursen et al.
In: Infection, Vol. 53, No. 6, 12.2025, p. 2757-2767.

1060. **In silico prediction of optimal multifactorial intervention in chronic kidney disease.** / Latosinska, Agnieszka; Mina, Ioanna K; Nguyen, Thi Minh Nghia et al.
In: Journal of Translational Medicine, Vol. 23, No. 1, 943, 12.2025, p. 943.

1061. **Left ventricular ejection fraction reserve and its association with myocardial perfusion, coronary calcification, and strain in type 2 diabetes without overt cardiovascular disease.** / Chebli, Adam; Rasmussen, Ida K.B.; Skriver-Møller, Anne-Cathrine et al.
In: Cardiovascular Diabetology, Vol. 24, No. 1, 352, 12.2025.

1062. **Study protocol for the investigator-initiated Danish pragmatic randomised STENO INTEN-CT trial: does screening and intervention for subclinical coronary artery disease in type 2 diabetes reduce cardiovascular events?** / Funck, Kristian Løkke; Borregaard, Britt; Egstrup, Kenneth et al.
In: BMJ Open, Vol. 15, No. 12, e106018, 15.12.2025, p. e106018.

1063. **Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.** / Rossing, Peter; Lindhardt, Morten; Tikkanen, Christian Klyver et al.
In: Cardiovascular Diabetology, Vol. 25, No. 1, 32, 20.12.2025.

1064. **Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.** / Vaduganathan, Muthiah; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 41, No. 1, 23.12.2025, p. 161-170.

1065. **Abdominal waist circumference and subcutaneous adipose tissue thickness predicts development of post-transplant diabetes mellitus.** / Kanbay, Mehmet; Yagmur, Feyyaz H; Karadeniz, Bilge et al.
In: International Urology and Nephrology, Vol. 58, No. 12, 2026, p. 5481–5489.

1066. **A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis.** / Heerspink, Hiddo J L; Little, Dustin J; Gasparyan, Samvel B et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 5, 2026, p. 791-800.

1067. **Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease.** / Caramori, M Luiza; Repetto, Enrico; Perkins, Christopher et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 5, 2026, p. 4344-4351.

1068. **Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.** / Mann, Johannes F E; Badve, Sunil V; Baeres, Florian M M et al.
In: The Lancet Diabetes and Endocrinology, Vol. 14, No. 10, 2026, p. 818-830.

1069. **Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.** / Tuttle, Katherine R; Mann, Johannes F E; Mayrdorfer, Manuel M et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 5, 2026, p. 841-851.

1070. **Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.** / Neves, João Sérgio; Leite, Ana Rita; Vasques-Nóvoa, Francisco et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 7, 2026, p. 6022-6033.

1071. **Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease.** / Tuttle, Katherine R; Meyerhoff, Juliane; Sun, Zhichao et al.
In: Sage open chronic disease, Vol. 17, 27558428251411738, 2026.

1072. **RAAS Inhibitors for the Primary Prevention of CKD in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-analysis.** / Bannuru, Raveendhara R; Fazioli, Katherine; de Boer, Ian H et al.
In: Diabetes, Obesity, and CardioMetabolic CARE, Vol. 1, No. 4, 2026, p. 691-701.

1073. **SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis.** / Bannuru, Raveendhara R; Fazioli, Katherine; Bhave, Nicole M et al.
In: Diabetes, Obesity, and CardioMetabolic CARE, Vol. 1, No. 4, 2026, p. 682-690.

1074. **Vitamin K status and vascular health in a general population.** / Lauridsen, Julie Aaberg; Friis Bryde Nielsen, Camilla; Kårhus, Line Lund et al.
In: Nutrition, Metabolism and Cardiovascular Diseases, Vol. 36, No. 11, 104808, 2026.

1075. **Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.** / Katayama, Shigehiro; Anker, Stefan D; Zhu, Dalong et al.
In: Journal of Diabetes and its Complications, Vol. 40, No. 1, 109213, 01.2026.

1076. **Exome-Wide Analysis Identifies a Rare EXD3 Missense Variant Associated With Diabetic Kidney Disease.** / Sandholm, Niina; Cole, Joanne B; Nair, Viji et al.
In: Kidney International Reports, Vol. 11, No. 1, 01.2026, p. 219-232.

1077. **Dickkopf 3 in Urine: A Help for Prioritizing Management of Kidney Disease in Type 2 Diabetes.** / Rossing, Peter.
In: Diabetes, Vol. 75, No. 1, 01.01.2026, p. 17-18.

1078. **Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD.** / Bakker, Wisanne M; Heerspink, Hiddo J L; Jongs, Niels et al.
In: Journal of the American Society of Nephrology, Vol. 37, No. 1, 01.01.2026, p. 101-109.

1079. **Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.** / Agarwal, Rajiv; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 1, 01.01.2026, p. 72-82.

1080. **Joslin Kidney Panel of Circulating Proteins: A Tool for ESKD Risk Discrimination and Individualized Diabetic Kidney Disease Treatment.** / Krolewski, Andrzej S; Haukka, Jani K; Md Dom, Zaipul I et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 1, 01.01.2026, p. 46-60.

1081. **Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD.** / Gashaw, Isabella A; Tuttle, Katherine R; Monroy Kuhn, Manuel et al.
In: European Journal of Endocrinology, Vol. 194, No. 1, 01.01.2026, p. 46-57.

1082. **SBP Response to Vicadrostat with and without Empagliflozin in CKD: A Post Hoc Analysis in Patients with and without Uncontrolled Hypertension or Diuretic Use at Baseline.** / Rossing, Peter; Cronin, Lisa; Meyerhoff, Juliane et al.
In: Nephrology nursing journal : journal of the American Nephrology Nurses' Association, Vol. 53, No. 1, P022, 01.01.2026, p. 89.

1083. **Effect of Finerenone on Morbidity and Mortality in CKD.** / Ostrominski, John W; Filippatos, Gerasimos; Claggett, Brian L et al.
In: Journal of the American Society of Nephrology, Vol. 37, No. 2, 01.02.2026, p. 312-325.

1084. **iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025.** / Anker, Stefan D.; Ji, Linong; Kindel, Tammy et al.
In: Journal of Cachexia, Sarcopenia and Muscle, Vol. 17, No. 1, e70167, 01.02.2026.

1085. **Echocardiography and inflammatory biomarkers for predicting mortality and major adverse cardiovascular events in type 1 diabetes.** / Bahrami, Hashmat Sayed Zohori; Jørgensen, Peter Godsk; Hove, Jens Dahlgaard et al.
In: Cardiovascular Diabetology, Vol. 25, No. 1, 35, 12.2026, p. 35.

1086. **Feasibility and cost-effectiveness of at-home self-sampling screening for type 2 diabetes: a pilot screening study in Denmark.** / Mateu, Nuri Cayuelas; Rossing, Peter; Neergaard, Kirsten Piepgras et al.
In: BMJ open diabetes research & care, Vol. 14, No. 1, e005539, 11.02.2026.

1087. **Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.** / Agarwal, Rajiv; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Journal of the American College of Cardiology, Vol. 87, No. 7, 24.02.2026, p. 772-784.

1088. **Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes.** / Ostrominski, John W; Neuen, Brendon L; Claggett, Brian L et al.
In: Journal of the American College of Cardiology, Vol. 87, No. 7, 24.02.2026, p. 788-792.

1089. **Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations.** / Heerspink, Hiddo J L; Agarwal, Rajiv; Amor, Antonio J et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 41, No. 3, 27.02.2026, p. 556-565.

1090. **A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD.** / Singh, Ajay K; Anker, Stefan D; Pitt, Bertram et al.
In: Kidney International Reports, Vol. 11, No. 3, 103704, 03.2026.

1091. **The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.** / Furth, Susan L; Colhoun, Helen M; Kanbay, Mehmet et al.
In: Kidney International, Vol. 109, No. 3, 03.2026, p. 442-464.

1092. **Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy.** / Mendoza, Jair Munoz; Weir, Matthew R; Anker, Stefan D et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 3, 01.03.2026, p. 414-424.

1093. **Vitamin B12 and Neuropathy in Type 1 Diabetes.** / Brødsgaard, Rasmus Budde; Mizrak, Hatice Isik; Brock, Birgitte et al.
In: Diabetes Care, Vol. 49, No. 3, 01.03.2026, p. e38-e39.

1094. **Finerenone in Type 1 Diabetes and Chronic Kidney Disease.** / Heerspink, Hiddo J L; Birkenfeld, Andreas L; Cherney, David Z I et al.
In: The New England journal of medicine, Vol. 394, No. 10, 05.03.2026, p. 947-957.

1095. **Early Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial.** / Vaduganathan, Muthiah; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Journal of the American College of Cardiology, 24.03.2026.

1096. **Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.** / Pabon, Maria A; Ostrominski, John W; Wang, Xiaowen et al.
In: European Heart Journal, 26.03.2026.

1097. **Effect of Finerenone Treatment Discontinuation on Kidney and Cardiovascular Outcomes: A Fidelity Analysis.** / Singh, Ajay K; Anker, Stefan D; Pitt, Bertram et al.
In: American Journal of Nephrology, 31.03.2026, p. 1-12.

1098. **Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITY.** / Weingold, Robert; Filippatos, Gerasimos; Anker, Stefan D et al.
In: Journal of Diabetes and its Complications, Vol. 40, No. 4, 109274, 04.2026.

1099. **The association between mineralocorticoid receptor antagonist use and diabetes occurrence and progression: A systematic review and meta-analysis.** / Kanbay, Mehmet; Guldan, Mustafa; Ozbek, Lasin et al.
In: British Journal of Clinical Pharmacology, Vol. 92, No. 4, 04.2026, p. 1011-1022.

1100. **Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.** / Mottl, Amy; Scott, Charlie; Green, Jennifer B et al.
In: Journal of the American Society of Nephrology, Vol. 37, No. 4, 01.04.2026, p. 764-776.

1101. **Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials.** / Ostrominski, John W; Neuen, Brendon L; Claggett, Brian L et al.
In: European Heart Journal, 07.04.2026.

1102. **Psychological and emotional aspects in people with diabetic foot disease: a systematic scoping review.** / Cardon, Alice; Andersen, Tue Helms; Akerkar, Abhilasha et al.
In: BMC Psychology, Vol. 14, No. 1, 789, 15.04.2026.

1103. **Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial.** / Duus, Lisa Steen; Lassen, Mats C H; Johansen, Niklas D et al.
In: European Journal of Preventive Cardiology, 30.04.2026.

1104. **Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real-World Evidence Study.** / Pandey, Ambarish; Repetto, Enrico; Perkins, Christopher et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 5, 05.2026, p. 4352-4355.

1105. **Cell Therapy: The Next Frontier in CKD Management?** / Rossing, Peter.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 5, 05.2026, p. 733-734.

1106. **Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD.** / Rossing, Peter; Hauske, Sibylle J; Canziani, Maria Eugenia et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 87, No. 5, 05.2026, p. 704-708.

1107. **Intra-Individual Variability of Urinary EGF and Clusterin, and Effect of Frozen Storage on Stability: Results from UVALID.** / Moedt, Erik; Vos, Rémon; Ju, Wenjun et al.
In: International Journal of Molecular Sciences, Vol. 27, No. 9, 3838, 05.2026, p. 3838.

1108. **Oral versus injectable GLP-1 receptor agonists in clinical practice!** / Curovic, Viktor Rotbain; Rossing, Peter.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 06.05.2026.

1109. **Mapping shared genetic determinants of eGFR and albuminuria with a focus on type 2 diabetes: a large-scale European study.** / Naaman, Cilia; Persson, Frederik; Kümler, Thomas et al.
In: BMJ open diabetes research & care, Vol. 14, No. 3, e005863, 26.05.2026.

1110. **Albuminuria and Carotid Atherosclerosis in Type 1 Diabetes Evaluated Using Three-Dimensional Vascular Ultrasound.** / Ferreira-Divino, Luis F; Poulsen, Christina G; Rotbain Curovic, Viktor et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 6, 06.2026, p. 5020-5028.

1111. **iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.** / Anker, Stefan D; Ji, Linong; Kindel, Tammy et al.
In: American Journal of Preventive Cardiology, Vol. 27, 101445, 06.2026.

1112. **High-Dose Semaglutide Is Associated with Preservation of Kidney Function in People Living with Obesity without Diabetes.** / Rossing, PETER; Jacobsen, CHRISTINE SOFIE FUCHS; Hjelmesæth, JØRAN et al.
In: Diabetes, Vol. 75, No. Supplement_1, 2700-LB, 01.06.2026.

1113. **Impact of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Levels and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.** / Rossing, Peter; Heerspink, HIDDO; Amor, ANTONIO J. et al.
In: Diabetes, Vol. 75, No. Supplement_1, 1394-P, 01.06.2026.

1114. **Inflammation, Body Mass Index, and Cardiovascular Outcomes in Chronic Kidney Disease and Type 2 Diabetes.** / Ostrominski, John; Filippatos, GERASIMOS; Rossing, PETER et al.
In: Diabetes, Vol. 75, No. Supplement_1, 1764-P, 01.06.2026.

1115. **Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.** / Rossing, Peter; Perkovic, Vlado; Rasmussen, Søren et al.
In: Diabetes Care, Vol. 49, No. 6, 01.06.2026, p. e92-e93.

1116. **VICM, a Biomarker of Macrophage-Driven Inflammation, as a Risk Marker of Diabetic Kidney Disease Progression in People with Type 2 Diabetes and Microalbuminuria.** / Møller, ALEXANDRA L.; Von Scholten, BERNT JOHAN; Rossing, PETER.
In: Diabetes, Vol. 75, No. Supplement_1, 1398-P, 01.06.2026.

1117. **Workforce Detachment in Persons with CKD.** / Rørth, Rasmus; Koch, Milos M; Gerds, Thomas A et al.
In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 21, No. 6, 01.06.2026.

1118. **Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.** / Tuttle, Katherine R; Bakris, George L; Baeres, Florian M M et al.
In: Journal of the American College of Cardiology, Vol. 87, No. 21, 02.06.2026, p. 2996-3012.

1119. **Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).** / Neuen, Brendon L; Heerspink, Hiddo J L; Perkovic, Vlado et al.
In: Lancet (London, England), Vol. 407, No. 10546, 13.06.2026, p. 2375-2386.

1120. **Extracellular matrix proteins as risk markers for complications in type 1 diabetes.** / Rygg, Marte Opseth; Møller, Alexandra Louise; Curovic, Viktor Rotbain et al.
In: Diabetic Medicine, 20.06.2026.

1121. **Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.** / Brødsgaard, Rasmus Budde; Laursen, Jens Christian; Mizrak, Hatice Isik et al.
In: Diabetes & Metabolism, Vol. 52, No. 4, 101773, 07.2026.

1122. **Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes.** / Ostrominski, John W; Neuen, Brendon L; Claggett, Brian L et al.
In: JACC. Heart failure, Vol. 14, No. 7, 103006, 07.2026.

1123. **Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses.** / Cherney, David Z.I.; Rossing, Peter; Canziani, Maria Eugenia et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 7, 07.2026, p. 6324-6333.

1124. **Efficacy and safety of dapagliflozin in patients receiving dialysis: a post-hoc analysis of the DAPA-CKD trial.** / Bakker, Wisanne M; Jongs, Niels; Chertow, Glenn M et al.
In: Clinical kidney journal, Vol. 19, No. 7, fag170, 07.2026.

1125. **Glucagon-like peptide-1 receptor agonists: an emerging hope against nephrolithiasis risk reduction via body weight reduction.** / Kanbay, Mehmet; Copur, Sidar; Covic, Adrian et al.
In: International Urology and Nephrology, Vol. 58, No. 7, 07.2026, p. 2603-2607.

1126. **Post-Hoc Analysis on the Effects of Vicadrostat/Empagliflozin by CKD Severity/Hypertension Status.** / Correa-Rotter, Ricardo; Rossing, Peter; Canziani, Maria Eugenia et al.
In: Kidney International Reports, Vol. 11, No. 7, 106545, 07.2026.

1127. **Response to the Letter to the Editor Entitled "A Missing Genomic Dimension: The Small but Central Mitochondrial Genome in Diabetic Kidney Disease Genetics".** / Sandholm, Niina; Cole, Joanne B.; Nair, Viji et al.
In: Kidney International Reports, Vol. 11, No. 7, 106572, 07.2026.

1128. **Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical Trials.** / Lo, Kevin Bryan; Ostrominski, John W; Hamatani, Yasuhiro et al.
In: JAMA Cardiology, Vol. 11, No. 7, 01.07.2026, p. 679-684.

1129. **Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.** / Yahya, Rafal; Iversen, Esben; Sivalingam, Suvanjaa et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 03.07.2026.

1130. **Prevalence, incidence, mortality, and years of life lost to diabetes from 1996 to 2024 in Denmark.** / Wibaek, Rasmus; Kosjerina, Vanja; Byberg, Stine et al.
In: BMJ open diabetes research & care, Vol. 14, No. 4, e006129, 10.07.2026.

1131. **A short-term randomized clinical trial testing feasibility of and physiological responses to a Ruminococcus torques strain in healthy overweight humans.** / Gæde, Joachim; Fan, Yong; Lyu, Liwei et al.
In: Genome Medicine, Vol. 18, No. 1, 150, 16.07.2026.

1132. **A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men.** / Gæde, Joachim; Fan, Yong; Lyu, Liwei et al.
In: Diabetologia, Vol. 69, No. 8, 08.2026, p. 2338-2346.

1133. **Distinct proteomic signatures of urinary extracellular vesicles link to albuminuria and treatment responses in diabetic kidney disease.** / van Heugten, Martijn H; Beckmann, Sebastian B; Salib, Madonna et al.
In: Kidney International, Vol. 110, No. 2, 08.2026, p. 438-450.

1134. **Urine peptides enable non-invasive differential diagnosis of nodular diabetic nephropathy.** / Kondyli, Margarita; Siwy, Justyna; Jaimes Campos, Mayra Alejandra et al.
In: Diabetes Research and Clinical Practice, Vol. 238, 113396, 08.2026.

1135. **Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.** / Beernink, Jelle M; Heerspink, Hiddo J L; Birkenfeld, Andreas L et al.
In: Diabetes Care, Vol. 49, No. 8, 01.08.2026, p. 1434-1441.

1136. **Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis.** / Foà, Alberto; Pabon, Maria A; Filippatos, Gerasimos et al.
In: Journal of the American College of Cardiology, Vol. 88, No. 5, 04.08.2026, p. 628-641.

1137. **The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.** / Inciardi, Riccardo M; Ostrominski, John W; Claggett, Brian L et al.
In: Journal of Cardiac Failure, 10.08.2026.

1138. **Pooling cohorts for deep learning analysis: a potential source of bias for electrocardiogram analysis.** / Mørch-Pedersen, Marie; Nørregaard, Malene; Graff, Claus et al.
In: Biomedical Signal Processing and Control, Vol. 122, 110424, 15.08.2026.

1139. **Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis.** / Ruppert, Mihály; Vaduganathan, Muthiah; Claggett, Brian L et al.
In: European Heart Journal, 18.08.2026.

1140. **Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.** / Rayner, Brian; Mahaffey, Kenneth W; Mann, Johannes F E et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 41, No. 9, 27.08.2026, p. 1696–1708.

1141. **Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE Trial.** / McGill, Janet B; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 9, 09.2026, p. 7964-7973.

1142. **Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.** / Agarwal, Rajiv; Correa-Rotter, Ricardo; Navaneethan, Sankar D et al.
In: Hypertension, Vol. 83, No. 9, 09.2026, p. e27036.

1143. **The Kidney in the Middle: Kidney Disease: Improving Global Outcomes (KDIGO) guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome.** / Levin, Adeera; Bansal, Nisha; de Boer, Ian H et al.
In: Kidney International, Vol. 110, No. 3, 09.2026, p. 570-582.

1144. **Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.** / Agarwal, Rajiv; Correa-Rotter, Ricardo; Navaneethan, Sankar D et al.
In: Journal of the American Society of Nephrology, Vol. 37, No. 9, 01.09.2026, p. 1969-1978.

1145. **Differences in screen-detected type 2 diabetes in two targeted community-based screening campaigns in Denmark.** / Mateu, Nuri Cayuelas; Rossing, Peter; Neergaard, Kirsten Piepgras et al.
In: BMJ open diabetes research & care, Vol. 14, No. 5, e006034, 15.09.2026.

1146. **Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis.** / Shafi, Tariq; Anker, Stefan D; Pitt, Bertram et al.
In: European Journal of Heart Failure, 28.09.2026.

1147. **Aldosterone synthase inhibition for treatment of people with chronic kidney disease.** / Tuttle, Katherine R; Trbojevic-Stankovic, Jasna B; Alicic, Radica Z et al.
In: Clinical kidney journal, Vol. 19, No. Suppl 1, 10.2026, p. i14-i25.

1148. **Impact of air pollution exposure on chronic kidney disease and type 2 diabetes: A FIDELITY analysis.** / Al-Kindi, Sadeer; Chen, Zhuo; Dazard, Jean-Eudes et al.
In: American Journal of Preventive Cardiology, Vol. 29, 101670, 10.2026.

1149. **Impact of Albuminuria-Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials.** / Pigsborg, Kristina; Kienle, Simon Maria; Wretlind, Asger et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 10, 10.2026, p. 9346-9355.

1150. **International Society of Nephrology International Expert Forum: exploring the nexus of cardiovascular-kidney-metabolic health.** / Pecoits-Filho, Roberto; Banerjee, Debasish; Jardine, Meg J et al.
In: Kidney International, Vol. 110, No. 4, 10.2026, p. 812-828.

1151. **Leave no one behind: optimizing kidney protection in type 1 diabetes.** / Rossing, Peter; Heerspink, Hiddo J L.
In: Nature Reviews Nephrology, Vol. 22, No. 10, 10.2026, p. 673-674.

1152. **New insights from DAPA-CKD indicate that dapagliflozin modulates key pathways related to kidney outcomes.** / André de la Rambelje, Mark; Jongs, Niels; Greasley, Peter J et al.
In: Kidney International, Vol. 110, No. 4, 10.2026, p. 977-987.

1153. **Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.** / Moedt, Erik; Koshino, Akihiko; Jongs, Niels et al.
In: Journal of the American Society of Nephrology, Vol. 37, No. 10, 2210, 01.10.2026.

1154. **Blood-Derived DNA Methylation Biomarkers Predict Diabetic Kidney Disease and Map to Epigenomic Remodeling in Renal Cells.** / Khurana, Ishant; Hansen, Tine Willum; Persson, Frederik et al.
In: Diabetes, 01.10.2026.

1155. **Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; Aroda, Vanita R; Bajaj, Mandeep et al.
In: Diabetologia, 02.10.2026.

1156. **Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).** / Davies, Melanie J; Aroda, Vanita R; Bajaj, Mandeep et al.
In: Diabetes Care, 02.10.2026.

1157. **Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.** / Tuttle, Katherine R; Andersen, Margit R; Arici, Mustafa et al.
In: Kidney International, 20.10.2026.

1158. **GLP-1 receptor agonists in patients with Type 2 diabetes: cardiorenal protection versus ocular safety.** / Stougaard, Elisabeth Buur; Rossing, Peter.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 41, No. 11, 30.10.2026, p. 1931-1933.

1159. **Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial.** / Agarwal, Rajiv; Green, Jennifer B; Heerspink, Hiddo J L et al.
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 41, No. 11, 30.10.2026, p. 2042-2052.

1160. **Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE.** / Cherney, David Z I; Yi, Tae Won; Heerspink, Hiddo J L et al.
In: Kidney International Reports, Vol. 11, No. 11, 107083, 11.2026.

1161. **Finerenone-Empagliflozin Combination Therapy in Apparent Resistant Hypertension: A CONFIDENCE Trial Post Hoc Analysis.** / Agarwal, Rajiv; Navaneethan, Sankar D; Correa-Rotter, Ricardo et al.
In: JACC: Advances, Vol. 5, No. 11 Pt 2, 103388, 11.2026.

1162. **Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.** / Tuttle, Katherine R; Kanbay, Mehmet; Alicic, Radica Z et al.
In: Nature Reviews Nephrology, Vol. 22, No. 11, 11.2026, p. 784–802.

1163. **Prevalence, Incidence and Mortality of Chronic Kidney Disease in Type 1 and Type 2 Diabetes-A Nationwide Danish Register-Based Cohort Study.** / Lee, Christina J-Y; Gerds, Thomas A; Mikkelsen, Hjalte S et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 11, 11.2026, p. 9930-9940.

1164. **Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes.** / Muk, Tik; Okdahl, Tina; Kokla, Marietta et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 11, 11.2026, p. 10670-10682.

1165. **The association between prolactin and myocardial function in type 2 diabetes.** / Krogh, Jesper; Bahrami, Hashmat Sayed Zohori; Rørth, Rasmus et al.
In: Endocrine Connections, Vol. 15, No. 11, 01.11.2026.

1166. **Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial.** / Friedman, Allon N; Basile, Jan; Busch, Robert et al.
In: Diabetes, Obesity and Metabolism, 03.11.2026.

1167. **Making IMPACT (Improving Methodology for Proteinuria and Albuminuria measurement in Clinics and Trials): A Report of the 2025 Proteinuria-Albuminuria Workshop Sponsored by the National Kidney Foundation.** / Heerspink, Hiddo J L; Inker, Lesley; Jongs, Niels et al.
In: American journal of kidney diseases : the official journal of the National Kidney Foundation, 14.11.2026.

1168. **Associations between cardiac adipose tissue volume, measures of coronary calcification, myocardial microvascular function and systemic inflammation in individuals with type 2 diabetes free of overt cardiovascular disease.** / Jensen, Morten Steen; Rasmussen, Ida K B; Skriver-Møller, Anne-Cathrine et al.
In: Cardiovascular Diabetology, Vol. 25, No. 1, 307, 12.2026.

1169. **Complication rates of 16- and 18-gauge needles for native kidney biopsies: a systematic review and proportional meta-analysis.** / Møller, Marie; Andersen, Tue H; Borg, Rikke et al.
In: Renal Failure, Vol. 48, No. 1, 2665032, 12.2026.

1170. **Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases.** / Mina, Ioanna K; Hussain, Yaqza; Siwy, Justyna et al.
In: Molecular medicine (Cambridge, Mass.), Vol. 32, No. 1, 158, 12.2026.

Projects

Deep phenotyping of the heart with advanced imaging modalities in type 2 diabetes – implications for pathophysiology and prognosis (DIA-HEART study)
Kjær, A. (Project participant), Ribel-Madsen, R. (Project participant), Hasbak, P. (Project participant), Rasmussen, I. K. B. (Project participant), Zobel, E. H. (Project participant), Rossing, P. (Project participant) & Holmvang, L. (Project participant)
01/08/2019 → 01/08/2024

GALAXY - Gut-and-liver axis in alcoholic liver fibrosis
Rossing, P. (Project participant)
01/01/2016 → 31/12/2021

Personalizing Treatment of Diabetic Nephropathy
Rossing, P. (Project participant)
01/06/2015 → 30/06/2021

Prevention of early renal function decline
Rossing, P. (Project participant)
20/12/2012 → 02/11/2019

PRIMETIME
Rossing, P. (Project Coordinator), Persson, F. (Project participant) & Hansen, D. (Project participant)
31/12/2019 → 31/12/2024

PRIORITY: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria.
Rossing, P. (Project participant) & Persson, F. (Project participant)
02/01/2012 → 31/12/2018

Type 2 diabetes and chronic kidney disease - Trends in demography, cardio-kidney risk factors, acute and chronic cardio-kidney complications and cardio-kidney protective medication use in a nationwide diabetes register in Denmark
Rossing, P. (Project participant), Amadid, H. (Project participant) & Vistisen, D. (Project participant)
01/06/2021 → 01/03/2023